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There is a need in the pharmaceutical industry for more informative and 
functional in vitro human models for drug testing as the currently used animal 
models have poor correlation to their human counterparts. The liver is the 
main organ of metabolism and xenobiotics detoxification. As such, a human 
hepatic in vitro model with improved metabolic functions similar to primary 
human hepatocytes (PHHs) could reduce the number of animals needed in 
pre-clinical testing and enhance the relevance of data obtained for 
subsequent in vivo testing.  
Most immortalized hepatic cell lines are derived from carcinomas and do not 
retain a full range of functional activity in vitro. Here we have compared a 
novel hepatic cell line (HepaRG™), an intrinsic co-culture of hepatocyte and 
cholangiocyte-like cells, with the commonly used C3A cell line which is a 
derivative of HepG2 cells, in terms of metabolic competency. We found that 
the HepaRG™ cells out-perform C3As in a number of metabolic functions 
that include phase I and II metabolism as well as CYP activity. This makes 
the HepaRG™ cell line a strong alternative to PHHs for in vitro pre-clinical 
drug testing. 
Next, we considered the platform for in vitro modelling. There are currently 
many tissue engineering models available with improved cell culture 
characteristics such as 3D spheroids, microfluidic models or 3D printing. 
However, these methods are costly and time consuming. We have used 
nanopatterned culture plates to develop a cheaper and faster platform that 
  iii 
will produce an enhanced human hepatic culture capable of sustaining a 
differentiated state for several weeks. Such a model will also allow for multi-
experimentation or repeat dosage and would be a significant step towards 
reducing small animal in vivo testing and may correlate better to pre-clinical 
human trials.  
We have specifically selected a nanopatterned and oxygen plasma treated 
culture system that has shown promise in differentiating other stem-like cells 
into organ specific cultures without the use of additional chemicals or 
hormones. By growing HepaRG™ progenitor (HepaRG-P™ ) cells on these 
prototype plates, we showed a much earlier differentiation compared with the 
established HepaRG-P™  cell culture protocols. Improved functionality at this 
early time point can also be seen in terms of CYP activity and markers of 
maturation. There is also some evidence to suggest specific zonation of 
mature HepaRG™s within this model. 
Finally, a real-time, label–free monitoring of cell culture fitness, that 
encompasses a quantitative analysis of cell culture during treatment with a 
pharmacological agent, is desirable.  An electrical cell impedance substrate 
(ECIS) platform that fulfils the above criteria was validated for real-time, non-
invasive, monitoring of the HepaRG™ cell culture. Chlorpromazine (CPZ), a 
model cholestatic drug, was used to assess its effect on the HepaRG™ cells 
using ECIS. This study also gave us the opportunity for a more in-depth 
analysis of CPZ-induced cholestasis by not only analysing tight junctions, 
adhesion and cell membrane integrity, but also by studying the bile acid and 
xenobiotic transporters and the inflammatory and adaptive responses to 
CPZ-induced injury. We have shown disruption of membrane integrity, 
  iv 
changes in bile acid transporters and the regulation of both xenobiotic and 
phospholipid transporters as well as inflammatory markers.  
In conclusion, in this thesis I have demonstrated that by using a novel cell 
line with novel prototype culture plates (nanopatterned) and a label free 
technique (ECIS) to measure cellular fitness, a much improved in vitro model 
of drug testing can be developed.  
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Lay Summary 
The liver is the main organ of metabolism of drugs and nutrients. There is 
currently a need in the pharmaceutical industry for human cell models for use 
in drug testing as the currently used animal models have poor correlation to 
their human counterparts. There are two types of liver cells used in drug 
toxicity testing, immortalised human cells taken from tumours and primary 
cells from patients undergoing surgery. Primary cells are difficult to obtain 
and use for experimentation as they only last a few days, while immortalised 
cells can be kept for long periods within the laboratory and used for repeat 
experimentation. Though immortalised cells are more reproducible in 
experimentation they often lack some functions of primary liver cells. A 
human model using immortalized cells with improved metabolic functions, 
similar to primary human liver cells, could reduce the number of animals 
needed in pre-clinical testing and enhance the relevance of data obtained for 
subsequent pre-clinical human drug trials.  
Here we have compared two immortalised lines, the novel liver cell line, 
HepaRG™, with the commonly used C3A cell line. The difference in these 
lines lies in the types of cells within each culture. HepaRG™ cells contain 
both liver cells which carry out major functions of the liver, and biliary cells 
which are part of the system responsible for moving bile throughout the liver 
while C3As contain only liver cells. This alone sets the HepaRG™ cell line 
apart making it more relevant in drug toxicity modelling as it shows potential 
for evaluating two intrinsic cells of the liver and gives the ability to also study 
drug transport mechanisms. In terms of metabolism, we found that the 
  vi 
HepaRG™ cells out-perform C3As in a number of metabolic functions and 
contain more enzymes akin to primary liver cells. This makes the HepaRG™ 
cell line a strong alternative to primary cells for pre-clinical drug testing. 
Next we considered the way cells are grown for use in drug toxicity studies. 
There are currently many models available which manipulate the cells to 
improve enzymatic activity, and make them more like primary liver cells, such 
as growing cells into 3D spheres, using microfluidic models or 3D printing. 
However, these methods are costly and time consuming. We have used 
nanopatterned culture plates to develop a cheaper and faster platform that 
will produce an enhanced human liver cell culture capable of sustaining a 
mature and functional state for several weeks. Nanopatterned plates are 
different from traditional plates in that they contain small holes on the surface 
which may help the cells to adapt to their environment, as it may reflect and 
be more similar to the internal surface of the liver. Such a model will also 
allow for multi-experimentation or repeat dosage and would be a significant 
step towards reducing small animal testing.  
By growing HepaRG™ progenitor (HepaRG-P™) cells on these novel plates, 
we showed that cells can become mature much earlier compared with the 
established HepaRG-P™ cell culture protocols. Improved functionality at this 
early time point can also be seen in terms of enzymatic activity.  
Finally, the ability to monitor a cell line in real-time and quantify damage 
caused by drugs would be very beneficial in the pharmaceutical industry. We 
have used an electrical impedance platform (ECIS) that fulfils the above 
criteria and has been validated for real-time, non-invasive, monitoring of the 
HepaRG™ cell culture. Chlorpromazine (CPZ) is a drug used to treat 
  vii 
schizophrenia. It also causes damage to biliary cells which can promote 
jaundice and other liver diseases in patients. We used this drug and 
assessed its effect on the HepaRG™ cells using ECIS impedance. Electrical 
impedance monitoring involves using a small electrical current run 
underneath the cells to measure their ability to attach or adhere to the 
surface. Any disturbance to the cell culture caused by environment or 
chemicals can easily be seen through a loss of impedance. This study also 
gave us the opportunity for a more in-depth analysis of CPZ-induced toxicity 
by analysing the tight junctions between cells, the cells’ ability to adhere to 
the culture surface and cell membrane integrity. We also assessed the 
proteins responsible for expelling toxic compounds out of the cell and found 
that these proteins were affected and disrupted based on the dose of CPZ.  
Primarily, the protein responsible for bile acid transport was impaired. Since 
bile acids are toxic to the cell, this highlights a possible mechanism for CPZ 
induced toxicity. We also assessed the inflammatory and adaptive responses 
to CPZ-induced injury and found that the inflammatory response increased 
as the dose of CPZ increased.  
Here we have shown disruption of cell membrane integrity, changes in bile 
acid transporters and changes in the regulation of transport proteins 
responsible for expelling fats and drugs from the cell which may give insight 
into the damage caused by CPZ.  
In conclusion, in this thesis I have demonstrated that by using a novel cell 
line with novel cell culture surfaces (nanopatterns) and a real-time 
impedance based technique (ECIS) to measure cellular fitness, a much 
improved in vitro model of drug testing can be developed.  
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Chapter 1 Introduction 
1.1 The liver 
The liver is located below the diaphragm in the right upper quadrant of the 
abdominal cavity. It is the largest organ in the body, weighing approximately 
1.4kg. It is separated into a large right and smaller left lobe by the falciform 
ligament, and is able to regenerate in response to injury, but can fail when 
exposed to repeated toxic or metabolic insult.  
1.2 Functions of the liver 
The liver is responsible for synthesizing and breaking down molecules that 
are used to support homeostasis. These molecules comprise the main 
metabolic pathways within the liver. Although the liver is responsible for over 
500 different metabolic functions they can be divided into 4, mainly; 
carbohydrate, lipid and protein metabolism and phase I and II detoxifying 
metabolic enzymes such as cytochrome P450s. 
Carbohydrate metabolism is critical to maintain concentrations of dietary and 
endogenous glucose in blood within a narrow, normal range. Too much or 
too little glucose over an extended period of time can lead to pathologies 
such as diabetes, metabolic syndrome and non-alcoholic liver disease. There 






production of glycogen or breakdown of glucose within the liver. However, 
the initiation of glycolysis or gluconeogenesis is governed by hormones 
produced within the pancreas.  
The pancreas is made up of the islets of Langerhans (Lackie, 2010) 
containing a variety of cell types. Within the centre of the islet, β cells secrete 
insulin and amylin in response to blood glucose levels, but also in response 
to the rate at which the blood glucose levels are changing (Rang and Dale 
2007). These β cells are surrounded by α cells which secrete glucagon, and 
Δ cells which secrete somatostatins (Rang and Dale 2007). Glucagon 
opposes insulin and somatostatins can inhibit both the secretion of insulin 
and glucagon. Secretion of these hormones is governed by potassium 
channels which determine the resting membrane potential of the cell (Rang 
and Dale 2007). ATP is the molecule which blocks potassium channels in 
islet cells and works alongside the membrane transporter glut-2 which work 
in tandem as a ‘glucose sensor’ (Rang and Dale, 2007). These membrane 
bound proteins are instrumental in the response to blood glucose levels and 
release the hormones mentioned above to maintain homeostasis in response 
to glycolysis or gluconeogenesis which mostly take place within the liver 
(Rang and Dale 2007).  
Gycolysis, or the lysing of glucose to produce energy, takes place in the 
cytoplasm of cells throughout the body. Glycolysis is a ten step process that 






carbon molecules of pyruvate. By doing this a net of 2 ATP and 2 NADH are 
created.  
As NAD is needed to fuel glycolysis, NADH donates its hydrogen electron to 
the electron transport chain creating more ATP and leaving behind NAD+, 
which is then recycled back into the pathway to fuel glycolysis (Fantin et al., 
2006). Pyruvate, as the final product of glycolysis, enters the citric acid cycle 
after transformation into Acetyl-CoA where it is used for further energy 
production in a process known as oxidative phosphorylation (Lunt & Vander 
Heiden, 2011 & Kumari, 2018).  
Although glycolysis is present throughout all tissues, gluconeogenesis mainly 
takes place in the liver though gluconeogenesis can also be seen in the 
kidney cortex to a lesser extent (Gerich et al., 2001, Lemaigre and 
Rousseau, 1994). Gluconeogenesis is essentially the reverse of glycolysis as 
it generates glucose from non-carbohydrate substrates such as glycerol and 
amino acids (Gerich et al., 2001)(Figure 1.1). However, there are some 
differences in enzymes which are needed to circumvent the irreversible steps 
of glycolysis. This allows for the production of a glucose molecule which is 
readily available and secreted into the bloodstream. The gluconeogenic 
pathway assists in the maintenance of blood glucose levels through 
unidirectional enzymes; fructose-1,6-bisphosphatase, glucose-6-
phosphatase and Phosphoenolpyruvate carboxykinase which are 






glucorticoids (Yoon et al., 2001). These hormones are produced in response 
to significant fluctuations of glucose and dietary need and as such 
gluconeogenesis is a target therapy for type II diabetes where decreased 
insulin secretion decreases glucose production and increases uptake of 








Figure 1.1: Overview of glycolysis and gluconeogenesis metabolism and their 
relationship to the Citric Acid cycle. Substrates are shown in black. Enzymes unique to 
glycolysis are shown in red while enzymes unique to gluconeogenesis are shown in blue. 







The liver is also responsible for synthesizing around 800mg of cholesterol 
and phospholipids per day (Berg et al., 2002). These are packaged with 
lipoproteins and made available to the rest of the body or can be excreted in 
bile as cholesterol or bile acids  
The biliary system is responsible for transporting waste products, bile and 
bile acids out of the liver. Bile acids emulsify fat by making the surface area 
of the fat molecule more available for digestion. Unsaturated fatty acids and 
cholesterol are important precursors for hormone production, while excess 
carbohydrates and proteins are converted into fatty acids and triglycerides 
which are then oxidised to produce energy.  
Protein metabolism is responsible for deamination and transamination of 
amino acids, removal of ammonia from the body and synthesis of plasma 
proteins. Deamination is the breakdown of amino acids within the liver. 
Ammonia resulting from this process is toxic and therefore requires 
conversion to urea via the urea cycle, which is then easily excreted via the 
kidneys. Enzymes involved in deamination/transamination of amino acids are 
often used as clinical markers to assess liver damage. Alanine transaminase, 
alkaline phosphatase and aspartate aminotransferase are enzymes which 
can be used to analyse hepatic transport, damage and blockage of bile 
ducts. When abnormal concentrations of these enzymes appear in the blood, 






enzymes are used within the liver can point to particular pathology when 
levels of these enzymes in blood are outside normal levels. 
The liver also synthesises proteins, mainly albumin which is responsible for 
maintaining osmotic pressure and transporting substrates, including, 
cholesterol, calcium, hormones, bilirubin and vitamins, throughout the body. 
1.3 Microanatomy of the liver 
1.3.1 Cell types within the liver 
The liver is comprised of parenchymal hepatocytes and cholangiocytes and 
non-parenchmal cells including Kupffer cells, sinusoidal endothelial cells, 
oval cells and stellate cells.  
Hepatocytes are responsible for the major metabolic functions of the liver 
having a role in maintenance of homeostasis, storage, digestion, and bile 
production. Cholangiocytes are epithelial cells that line and form the bile 
ducts and are responsible for exchange of bile acids and other molecules 
excreted by hepatocytes.  
The oval cell is considered the hepatic progenitor cell as it retains the 
capability of differentiating into either a hepatocyte or cholangiocyte lineage 
(Takiya et al., 2013). This cell exhibits foetal markers such as alpha 
foetoprotein, but also hepatocyte specific and cholangio- specific markers 
albumin and cytokeratin 19 (CK19) respectively. Oval cells line the 






canals of Hering towards the portal vein. The positioning of these cells 
determines differentiation based on the functions which they are required to 
perform (Takiya et al., 2013). 
Also found in the liver are Kupffer cells which are part of the innate immune 
system and clear microorganisms, cellular debris and aged erythrocytes from 
the blood, while stellate cells are responsible for transport and storage of 
retinoids.  
1.3.2 Structure of the liver and microanatomy 
The liver is predominately made up of the right and left lobes divided by the 
falciform ligament. These lobes can be further devolved into 4 adding the 
caudate and quadrate lobes as anatomical markers or could be portrayed as 
8 sections which are used as anatomical and surgical landmarks as each 
segment has its own vasculature and biliary drainage (Germain et al., 2014) 








Figure 1.2: Depiction of the main quadrants and segments of the liver in 
correlation to vasculature: The right and left lobes of the liver can be 
divided into 8 sections each with their own vasculature. Here the vasculature 
of the liver is also represented in the form of the portal vein, hepatic artery, 
bile duct and hepatic vein. (Adapted from image © Spears-Graber, T. and 







The lobes of the liver are comprised of microscopic units referred to as 
lobules. Each lobule is hexagonal and has at its centre the central vein, whilst 
the portal triads (made up of the portal vein, hepatic artery and bile duct) can 
be seen at the periphery joined to the central vein by sinusoids (Figure 1.2). 
Hepatocytes form cords between sinusoids of the liver lobule. 
Cholangiocytes form the biliary ductules at the portal triad and thereafter the 
bile ducts.  
The concept of the liver acinus was proposed in terms of delineating zones of 
specific liver function by shifting the focus of the central vein to the portal 
triad (Rappaport, 1958). Within the acinus the portal triad is central and 3 
zones are delineated by function along the sinusoids culminating at the 







Figure 1.3: The liver lobule with specific zonation of the acinus: 
Histology slide depicting the hexagonal liver lobule with central vein and 
portal triad as well as representing the 3 zones of liver zonation which centre 








The portal triad enables blood supply of the acinus via the portal vein and 
hepatic artery and supports the concurrent counter flow of bile. Oxygen 
gradient within the acinus is thought to be one of the most important 
regulators of the 3 zones (Keitzman, 2017). Zone 1 is located near the portal 
triad where oxygenated blood enters the liver. A gradient of oxygenation then 
occurs through zone 2 culminating in poor oxygenation in zone 3. Various 
pathways have been studied in an attempt to further categorise and 
understand liver zonation (Wnt/β-catenin, hedgehog). However, these 
pathways are often modulated by hypoxia (Keitzman, 2017). The concept of 
oxygenation in zonation will be discussed further in Chapter 4.	
The sinusoids within the acinus are lined predominately with hepatocytes and 
cholangiocytes. However, oval cells, Kupffer cells and stellate cells are also 
found along the acinus. 
1.4 Detoxification within the liver  
1.4.1 Liver zonation 
The acinus is split into 3 functional zones which are relative to their distance 
from the arterial blood supply. These zones are defined by a gradation of 
enzymes and functions as blood, metabolites and drugs pass through the 
sinusoids before entering the central vein. Within the gradient of the acini, 






is determined by the position of the cell and function along the gradient. For 
example, cytochrome P450 enzymes (CYPs) needed for drug detoxification 
are located in the perivenous region, the last cell population which can 
detoxify blood before it is recirculated. 
	
While this zonation is present in vivo, it is currently not possible to mimic liver 
zonation in vitro. Developing an in vitro model capable of in vivo-like 
metabolism that could represent one or more of the specific zones of the liver 
could be beneficial in drug toxicity testing and could further inform drug 
development. 
1.4.2 Phase I/II/III metabolism 
Metabolism within the liver involves enzymatic conversion of a substrate into 
various small molecules known as metabolites. Metabolites can be 
hydrophobic or hydrophilic. Hydrophobic compounds are not excreted by the 
kidneys so must undergo further metabolism into hydrophilic (or polar) 
compounds before they can be excreted in urine (Rang and Dale 2007).  
 
The enzymes responsible for metabolism of drugs are found mostly in the 
liver. The main type of enzymes responsible for drug metabolism are 
cytochrome P450 enzymes. These enzymes are haem proteins categorized 
by the letters CYP and a further sequence of numbers and letters to 
distinguish specificity (Rang and Dale 2007). CYP enzymes metabolise drugs 






prostaglandins and are involved in cholesterol production (Zanger and 
Schwab, 2013).  
 
Specific CYP enzymes can be induced by chemicals and therefore are 
important in understanding specific metabolic pathways and can be used in 
the study of liver zonation as most CYPs are highly expressed in the 
perivenous region of the acinus (Oinonen and Lindros, 1998). As such CYP 
enzymes differ between species and also within a human population and 
therefore can be a source of variability in DILI studies (Zanger and Schwab, 
2013). It is also possible for more than one CYP enzyme to metabolise a 
particular substrate. For instance, CYP2E1, CYP3A4 and CYP1A2 all 
metabolise paracetamol (Tonge et al., 1998). 
 
There are 3 main phases of drug metabolism. Phase I reactions are catabolic 
and often produce toxic products by way of oxidation, hydroxylation, 
deamination or hydrolysis (Rang and Dale, 2007). Phase II reactions usually 
follow on from phase I and involve conjugation of the products of phase I into 
more polar, or hydophillic, molecules making them less toxic (Rang and Dale, 
2007). However, depending on the rate of the enzymatic reactions and 
availability of anti-oxidants, toxic products may not always be conjugated into 
less harmful metabolites and can cause damage leading to disease (Daly, 







As phase II metabolites pass back into the small intestine the antiporter 
system, found within the liver and on the tips of the villi of the small intestine, 
move phase II metabolites out of the hepatocytes and mediate their excretion 
through the intestinal tract. This efflux system containing proteins such as P-
glycoproteins and multidrug resistance associated proteins can be referred to 
as phase III metabolism and is crucial in the understanding of enterohepatic 
circulation (Xu et al., 2005). 
 
1.5 Current hepatic models in drug development  
There are three main stages of drug toxicity testing within the context of drug 
development. Initially, in vitro human cell lines are used to give an indication 
of toxicological effects of drugs. This is normally carried out on primary cells, 
immortalized cell lines or tissues from donors. After assessment of in vitro 
models, drugs and new pharmaceutical compounds are tested on small 
animals. Around, 79% of candidate drugs still enter clinical trials when liver 
toxicity has been shown in rodent and non-rodent experimentation (Ballet, 
2015). This is because animals are used solely to determine the target organ, 
and not necessarily the level of toxicity, due to the interspecies differences in 
metabolism.  
Initially, the target organ of toxicity is identified and toxic and therapeutic 
doses are established. Once a non-toxic, but therapeutic dose is determined, 






the third phase, clinical trials in humans. New compounds commonly fail at 
this stage due to metabolic differences between animals and humans. It is 
estimated that it takes 9 years for a new drug to be tested, validated and 
accepted (Chapman et al., 2013). False positives of liver toxicity are one of 
the major causes of drugs being withdrawn before pre-clinical human testing. 
While a holistic approach to drug toxicity is used in animal models, it is often 
due to the interspecies differences of CYP enzymes within the liver which 
mean that there can be no correlation between an animal and human model. 
A human hepatic in vitro model replicating in vivo CYP activity, capable of 
phase I-III metabolism would be beneficial in identifying the mechanisms 
behind liver toxicity in drug trials by helping to identify toxic metabolites at an 
early stage in toxicity testing. A model capable of real time assessment of 
hepatic cells would give an immediate indication of toxicity and show a profile 
of cell health before and after the addition of the test compound. Such a 
model may reduce the amount of animals needed and provide a better 
indication of how a compound will perform in the third stage of clinical trials.  
Within this chapter, the disparity of current models used for drug 
development will be discussed alongside ways of improving these models to 
ensure a more in vivo like hepatic construct. Platforms using hepatic cell lines 
in toxicity testing will also be investigated, highlighting pros and cons. Finally, 
a full model comprising cell type, platform and techniques of investigation will 







1.5.1 Disparity of current models 
There are several issues with the current in vitro and in vivo models used 
within drug development. Firstly, most cell lines used are immortalized lines 
derived from carcinomas and do not retain a full range of functional activity in 
vitro. Secondly, small animals do not always mimic the same conditions that 
may be seen in human trials (Jemnitz et al., 2008). One main reason for this 
is the disparity CYP enzymes, especially in small animal models. This often 
leads to false positives and false negatives when used in clinical trials. Within 
the pharmaceutical industry, evaluation of new compounds and 
pharmaceuticals requires use of regulated animal models before passing on 
to pre-clinical human studies. This regulates the safety aspect of a new 
compound by testing specific organ toxicity and identifying compounds likely 
to be toxic to humans. However, animal models, large and small, used in 
prediction of human safety should regularly be reviewed, in light of these 
interspecies variations (Ballet, 2015). For instance, it has been shown that 
CYP450 enzymes in mice are structurally and functionally different from 
those of humans or that mice can be devoid of certain CYP enzymes 
altogether. (Ballet, 2015, Martignoni et al., 2006, Turpeinen et al., 2008). 
Therefore, it is not certain in rodent/murine models, that their metabolism of 
drugs or their model of drug induced liver injury (DILI) will be directly 
comparable with that of humans.  
As scientific understanding and technology advances, in vitro models of drug 






species variations and understand the mechanistic pathways involved in 
individual drug toxicity studies.  
Earlier use of appropriate hepatic in vitro models in the drug development 
process would ensure a more relevant use of animals saving both time and 
money reducing the possibility of pre-clinical attrition. 
 
1.5.2 The need for better in vitro models in drug development 
Considering the complications and limitations around drug withdrawl from the 
market, there is currently a need to improve the lengthy and costly process of 
developing therapeutics and make it more likely that they will be used at the 
bedside. The UK government is committed to ensuring the licenses granted 
under the Animals for Scientific Procedures Act (1986) must comply with the 
ethos of the 3R’s. The 3R’s consist of replacement, reduction and refinement 
of the use of animals within research. While there are rigid and detailed rules 
for the use of animals in experimentation, the model is still lacking in 
screening potential therapeutics and arriving at safe and effective 
compounds for general use. 
1.6 Establishing an improved hepatic model of in 
vitro drug testing 
A good hepatic in vitro toxicology model should have three key aspects.  







2. A platform for cell culture which is accessible, promotes best conditions for 
growth, maturation and viability and is cost effective. 
3. Techniques to assess toxicity encompassing a variety of methods which 
consider aspects of cellular health and viability, timely measurements of 
toxicity to gain insight into possible mechanisms of action and assessment of 
molecular markers and protein translation. 
 
1.6.1 Cell lines commonly used in hepatic drug/toxicity 
testing 
1.6.1.1 Primary Human Hepatocytes (PHHs) 
PHHs have been considered the ‘gold standard’ within toxicological and 
therapeutic research. Although this provides a human model without the 
inter-species issues described above, there are inevitably intra-species 
differences. Within a given human population, the level of CYP enzymes 
used in drug metabolism differ between individuals based on age, race, 
lifestyle and genetics. PHHs are difficult to obtain and can be derived from 
individuals already undergoing a procedure for liver disease suggesting the 
cells may not always represent a healthy population. However, it is possible 
to use hepatocytes from healthy donors. While this is preferable, there is still 
the issue of reproducibility as PHH represent one phenotype within a given 
population. Although using various phenotypes of PHH in drug toxicity testing 






not ideal at faithfully proving the initial toxicity of a compound. In the early 
stages of toxicity testing reproducibility of toxicity and dose response on a 
stable culture is preferred. In addition, PHHs are expensive to produce, and 
difficult to culture. Most PHHs survive only days in culture as opposed to 
immortalized cell lines which can survive for weeks (Nelson et al., 2015).  
Therefore, a model based on PHHs is not sustainable for repeated 
experimentation due to the quantity of cells being finite, while using PHHs 
from different donors within a drug study will adversely affect reproducibility 
of results as even minor genetic variations can cause drug metabolism to 
vary, and complicate dosing regimes. 
An alternative that is both comparable to human physiology and robust 
enough to remain viable in vitro for several weeks at a time is needed for 
many forms of liver research to continue, especially in light of current 
legislation to reduce animal testing across Europe and throughout the world.  
1.6.1.2 Immortalized cell lines 
Hepatic cell lines are commonly obtained from patients with hepatocellular 
carcinoma. These cell lines have been transformed by the molecular 
changes caused by the carcinoma and are immortal, meaning they can be 
maintained in vitro for many generations, allowing for reproducibility and high 
throughput experimentation. In the past, such cell lines have been found to 
be genetically unstable. There are a variety of immortalised human hepatic 
cell lines available including Huh-7, Fa2N-4, HepG2/C3A, Hep3B and 






that many exhibit lower hepatic functionality and CYP activity. While each of 
these cell lines has a niche for in vitro work they fall short in overall 
interrelation to PHHs. For example, Huh-7 cells are known for their ease of 
transfectability and have been used extensively in Hepatitis C 
experimentation (Gomez-Lechon et al., 2010), Fa2N-4 cells display highly 
inducible CYP enzyme expression, though they are not always as high as 
PHHs (Hariparsad et al., 2008) The next section will focus on the most widely 
used cell lines, the HepG2/C3As and the HepaRG™. 
1.6.1.2.1 HepG2/C3A 
In recent years, the cell line of choice has been HepG2 and their derivative 
culture, C3As.  
HepG2/C3As have been a favoured line because they are transfectable and 
can be induced to increase CYP expression (Lu and Cederbaum, 2008). As 
extensive work and characterization has been done within the Hepatology 
laboratory with the HepG2/C3A cell line it will serve as a standard cell line for 
comparison with emerging hepatic cell lines. 
However, HepG2/C3A cells still show differences compared to PHHs. For 
example, it has been observed that even when grown in 3D hydrogel, polarity 
in HepG2 cells is less evident than in other cell lines (Bhattacharya et al., 
2012). Furthermore, to establish acceptable levels of CYP activity within the 
C3A cell line, transfection, co-culture and metabolic pre-conditioning (Filippi 
et al, 2004) have to be routinely used to force these cells into an acceptable 






deficient in terms of hepatic polarity and also phase II and III metabolism, 
making them unsuitable for many in vitro applications (Nelson et al., 2017). 
1.6.1.2.2 HepaRG™ cell line 
The human organotypic HepaRG™ cell line was isolated from a female in her 
30’s who had grade I differentiated hepatocellular carcinoma, concurrent to 
hepatitis C (Gripon et al., 2002). The HepaRG™ cells are unique in that they 
are a bipotent line, which can be differentiated to generate an intrinsic co-
culture of hepatocytes and cholangiocyte-like cells. This culture shows 
stability for 4 weeks and beyond, by retaining differentiated characteristics, 
which presents HepaRG™ cells as a viable model for drug toxicity testing. 
They are comparable in phenotype and function to PHHs, and can also be 
used for repeat experimentation (Nelson et al., 2017). 
One of the main reasons for their functionality could be attributed to their 
plasticity as a bipotent adult progenitor/hepatoblast cell line. HepaRG™ cells 
can be taken through a formal differentiation program which provides 
researchers with a tool for in vitro study of early hepatic development and 
possibly also hepatocyte dedifferentiation in response to injury or metabolic 
challenge  
In contrast to other hepatic cell lines, fully differentiated HepaRGs™ are a 
unique co-culture of cholangiocyte-like and hepatocyte-like cells, which 
makes them a useful model for drug transporter studies and for use in 
cholestatic models such as cholestasis, fibrosis and cirrhosis (Figure 1.3) (Le 














Figure 1.4 HepaRG™ progenitor (HepaRG-P) time line: Phase microscopy 
showing a typical HepaRG-P cell culture at days 1, 10 and 28 and timeline of proliferation 
and differentiation phases. HepaRG-P cells go through two distinct phases of proliferation 
and differentiation over a period of 28 days. DMSO is added at day 14 to induce and 
maintain differentiation and a co-culture of hepatocytes and cholangiocytes is seen at day 









Spectral karyotyping of HepaRG’s™ has revealed a stable and unique 
phenotype which is still consistent after several passages. Only 2 
abnormalities have been seen after 40 mitoses. All samples tested, have 
shown evidence of an additional chromosome located at chromosome 7 and 
a translocation between chromosome 22 and 12, though no reported loss of 
sequence is evident (Gripon et al., 2002). (Figure 1.4) Even taking these two 
anomalies into consideration, HepaRG™ cells display a robust phenotype 
after multiple passages lending confidence to their repeated and extensive 
use in pre-clinical drug testing. (Guguen-Guilliozo, 2014). 
HepaRG™ cells are also available in a progenitor (HepaRG™-P) culture. 
These cells have de-differentiated into a hepatoblast-like cell and although 
bipotent, still retain a plasticity not seen in the fully differentiated HepaRGs™. 
These cells eventually differentiate into a co-culture of hepatocytes and 
cholangiocyte-like cells after 4 weeks following the introduction of 
dimethylsulfoxide (DMSO) to the media at day 14. The advantages of this 
line over the fully differentiated HepaRG™s is the ability to study 
developmental and maturation markers under a variety of conditions. The 
HepaRG™-P cells differentiation capacity allow the study of various tissue 
engineering platforms, taking advantage of their plasticity by culturing them 
on scaffolds and various surface substrates that may give rise to an improved 
phenotype and may provide a more realistic biochemical basis for future drug 






HepaRG™ cells have been widely reported as a surrogate to PHH. Since 
2002 many studies have characterised HepaRG™s in terms of its use in DILI 
studies, CYP activity, urea cycle, expression of membrane bound 
transporters, viral infectibility, spheroid production and uses within tissue 
engineering. Table 1 highlights advantages and disadvantages highlighted 
within this chapter. 
 
 
Table 1: Characteristics of HepaRG™ co-culture 
Advantage Disadvantage 
Co-culture of Hepatocytes and 
cholangioccytes (Cerec et al., 2007) 
Cost (cost of cells and specialised 
media) 
Ability to transdifferentiate through a 
bipotent progenitor culture which 
shows plasticity relevant to PHH 
(Cerec et al., 2007) 
Derived from human hepatocellular 
carcinoma. 
Longevity in culture (up to 4 weeks) 
(Guillouzo et al., 2007) 
Limited nitrogen fixation and 
presence of Carbomyl Phosphate 
Synthetase through urea cycle 







Functional sinusoidal and canalicular 
drug transporters similar to PHH 
(OCT1, OATP-B, OATP-C, NTCP, 
MRP2, MRP3, BSEP and P-
glycoprotein) (Le Vee et al., 
2006)(Guillouzo et al., 2007) 
Glutathione transferase M3 gene less 
expressed than other hepatic cultures 
(Gerets et al., 2012) 
Supports infection with Hepatitis B 
(Gripon et al., 2002) 
Poor CYP2D6 expression (Gerets et 
al., 2012) 
Higher levels of albumin than PHH 
(Lubberstedt et al., 2011) 
Cells not as predictive for 
induction/DILI studies (Gerets et al., 
2012)(Sison-Young et al., 2017) 
Higher CYP activity than 
HepG2/C3A. CYP levels comparable 
to PHH for main CYPs such as; 
CYP3A4, CYP1A2, CYP2C9, 
CYP2C19 and CYP4B1 (Nelson et 
al., 2015)(Gerets et al., 2012)( 
Guillouzo et al., 2007) 
 
Phase I, II and III enzymes along with 
nuclear receptors CAR PXR and AhR 
(Gerets et al., 2012)(Aninat et 







3D spheroids viable for several 
weeks in culture which maintain high 
functionality compatible with high 
throughput analysis (Martucci et al., 








Figure 1.5 Karyotype of fully differentiated HepaRG™ cells shown at 
passage 12. Karyotyping of fully differentiated HepaRG ™cells shows a stable karyotype 
for up to 20 passages. A translocation is present between chromosomes 22 and 12 and 
there is evidence of an additional chromosome located at chromosome 7. No loss of 
sequence is evident and cells remain viable after 46 mitosis.(Figure obtained from Biopredic 










1.6.1.3 Improvement of current models by altering phenotype using 
tissue engineering techniques 
It is known that surface topography in cell culturing impacts proliferation, 
adhesion, phenotype, gene expression and function of cells (Dalby et al., 
2007)(Schernthaner et al., 2012)(Galli et al., 2012)(Kim et al., 2013). The 
interactions of cells with their environment is central to many biological 
processes, and it is well known that cells respond to environmental, chemical 
and topographical cues in vivo. This interaction can be exploited with the use 
of tissue engineering techniques by culturing cells on various synthetic 
materials, substrates and scaffolds, including 3D scaffolds, to manipulate 
cells into a desired response (Martucci et al., 2018) prompting earlier 
differentiation through environmental cues. One way to create an altered 
surface topography is with the application of ‘roughness’ to traditional cell 
culture substrates (Wei et al., 2013) Various types of sandpaper, polymers 
and chemicals have been used to create rough surfaces that enhance cell 
adhesion (Wang et al., 2016) (Lin et al.,2014). However, it is difficult to get 
accurate reproducibility as this is a manual technique applied to the surface 
of culture plates and varies with each application.  
Grooves, pores, nodes and other notches and depressions are found within 
the basement membranes of cells/tissues in the body. Various types of 






membranes and to provide a more relevant cell culture for in vitro 
experimentation (Micholt et al., 2013). 
1.6.1.3.1 Nanopatterning  
Nanopatterning has been used to create an uneven surface of pits, either 
random or patterned, within the surface of the tissue culture plastic, which 
has been shown to have an effect on cell adhesion and migration (Qian and 
Wang, 2010).  
1.6.1.3.2 Origins of nanopattern substrates 
Textured substrates have been used for more than 100 years in cell culture 
and in vitro applications (Qian and Wang, 2010). In recent years the use of 
nanopatterned substrates (NPS) has gained popularity in applications such 
as orthopaedics where Dalby’s (2007) use of nanopatterns with 
mesenchymal stem cells promoted a spontaneous differentiation into 
osteoblasts without the use of specialized media.  
Nanotopography has been increasingly used in the assessment of cellular 
adhesion, proliferation and function of stem-like and progenitor cell lines. To 
mimic the in vivo effect of pattern or pores, multiple cell types such as 
mesenchymal stem cells, fibroblasts, smooth muscle cells and endothelial 
cells have been exposed to NPS or nanopits to assess their adhesion, 
migration, differentiation and function (Yim et al 2005).  
The benefit of using a pattern over techniques such as roughness is the 






templates can be created to imprint the same pattern on multiple cell culture 
slides, making them highly reproducible.  
Cellular migration is controlled by two cues; internal phenotypic cues and 
external mechanical cues (Qian and Wang, 2010). Internal cues are usually 
governed by integrin mediated adhesions, formation of attachments (which 
includes altered actin organisation), and the ability to contract and detach 
from the substrate (Qian and Wang, 2010). While external cues pose a 
structure for the cell to grow around (as in the case of scaffolds) or constrain 
the cell culture in terms of space causing a change in cell behaviour 
(Dorcemus et al., 2017). It has been shown in various experiments with 
different cell types that cells grown on nanopatterns exhibit filopodia (Qian 
and Wang, 2010).  This is an example of internal cues causing 
conformational changes to cell structure resulting in altered cell function, i.e. 
on a molecular level.  
To illustrate deeper the molecular changes caused by patterned substrates, 
we can consider the translocation of β catenin which is a multifunctional 
protein regulating cell adhesion and gene transcription (Schernthaner et al., 
2012). Schernthaner et al., (2012) showed a difference in translocation of β-
catenin between cells cultured on flat, nano rippled and nano walled 
surfaces.  On flat polyethylene terephthalate (PET) β-catenin was mainly 
localised around cell-cell adhesions.  However, on PET surfaces with 
nanostructured foils and ripples, β-catenin was seen primarily in the nucleus 






This shows a type of molecular/nuclear activation induced following culture of 
cells on nanopatterned substrates. Taking into consideration that further 
initiation of transcriptional programs such as β-catenin is usually destroyed in 
the cytosol, and does not migrate to the nucleus if there is absence 
of Wnt signalling, it is logical to presume an activation of Wnt signalling in the 
cells grown on nanopatterned ripples, as β-catenin was found predominantly 
in the nucleus (Schernthaner et al., 2012). These are just some examples 
of the morphological and molecular changes that can be seen in an 
established culture when grown on nanopatterned surfaces.  
 
1.6.1.3.3 Nanopattern manufacturing techniques 
The two main methods of nanopatterning used today are soft lithography and 
electron beam lithography. Soft lithography is a technique that uses a 
polydimethylsiloxane (PDMS) stamp to transfer patterns by micro-contact 
printing (Qian and Wang, 2010). The surface is coated with a photoresist film 
and exposed to ultraviolet (UV) light on a silicon support. A mask can be 
applied and the photoresist dissolved leaving a master pattern around the 
original mask (Qian and Wang, 2010). At this point, functional proteins and 
molecules can be added to enrich the nano-environment for cells. This form 







Electron beam lithography (EBL) is a positive printing method that has been 
used to create ordered arrays (Vieu et al., 2000) Within this model a mould is 
produced using a set pattern and can be repeatedly used to print this pattern 
into a heated polymer. This polymer is then coated with either oxygen plasma 
or a corona surface treatment that allows cells to adhere in culture. However, 
the nanotopography of the extracellular matrix ECM in vivo is not as uniform 
or ordered as these arrays and therefore it can be hard to extrapolate 
similarities and differences between EBL topography and in vivo ECM 
conditions. This method is usually more costly than other methods, but is the 
most reproducible (Qian and Wang, 2010). 
The initial mould development is both time consuming and expensive, and 
therefore not convenient for prototype production. However, the use of pre-
existing moulds is more affordable and enables high through-put production 
(Stormonth-Darling and Gadegaard, 2012). The University of Glasgow (UoG) 
have developed a nanopattern manufacturing protocol that, once established, 
reduces the cost of electron beam lithography (EBL) and facilitates high 
throughput manufacturing of NPS using injection moulding for biological 
applications. (Stormonth-Darling and Gadegaard, 2012). This technique is 
also more reproducible and expedient than focused ion beam or laser 
ablation and provides a platform on which a variety of inlays can be used in 
different configurations to replace the need for multiple tools (Stormonth-






1.6.1.3.4 Cell types used in nanopatterned cultures 
There are many examples of different tissues which have been cultured 
successfully on nanopatterned substrates under a variety of experimental 
conditions. Using the human fibroblast h-tert cell line, Curtis et al. (2004) 
compared the orientation of cell culture on hexagonal or orthogonal patterns, 
plated in such a way that low adhesion and cell-cell interactions would not 
interfere with measurement of orientation. At 24 hours, cells grown on 
orthogonal patterns showed a disposition of 90 degree separated orientation 
while those grown on hexagonal patterns showed a 120 degree orientation 
indicating that surface pattern affects cell growth (Curtis et al., 2004). 
This work also showed that adherence to ordered NPS is low when 
compared to unpatterned planar controls (UP), while adherence to random 
patterns is not dissimilar to UP. They further demonstrated that after 24 hours 
growth on NPS, cells appear more organised as compared cells grown on 
tissue culture plastic (TCP) (Curtis et al., 2004).  
Dalby et al., (2007) used ordered and disordered nanopits to examine how 
mesenchymal stem cells (MSCs) adhere to nanotopography and whether 
surface topography could direct their differentiation toward an osteoblastic 
lineage. Their plates were embossed with nanopits of 120nm in diameter and 
100nm in depth, arranged in 5 different topographies; an ordered square 






displaced at 50nm apart, disordered square array (DSQ50), and a disordered 
array with pits displaced at 20nm apart (DSQ20) and a random placement of 
pits (RAND). Ordered nanopits had negligible effect on MSC adhesion or 
differentiation, whereas, MSCs grown on disordered nanopits displayed 
improved adhesion and differentiation in the absence of supplements that 
normally drive differentiation. MSCs grown on DSQ50 showed an aggregated 
cell population with early formation of nodules containing osteopontin (OPN) 
and osteocalcin (OCN) positive regions. Extending culture to 28 days, 
minearlization within discrete nodules was observed. It is important to note 
that cell aggregation, expression of OPN and OCN and evidence of 
mineralization was only seen on DSQ50 (disordered array with pits displaced 
at 50nm apart). To further confirm osteoblastic formation, osteospecific 
macroarrays were used to analyse mesenchymal stem cell (MSC) 
differentiation across all 5 nanotopographies. This confirmed that MSCs 
cultured on DSQ50 exhibited up-regulation of osteogenic markers required 
for osteoblast adhesion, differentiation and collagenous matrix formation. 
1.6.1.3.5 Applications of nanotopography 
Medical implant devices are now being manufactured to promote increased 
adhesion of native cell populations which will aid in patient recovery. This is 
most notably being applied in orthopaedics where implants treated with 
chemicals to induce a ‘roughness’ aid in joint replacement by promoting 






Most notably, this technique also provides the ability to assess bacterial 
adhesion to medical implants. One of the drawbacks of medical implants 
such as knee, hip and shoulder replacement namely, is the ability of bacteria 
to form biofilms which can become resistant to antibiotic intervention. It has 
been shown that using specific patterns and types of roughness can 
discourage the growth of bacteria and improves cellular adhesion of healthy 
tissue while remaining biocompatible with bone regeneration and innate 
tissue response (Jaggessar, et al., 2017).  
Nanotechnology is also useful in other areas, for example on biocompatible 
titanium in vascular stents where it reduces platelet adhesion, increases nitric 
oxide and enhances viability (Mohan et al., 2012), thus reducing the 
likelihood of late stent thrombosis sometimes seen when using unpatterned 
metallic stents. 
Other applications have included investigating the effect of nanotopography 
on cell cycle. 
Skeletal stem cells showed variation in cell cycle which affected growth and 
renewal when grown on specific patterns similar to those used in previous 
studies on MSCs (Lee et al., 2017). In this instance, transcriptomic and 
western blot analysis was used to monitor pathways involved in cell cycle 








While nanotopography shows promise in terms of regulating cellular 
differentiation, highlighting pathways involved in regeneration and in the 
advancement of medical implants, there are drawbacks with this technology.  
First, there is currently an aspect of ‘trial and error’ when assessing NPS for 
use in specific tissue. What is optimal for one cell type, may not be optimal 
for another. Introducing a new cell type requires analysis on many different 
types of nanopatterns, to investigate if changes are occurring. Secondly, 
current models operate on a 2D surface which does not completely mimic the 
highly structured 3D extra cellular matrix. These drawbacks, alongside the 
cost of producing nanotopographical substrates, will need to be overcome to 
accentuate the usefulness of this technology. 
1.6.1.3.6 Surface treatment of cell culture plates 
While nanotopography plays a key role in regulating adhesion, proliferation 
and differentiation, surface chemistry may also be important. All cell culture 
plates (NPS or TCP) are coated in some way to create an environment 
promoting cellular adhesion (Ramsey et al.,1984). Hydrophillic surfaces allow 
proteins in media to adhere to the substrate and form a layer whereby cell 
adhesion is supported. If cell culture surfaces are not treated, they remain 
hydrophobic and cells will not attach. There are two main types of surface 
chemistry, each having pros and cons for manufacture and cell growth. 
1.6.1.3.6.1 Oxygen plasma: 
One technique used to create an adhesive surface is oxygen plasma coating. 






Application of a charge across inductive electrodes produces a plasma 
yielding ozone that coats the plate. The type, or description, of oxygen 
plasma treatment is determined by wattage and time of exposure. For 
example, a plate could be treated at 40W for 30s or 80W for 60s or any 
variation of time and wattage. However, this process needs to be optimized 
for individual cell lines or applications as cellular adhesion differs from one 
cell line to another. A high wattage for a long period of time could have 
implications on the physical surface of the culture plate while a short low watt 
treatment may not be sufficient for cellular adhesion (Nedela, Slepicka and 
Svorcik, 2017). 
1.6.1.3.6.2 Corona treatment: 
A corona treatment is currently used in many industry standard tissue culture 
plates. Plates are coated on the bench using a discharge of high voltage to 
create a corona plasma that ionizes the air around a conductor. In contrast to 
oxygen plasma, both oxygen and nitrogen are used in coating plates 
(Izdebska, 2015).  
1.6.1.3.6.3 No treatment: 
It is also important to mention untreated cell culture grade plastic. Untreated 
plates are hydrophobic, and are used when adhesion is not wanted or 
necessary such as the study of cells in suspension or within microbiology 







Considering the plasticity of the HepaRG™-P cells we will assess this culture 
on a variety of NPS based on Dalby et al’s (2007) technique and prototype 
NPS. We will aim to assess whether NPS accelerates differentiation and 
maturation of HepaRG™-P cells without the addition of DMSO and compare 
to standard cultures grown on TCP.  
While some laboratories use a technique of measuring the angle of a water 
drop to assess adhesive properties of a rough or patterned surface, we will 
be assessing adhesion of cells by comparing treated vs untreated plates 
(Martines et al., 2005, Olin et al., 2013). This is again is to improve 
reproducibility and possible contamination of the model. Water angle 
measurements can be influenced by temperature, humidity, ambient airflow 
and other variables on the day of analysis. Whereas, assessing adhesive 
properties of plates is better regulated as both treated and untreated plates 
can be handled and assessed at the same time and under the same 
conditions. By growing cells on plates (treated and untreated) and assessing 
morphology and viability we will compile a more complete and reproducible 








1.6.2 New techniques: real time impedance-based assays 
1.6.2.1 Improving current models of drug toxicity analysis using a real-
time impedance-based assay 
While tissue engineering, in the form of substrate manipulation, plays a role 
in attempting to reproduce a more in vivo-like environment, it can only be 
visually assessed through changes in morphology or quantitatively assessed 
through assays. As most assays are end-point, they only provide a snapshot 
of how a drug or compound has affected the cell culture after it has been 
administered. A real time assessment of a culture before, during and after 
administration of a compound would be beneficial to informing the 
pharmaceutical industry. 
 
1.6.2.1.1 Impedance based assays 
Currently, there are a number of assays available to measure aspects of 
cellular health before and after administration of a drug or compound. Some 
are end-point assays such as the Promega Cell titer-glo™ which measures 
total ATP in total cell lysates. By comparison, non-lytic assays like 
PrestoBlue™, can be used repeatedly on the same cell culture to give an 
indication of the rate of change in cell viability through the reducing capability 
of the cell. However, PrestoBlue™ still only gives an indication of cellular 
health at specific time points in culture. At best, you can create a series of 






A high throughput, real time, label-free means of measuring the cellular 
effects of drug toxicity would be beneficial to the pharmaceutical industry as it 
would supply a way to assess the effects of new compounds in real time.  
 
The use of electrical impedance-based monitoring of cell cultures has gained 
credence within the last decade and there are now a number of systems 
available for use in toxicology and wound healing models. Impedance based 
assays are capable of giving a real time assessment of cell culture health by 
growing cells on electrodes and using a small electrical current to assess 
cellular adhesion, tight junctions and overall membrane capacitance through 
measurements of impedance.  
 
1.6.2.1.2 Electric Cell impedance sensing (ECIS) 
There are various different platforms available to measure cellular impedance 
(TEER, CNBIO, xCelligence™, CellKey™ and Bionas Discovery™). 
However, none of these systems are capable of the mathematical modelling 
and sensitivity of the AB Biosciences ECIS Zθ™. This system is capable of 
measuring total impedance over time and then deconvolving this data into 
biologically relevant components measuring specifically: tight junctions (Rb), 
adhesion (α) and overall membrane integrity (Cm). This is achieved by 
measuring impedance on a multiple frequency setting which can identify the 
different pathways the current can take. By alternating the frequency of the 






there are gaps within your cell culture. At 10kHz and below, the current flows 
under and in between the cells. This allows for a measurement which 
indicates how well cells have adhered to the substrate as well as a 
measurement of cell-cell interaction or tight junctions. At higher frequencies, 
>40kHz, the current moves through the cells which exposes any compromise 
of cell membrane integrity as well as giving an indication of intracellular 
processes (Wegener, Keese & Giaver, 2000, Giaver & Keese, 1991).  
One consideration when analysing ECIS data is sensitivity. While this is a 
benefit, one must be aware that changes in temperature, pH, media 
composition and even the opening of the incubator door will appear as 
background noise or disruption of impedance. However, this level of 
sensitivity can be very beneficial in terms of providing insight into a number of 
variables in culture and could inform drug testing in terms of time of 
toxicological event and also indicate where a pathway of damage is occurring 
(eg. total impedance, TJ, adherence, or over all membrane capacitance) 
 
The ECIS model first reported by Nobel prize laureates Ivor Giaever and 
Charles Keese (1984) is a real-time, non-invasive, label free method of 
monitoring cell behaviour throughout the course of an experiment. Through 
their particular mathematical modelling of impedance, it is possible to render 
a measurement of cellular confluence and detect motion on the ECIS gold 
electrode array (Giaever and Keese, 1984) (Figure 1.5). This gives the 






addition of a substance or introducing a wounding assay, and recording and 
monitoring the outcome in real time.  
Within the ECIS model, cells are grown on a gold electrode through which an 
alternating current (AC) at a low voltage (V) of 1V is applied through a series 
resistance of 1MOhm to produce a small non-invasive current of 1microAmp. 
Impedance is the measurement of the resistance of this alternating electrical 
current as it meets opposition, caused in this case by the cell membrane 
acting as an insulator (Giaever and Keese, 1984). As cells grow to 
confluency, this increases the impedance of the low AC current (Figure 1.6). 








Figure 1.6: Schematic representation of current flow from ECIS Z theta 
system. Large scale representation of AC current flow within the ECIS theta 
system with magnification of cells grown on electrode. Cells are grown on 
working electrodes through which AC current flows under working electrode. 
AC current can flow under cells showing; adhesion (α), through cell 
membrane showing capacitance (Cm), and between tight junctions of cells 
(Rb). Alterations in current can give an indication of these three parameters 









Changes in impedance are then measured in real time giving a graphical 
read-out of impedance versus time. This measurement of total impedance in 
Ohms can then be deconvolved to give a prediction of the flow of current 
between cells (tight junctions/Rb), under cells (membrane capacitance/Cm) 
and through cytoplasm (transcellular current/alpha). Impedance 
measurement has been used in a variety of ways and is a very simple 
indicator of confluence and health of a cell culture. Any variance to the 
culture which causes injury or death to the cells is immediately visible as a 









Figure 1.7: Graphical example of measurement of impedance over time. 
This graph shows a low baseline of impedance just after seeding of cell 
culture and how impedance rises as cells become more confluent. Once cells 
are spread over an electrode the impedance measurement plateaus 
indicating confluency and cell synchronization (Figure reproduced with 







Figure 1.8: Graphical example of loss of impedance due to addition of a 
compound Graphical representation showing impedance over time where 
total impedance rises to plateau before the addition of drug/compound. After 
addition of a drug or compound a drop in impedance can be measured and 
interpreted as a disturbance of electrical current caused by changes or 
damage to cell culture. (Figure reproduced with permission from the author 









ECIS can simultaneously monitor cell adhesion, tight junction integrity, and 
overall cell membrane integrity, this offers a comprehensive, non-invasive, 
depiction of cellular integrity that cannot currently be accomplished by other 
impedance-based assays.  
Other applications of this system include the ability to reversibly permeabilize 
the cell membrane using a small electric field which causes electroporation 
(Stolwijk et al., 2011). This can be useful when delivering molecules into the 
cytoplasm of living cells. As this process is reversible, it can then trap 
compounds or molecules within the cell. Since this is a real-time model, the 
cell can be monitored before electroporation, during and after, providing an 
initial baseline before treatment and allowing post treatment monitoring. 
 
1.6.2.1.3 ECIS tissue cultureware 
A variety of tissue culture wells can be purchased to give flexibility to 
experimental design and offer various ways to use the ECIS system to 
monitor different cellular processes. Arrays are available with either one 
50nm gold electrode per well or multiple 50nm electrodes per well and are 
treated with oxygen plasma. Cells are seeded directly onto the wells 
containing the electrodes. The number of cells that can be observed at one 
time is limited to the size of the electrode (Xiao and Luong, 2003). As cells 






the current cannot take a path of least resistance between, under or through 
cells. Once cells become confluent, the impedance measurement plateaus. 
Once a reproducible and stable plateau is recognized through repeated 
experimentation, it can be used as a benchmark for further analysis eg. effect 
of addition of drugs.  
 
1.6.2.2 Using ECIS to investigate and illustrate drug toxicity 
Previously published work from our laboratory, measuring total impedance 
with ECIS technology, has shown a dose-dependant response in 
HepaRG™cells following exposure to the model hepatotoxin paracetamol 
(APAP) (Gamal et al., 2017). Within that study HepaRG™ cells were grown 
on ECIS 8 well 10+ electrode plates and monitored for 8 days. On day 8 
APAP was added to the culture and total impedance was monitored. A dose 
dependant response emerged and further deconvolution of data showed that 
the parameter of tight junctions/Rb (TJs) was most effected by APAP. This 
prompted further investigation into the possible mechanisms behind APAP 
toxicity.  
Here, the aim is to use the published HepaRG ™/ECIS model, with a 
prototype cholestatic drug, chlorpromazine (CPZ). We will use this model to 
determine if the impedance signature will be the same when cholangiocytes 
are the main target of toxicity. It is hoped that in modelling two hepatotoxins, 
each with a distinct mechanism of toxicity, that a pattern may start to emerge 






Chlorpromazine was chosen in the first instance because it is an 
antipsychotic drug known to cause intrahepatic cholestasis in a short period 
of time. Cholestasis is a condition characterized by an impaired ability of the 
bile ducts to secrete bile acids, bilirubin and cholesterol (Antherieu et al., 
2013). There is currently a need within the pharmaceutical industry to predict 
cholestasis in vitro before drugs are taken to pre-clinical trials. CPZ has long 
been used as an in vitro model of cholestasis as there is evidence that CPZ 
causes impaired biliary function, though the mechanisms behind this are not 
fully understood (Antherieu et al., 2012, Akerboom et al., 1991, Zimmerman 
and Lewis 1987, Moradpour et al., 1994 and Castell et al., 1996). Using the 
HepaRG™ cell line with its intrinsic co-culture of hepatocytes and 
cholangiocytes will offer a unique advantage in elucidating the effect of CPZ 
on both cell populations (Bachour-El Azziz, P et al., 2015). Understanding the 
mechanisms behind CPZ toxicity may also provide insight into studies of 
other xenobiotics that are also known to target the biliary 







Aims of the thesis 
 
1.7 Aims 
1. To compare the human hepatic C3A cell line to the co-culture 
HepaRG™ cell line in terms of CYP induction and inhibition, 
capabilities of phase I and II metabolism and integrin expression to 
determine which cell line is most suitable for use in an in vitro drug 
toxicity testing context. 
2. As there has been evidence to show roughness and patterns on cell 
surface substrate contributes to differentiation and alter cellular 
behaviour, it was our aim to assess whether seeding HepaRG™-P 
cells onto NPS accelerates differentiation and maturation into 
hepatocytes or whether they behave differently compared to those 
grown on industry standard Corning, tissue culture plastic (TCP). 
3. To demonstrate a real-time impedance-based assay using a model 
cholestatic drug to investigate the usefulness of this technique for 














Chapter 2 Materials and Methods 
This chapter will look at general materials and methods that are used 
throughout the thesis. Specific materials and methods will be outlined in 
future chapters. 
2.1 Chemicals 
Chlorpromazine (CPZ, C8138, Sigma-Aldrich, Dorset, UK) was stored at 
room temperature. A stock of 100mM in PBS buffer was prepared and stored 
at -20°C in aliquots. CPZ dilutions were made in HepaRG™ Maintenance 
and Metabolism Medium (MMM, ADD620, Biopredic International, Rennes, 
France) according to established dilutions by Antherieu et al., 2013.  
 
Phenacetin (77440, Sigma-Aldrich, Dorset, UK) MW 179.2Da was stored at  
-20°C. A stock of 1mg/ml was made in methanol (MeOH, 322415, Sigma-
Aldrich, Dorset, UK) and this was prepared fresh for every experiment as it 
was used for LC:MS/MS calibration and degradation could not be risked. 
 
Omeprazole (O104-100mg, Sigma-Aldrich, Dorset, UK) MW 345.32. Dilutions 
were made in 100% DMSO to concentration of 50mM and aliquots were 







Rifampicin >97% HPLC powder (R3501-1g, Sigma-Aldrich, Dorset, UK) MW 
822.94 was stored at -20°C in aliquots of 50mM diluted in 100% DMSO. A 
final stock concentration of 50µM was made in media. 
 
Fluvoxamine maleate (F2802-10mg, Sigma-Aldrich, Dorset, UK) Dilutions 
were made in 100% DMSO and 25mM aliquots were stored in -20°C. A final 
stock concentration of 25µM was prepared in media. 
 
Ketoconazole (K1003-100mg, Sigma-Aldrich, Dorset, UK) MW531.43 
Dilutions were made to final stock concentration of 25mM in 100% DMSO 
and aliquots were stored in -20°C. Final concentration of 25µM was prepared 
in media. 
 
2.2 Cell culture 
2.2.1 C3A cells 
C3A cells (CRL-10741™, ATCC®, Manassas, USA) derivative of HepG2: 
were cultured on Corning plates in Minimum Essential Medium Eagle (with 
Earle’s salts and L-glutamine, without sodium bicarbonate, MEME+, MO268, 
Sigma Aldrich, Dorset, UK – 10x1L) with 10% fetal bovine serum (FBS, Life 
Technologies, Paisley, UK) and 1% penicillin/streptomycin (pen/strep, 
15140122, Life Technologies, UK). The culture was maintained at 37°C in 






Media was prepared by adding a vial of 1L MEME to sterilized water and 
adjusting pH by adding 2.2g of Sodium Bicarbonate (S6297, Sigma-Aldrich, 
Dorset, UK). Media was then sterile filtered under the hood before adding 
FCS and penicillin/streptomycin. 
2.2.1.1 Trypsinisation 
C3As were trypsinized for passage and replating weekly. Trypsinisation was 
performed as below. 
Cells were passaged in T75 flasks. Supernatant was removed and cells were 
washed in 4ml Hanks Balanced Saline Solution (HBSS, 14025092, 
ThermoFisher, Massachusetts, USA). Trypsin EDTA (25300054, 
ThermoFisher, Massachusetts, USA) 5ml was added to the flask and cells 
were incubated in 37°C 5% CO2 for 5 minutes. The reaction was stopped by 
adding 5ml MEME and cells were transferred to 20ml universal and spun for 
3 min on a Sigma 4K15 Laboratory centrifuge at 500 RPM. After 
centrifugation, supernatant was removed and cells were resuspended in 
5ml MEME.  
2.2.1.2 Cell counting 
15µL of C3A cell suspension was taken and added to 15µl trypan blue 0.4% 
(T10282, Invitrogen, California, USA). Using an Invitrogen Countess™ 
automated cell counter, cells were counted twice and an average taken for 






and kept at 37C 5% CO2 for duration of culture. Medium was changed every 
other day.  
 
2.2.2 HepaRG™ Cells 
2.2.2.1 HepaRG™ Progenitors (HepaRG™-P) 
Progenitors were initially cultured in medium consisting of William’s E 
Medium + GlutaMAX™ (32551-020, Life Technologies, Paisley, UK) and 
Biopredic’s proprietary 711 Medium without Dimethylsulfoxide (DMSO,85190, 
Pierce™, ThermoFisher, Massachusetts, USA) HepaRG™-Ps were cultured 
in this medium for 14 days (with media changes on Mondays, Wednesdays 
and Fridays) before changing to William’s E + GlutaMAX™ and Biopredic’s 
proprietary 721 medium with DMSO. It was necessary to culture HepaRG™-
Ps in DMSO-free medium for the first two weeks to ensure a healthy culture 
that proliferated and grew to confluence before switching to a medium 
containing DMSO which was required for sustaining the differentiation stage 
of HepaRG™-P development. 
2.2.2.2 HepaRG™ fully differentiated cells 
HepaRG™ fully differentiated cells were plated in Biopredic’s proprietary 
General Purpose Medium (GPS) without DMSO for up to 2 days. Since 
traditional HepaRG™s are terminally differentiated it was necessary to 
provide a medium containing DMSO earlier for this culture than the 






changed to Biopredic’s proprietary Metabolism Maintenance Medium (MMM) 
containing DMSO. Here DMSO continues to support the fully differentiated 
state of the HepaRG™ cell throughout the life of culture.  
2.3 Immunocytostaining 
Immunocytostaining was performed identically for all cell cultures and 
experiments unless otherwise specified in relevant Chapter. Cells were 
washed with Tris-Buffered Saline (TBS) (TBS; T6664; Sigma-Aldrich, Dorset, 
UK) for 2 minutes prior to fixation in 4% formaldehyde (28908, Thermo 
Scientific, Massachusetts, USA) at 4°C for 1 hour. Cells were again washed 
with TBS and then permeabilized with 0.1% Triton X 100 (85111, 
ThermoFisher, Massachusetts, USA) for 30 minutes. Following a further TBS 
wash samples were blocked with 5% goat serum (G6767; Sigma-Aldrich, 
Dorset, UK) for 1 hour. Primary antibody was then added and incubated at 
4°C overnight (Table 2), after which, cells were washed on a shaker in TBS 
for approximately 20 minutes and then washed again briefly before adding 
secondary antibody, Hoescht and phalloidin. Secondary antibody incubation 







2.3.1 Primary antibody staining 
Primary Antibody Catalogue 
Number 
Dilution 
Z0-1 Santa Cruz Rabbit polyclonal primary 
antibody 
SC 10804 1:50 
HNF4α, monoclonal mouse, Abcam 
Cambridge, UK 
Ab41898 1:1000 
SOX9 Santa Cruz Rabbit polyclonal 
antibody 
SC20093 1:500 
Rabbit-anti-Transferrin FITC –primary 
antibody, abcam, Cambridge, UK 
Ab34670 1:200 
CYP3A4 primary antibody, Merck, Millipore 
Darmstadt, Germany 
Ab1254 1:500 
Anti- Carbamoyl phosphate synthetase 
(CPS) monoclonal mouse mAb primary 





Anti-Glutamine synthetase Rabbit primary 
antibody Sigma Aldrich, St Louis Missouri, 
USA 
G2781 1:1000 
Table 2: Dilutions of primary antibodies – Name, product number and 








2.3.2 Secondary antibody staining 
Secondary antibody goat-anti-rabbit Alexa Fluor 488 (11034, Life 
Technologies, UK 1:1000 dilution) was used for green fluorescent protein 
(GFP) and Alexa Fluor 555 (A31630, Life Technologies, UK, 1:1000 dilution) 
was used for red fluorescent protein (RFP) were combined with Hoescht 
33342 (HS1492; Life Technologies, UK, 10µg/mL) and Phalloidin-TRITC 
(R415; Life Technologies, UK, 3 U/mL 1:200 dilution). 
2.4 Microscopy 
All phase and fluorescent imaging was performed with an EVOS Auto FLO™ 
imaging platform (Thermo Scientific, Massachusetts, USA). Image 
magnification is specified on a figure by figure basis. 
2.5 General assays 
2.5.1 PrestoBlue™- resazurin based assay 
PrestoBlue™ 10% (v/v) (A-13262; Life Technologies Paisley, UK) was added 
to Phosphate Buffered Solution with calcium chloride and magnesium 
chloride (PBS +)(D8662, Sigma Aldrich, Dorset, UK, 500ml) in a 1:10 
solution. Cells were washed with PBS+ prior to addition of 100µl 
PrestoBlue™ suspension. Cells were then incubated for 30 minutes at room 






fluorescence signal on a GloMax-Multi™+ Microplate Multimode Reader 
(Promega, Southampton, UK)(Boncler et al., 2014). (Further optimisation of 
the PrestoBlue™ assay can be found in Chapter 7 Supplementary data) 
2.5.2 Promega CYP450-3A4 assay 
CYP3A4 activity was measured using the Promega P450-Glo™ CYP3A4 
assay with Luciferin-IPA (V9001; Promega; Southampton, UK).  
C3A and HepaRG™ cells were incubated in situ on the plate at 37°C for 24 
hours with testosterone and prototypical inducer rifampicin or rifampicin and 
ketoconazole. Cells were washed twice with HBSS and 50µl 3A4 substrate 
diluted 1:100 in media. Supernatant was transferred to a white walled/bottom 
plate and 50µl of 3A4 detection agent added. After a further 10-15 min 
incubation at room temperature fluorescence was read on the GloMax-
Multi™+ Microplate Multimode Reader (Promega, Southampton, UK) using 
the pre-loaded program designed specifically for this kit.  
2.5.3 Luciferin based assays 
Luciferin based assays are used routinely to measure specific cytochrome 
P450 activity and other cellular components such as ATP. Luciferins are 
luminescent proteins derived from various species. In this case, Promega 
sources luciferins derived from beetle luciferin. The assay is based on a 
proluciferin substrate of the specific CYP enzyme which is to be measured. 
Once the substrate is added to the cell culture, it binds specifically to the 






addition of Luciferin Detection Agent. This reaction creates a signal that can 
be read and measured, by a plate reader, where light produced is 
proportional to CYP activity. Here we use this method to assess CYP1A2, 
3A4 and also for quantification of total ATP.  
 
2.5.3.1 Promega CYP450-3A4 assay 
CYP3A4 activity was measured using the Promega P450-Glo™ CYP3A4 
assay with Luciferin-IPA (V9001; Promega; Southampton, UK).  
C3A and HepaRG cells were incubated in situ on the plate at 37°C for 24 
hours with testosterone and prototypical inducer rifampicin or rifampicin and 
ketoconazole. Cells were washed twice with HBSS and 50µl 3A4 substrate 
diluted 1:100 in media. Supernatant was transferred to a white walled/bottom 
plate and 50µl of 3A4 detection agent added. After a further 10-15 min 
incubation at room temperature fluorescence was read on the GloMax-
Multi™+ Microplate Multimode Reader (Promega, Southampton, UK) using 
the pre-loaded program designed specifically for this kit.  
2.5.3.2 Promega CYP450-1A2 assay 
CYP1A2 was measured with Promega P450-Glo CYP1A2 assay and 
screening system using Luciferin-ME (V8771; Promega; Southampton, UK) 
C3A and HepaRG cells were incubated for 24 hours at 37°C with phenacetin 
and prototypical inducer omeprazole or omeprazole and inhibitor 






Luciferin detection agent was added to the cells for 20 minutes incubation at 
room temperature before transferring to a white walled plate for reading using 
the GloMax-Multi™+ Microplate Multimode Reader. 
2.5.3.3 Promega Cell titer glo – total ATP assay 
PrestoBlue™ and ATP assays were always carried out on the same culture 
so data could be directly comparable. 
Post PrestoBlue™ experimentation, supernatent was discarded, and cells 
rinsed with PBS before addition of Promega Cell Titer Glo™ ATP lysis buffer 
to determine total cellular ATP levels using the CellTiter-Glo™ Luminescent 
Cell Viability Assay (G7570; Promega, Southampton, UK), as per vendor’s 
instructions. Briefly, incubation in substrate at room temperature for 20 
minutes was followed by adding ATP detection solution and bioluminescent 
signals were detected with the on a GloMax-Multi™+ Microplate Multimode 
Reader (Promega, Southampton, UK). ATP levels were normalized to no cell 
control. 
2.5.4 Induction assays for C3A and HepaRG™ cells 
When comparing CYP activity in HepaRG™ and C3A cells, it was decided 
that each culture should be induced with drugs known to instigate specific 
CYP isoform activity. For example, phenacetin is a known substrate of 
CYP1A2. Therefore, exposing cells to phenacetin should instigate CYP1A2 
activity. We chose phenacetin and testosterone to act as substrates to 






C3A cells derivative of HepG2: were cultured on Corning plates in Minimum 
Essential Medium Eagle (MEME) with 10% FBS and 1% 
penicillin/streptomycin. The culture was maintained at 37°C 5% CO2 until 
~80% confluent. HepaRG™ cells (terminally-differentiated cells, Biopredic 
International, Rennes, France) were seeded (following the suppliers 
protocols) on Corning plates and cultured to confluence at 37°C 5% CO2 for 
7 days. 
Cells were treated for 24h with prototypical inducers 50µM omeprazole 
(CYP1A2) or rifampicin (CYP3A4), with or without addition of CYP450 
isoform-specific specific inhibitors 25µM Fluvoxamine (CYP1A2) or 
Ketoconazole (CYP3A4), in MEME (C3As) or hepatocyte induction medium 
(HIM, Biopredic, Rennes, France). Cells were then washed twice with HBSS. 
Specific CYP450 enzyme activity was subsequently assessed using a non-
lytic luminescence assay using specific kits for CYP1A2 and CYP3A4, 
following the manufacturer’s instructions (P450-Glo™, Promega, 
Southampton, UK). Bioluminescent signals were detected with a GloMax-
Multi™+ Microplate Multimode Reader. Individual luminescent assay 
readings were background-corrected and normalized to cellular ATP content. 
2.6 Molecular assessment for genes of interest 
2.6.1 RNA extraction 
Where stated, RNAlater™ (AM7201, ThermoFisher, Massachusetts, USA)  






RNA was extracted with Life Technologies RNAqueous™ Total RNA 
Isolation Kit (AM1912, Life Technologies, UK). Cells were scraped in situ in 
NPS and transferred into Eppendorf tubes where they were spun (3min at 
10,000rpm) into a pellet. Supernatant was removed and cells were then lysed 
in the Eppendorf tube with lysis binding solution (64% ethanol/water) and 
immediately transferred into provided collection tubes with filter cartridge. 
Cells were spun as per before. Wash solution 1 was added (700µl) and 
collection tubes were spun again. A further two wash steps using 500µl 
Wash Step 2/3 solution were performed before eluting samples. Filter 
cartridge was transferred into new collection tube for elution step. Elution 
solution was heated to 75°C and 50µl was added to each filter cartridge and 
tubes spun as before. This step was repeated. 5µl samples of recovered 
mRNA were assessed for quantity and quality. The remaining samples were 
stored at -80°C until reverse transcription was performed. 
RNA quality was assessed using A Grant NanoDrop™ ND-1000 
Spectrophotometer which measures absorbance at 260 and 280nm. A ratio 
of 2 is considered to be uncontaminated with genomic DNA and of good 
quality/purity. Our total RNA samples showed high quality on nanodrop 
technologies i.e. (260/280 ratios: 1.8-2.0). However, for cells grown on NPS, 
the quantity of mRNA was relatively low. For this reason, when considering 








2.6.2 Reverse transcription (cDNA synthesis) 
Reverse transcription for both NPS experiments and CPZ experiments was 
carried out using Primer Design Precision nanoScriptTM 2 Reverse 
Transcription (Primer Design, Cambridge, UK) kit following manufacturers 
instructions. The following reagents were added to a 0.2ml DNAse and 
RNAse free PCR tube; Reverse transcription oglio-DT primer (1µl), RNA 
template (varied from 2-9µl due to concentration of RNA), and water (as 
needed to make final volume of 10µl). Samples were heated to 65°C for 5 
minutes. In all cases RNA was kept as concentrated as possible to ensure 
optimal reverse transcription. Tubes were then transferred to ice for addition 
of extension master mix which comprised 5µl nanoscript 2 buffer, 1µl dNTP 
mix 10mM, 3µl RNAse free water and 1µl nanoscript 2 enzyme. Tubes were 
incubated at 42°C for 20 minutes before a 10 minute heat inactivation at 
75°C. Samples were stored at -20°C. 
 
2.6.3 Quantitative Polymerase Chain Reaction (qRT-PCR) 
cDNA samples throughout were diluted to 5ng/µl, for normalisation, and qRT-
PCR was performed using Primer Designs Precision® PLUS Master Mix 
(Primer Design, Cambridge, UK) for real-time PCR. Each sample comprised 






Primer/Probe mix (1µl) and RNAse/DNAse free water (4µl). Samples were 
run in 96 well format using a Roche Light Cycler 96. As we used a SYBR® 
Green detection our qRTPCR steps were as follows; enzyme activation 2 
mins/95°C, denaturation 10s/95°C, data collection 60s/60°C. Data was 
analyzed using qBase+ (Biogazelle geNorm software Ghent, Belgium).  
2.7 Statistical Analysis 
Data evaluation and graphical illustration were performed with GraphPad 
Prism™ 5.0 and 7.0 (GraphPad Software, Inc., San Diego, CA, USA). Three 
technical replicates were assessed for each experimental condition across 
three separate experiments, unless stated otherwise, and results are 
presented as mean ± SD. Appropriate statistical analysis was performed for 
each experiment including one way ANOVA, t-test, multiple ANOVA and post 
hoc Tukey test, each detailed in individual chapters. Results were considered 









Chapter 3 Human hepatic HepaRG™ cells 
maintain an organotypic phenotype 
with high intrinsic CYP450 
activity/metabolism and 
significantly outperform standard 
HepG2/C3A cells for pharmaceutical 








As mentioned previously, PHHs have been regarded as the gold standard in 
in vitro models. However, they represent an isolated cell (hepatocytes only), 
are difficult to obtain, usually come from an already damaged liver, and 
introduce variability in experimental testing due to phenotypic differences 
between donors. PHHs are also limiting in that they only survive in a fully 
differentiated state for a few days in culture.  
One of the most frequently used cell lines are the HepG2 derived C3A cells. 
This cell line contains only isolated hepatocytes. It has been shown in 
previous studies, that when compared to PHHs, C3A cells show low CYP 
enzyme activity (Castell et al., 1996). For this reason, C3As often need to be 
manipulated to produce adequate CYP450 enzymes. (Filippi et al., 2004, 
Elkayam et al., 2006, Prot et al., 2011, Lu and Cederbaum, 2008) 
In contrast, the HepaRG™ cell line has been shown to express significant 
basal levels of CYP activity compared to C3A and PHHs (Grime, Ferguson 
and Riley, 2010, Antherieu et al., 2012).  
This co-culture, with cholangiocyte-like cells and bile duct formation 
alongside fully mature and functional hepatocytes offers a unique opportunity 
to assess the interaction of two key liver cell types at a time providing a 
model more comparable to in vivo studies (Antherieu et al., 2012, Gripon, et 






DILI could aid pharmaceutical companies in initially identifying compounds 
less likely to fail in moving from in vitro to in vivo animal and human pre-
clinical models. Such a model could also improve/inform pre-clinical trials 
while reducing the need for animal testing in line with government 
regulations. A hepatic cell line, such as the HepaRG™, comprising more than 
one liver cell type, that expresses CYP enzymes at levels comparable to 
PHHs, if proven, has the potential to provide a valuable platform for in vitro 
pharmacological testing. There is currently limited information directly 
comparing these cell lines. For this reason, we compare the CYP450 activity, 
induction and inhibition and metabolic competency of HepaRG™ and C3A 
cell lines.  
 
3.1.1 Aims 
To compare the metabolic strengths and weaknesses of both the HepaRG™ 
and the C3A cell line by evaluating their ability to  
1. Metabolise phenacetin and testosterone and analyse which cell line is 
most competent in elimination of compounds. 
2. To compare CYP450 activity between the two cell lines and in parallel, 
CYP450 inhibition in response to phenacetin and testosterone.  
3. To assess and compare levels of integrin expression in C3A, 






HepaRG™ cells as a marker in defining maturity and polarity of cells in 
culture. 
Rationale: To make a direct comparison between C3A and 
HepaRG™ cells to determine which cell line would be most 
appropriate as a model in future DILI studies. 
 
 
3.2 Materials and Methods 
The inducibility of CYP activity in C3A and HepaRG™ cells alongside 
inhibition of the same pathways were assessed to highlight functionality of 
each cell line. Cells were challenged with testosterone and phenacetin, 
known to be metabolized by CYP3A4 and CYP1A2 respectively, to assess 
metabolic competency. Primary and secondary steroid and drug metabolites 
were identified using liquid chromatography and tandem mass spectrometry 
(LC:MS/MS) and high performance liquid chromatography (HPLC). Further 
inhibition with ketoconazole and fluvoxamine was used to confirm specificity 
of induction and analyse how each cell type would respond to treatment. 
Finally, flow cytometry was used to compare integrin expression between 
C3A and HepaRG™ cell lines to determine maturity of the hepatic phenotype. 








In order to assess the CYP1A2 or CYP3A4-specific metabolic activity 
HepaRG and C3A cells were exposed to 50µM phenacetin (CYP1A2) or 
testosterone (CYP3A4) for 24 hours at 37°C. Reactions were stopped on ice, 
and supernatant of samples stored at -80°C and transferred for assessment 
via HPLC (testosterone) or LC-MS/MS (phenacetin). 
3.2.1 Induction/Inhibition of CYP enzymes 
Both C3A and HepaRG™ cells were treated for 24 hr with prototypical 
inducers 50µM omeprazole (OMP) (CYP1A2) or rifampicin (RIF) (CYP3A4), 
with or without the addition of CYP450 isoform-specific inhibitors 25µM 
fluvoxamine (FLUVOX) (CYP1A2) or ketoconazole (KETO) (CYP3A4) 
Compounds were added to media for the duration of incubation (in MEME for 
C3As or hepatocyte induction medium for HepaRG™s) 
The cells were then washed twice with HBSS. Specific CYP450 enzyme 
activity was subsequently assessed using a non-lytic luminescence assay 
using specific kits for CYP1A2 and CYP3A4, following the manufacturer's 
instructions (P450-Glo, Promega, Southampton, UK). Bioluminescent signals 








3.2.2 Liquid chromatography with tandem mass spectrometry 
Phenacetin metabolism was assessed using an ABI Applied Biosystems 
5500 QTrap Mass spectrometer and AB Sciex software, Analyst 1.5.1; and 
LightSight software to identify metabolites.  
This instrument was chosen as it is a triple quadrupole mass spectrometer 
which includes an ion trap. This allows for a qualitative 
measurement/identification of metabolites. Metabolites can also be quantified 
as a percentage of the parent molecule, but as the metabolic fate of 
phenacetin was unknown in context of hepatocyte cell line metabolism, we 
focused on the specific capability of the instrument to identify metabolites via 
MS/MS. 
Initially samples were fractionated within the HPLC column before 
identification and quantification by the mass spectrometer (MS) which 
separates ions on the basis of their mass to charge ratio (m/z). This happens 
within the Q1 chamber of the mass spectrometer. Ions are then moved into 
the Q2 chamber where collision energy is applied and the ions are further 
disassociated. Ions then move into the final Q3 chamber where they are 
separated a second time on the basis of their mass to charge ratio. The 
identification of ions at Q1 and Q3 based on their m/z ratio incorporates 
tandem mass spectrometry readings or MS/MS. This technique is well suited 
to the aims of this project because the ions that we are setting out to identify 






Initially, we looked for phenacetin with a known molecular weight of 179.2 
Daltons (Da). The LC-MS/MS was tuned using a standard solution of the 
parent ion phenacetin as this has a known, and unique, m/z ratio. The 
phenacetin standard was made up to 1mg/ml in MeOH. (0.0057g phenacetin 
in 5700µl of MeOH). The 1mg/ml stock solution was then serially diluted 1 in 
10 in methanol to a final dilution of 1:1000. Methanol is easily removed from 
the solution by evaporation during flight through the MS-MS, increasing the 
ratio of analyte to solvent, meaning the analyte should ionize more readily 
Samples were directly injected into the instrument in Electrospray ionization 
(ESI) mode. The machine was calibrated to identify molecular ions in the 50-
200 Da range as the phenacetin ion has an m/z of 180.1 and was detectable 
either as a singly or doubly charged species. 
A base line for paracetamol and its metabolites was generated using a 10µg 
paracetamol control and, as a source of paracetamol metabolites, a sample 
of urine (10µl) collected from a patient administered paracetamol. Acuity 
HPLC system and Light Sight software was used to collect and interpret the 
data.  
Experimental samples analysed included 7 Controls; untreated C3A or 
HepaRG™, 3 samples in duplicate of phenacetin treated HepaRG™ cells and 
3 samples in duplicate of phenacetin treated C3A cells. Using data generated 
from the phenacetin standard and the baseline of human urine for 






Phase ll metabolites of phenacetin. Control data was used to exclude 
background noise from untreated cells and media from experimental results. 
Samples were stored at -20ºC until use, when they were defrosted at room 
temperature for one hour. They were prepared for liquid chromatography by 
pipetting 200µl into an eppendorf tube and adding 200µl of acetyl nitrile to 
precipitate proteins, which were removed by centrifugation at 6000rpm for 5 
minutes.100µl of supernatant was transferred to LC vials for analysis. 
Samples ran on 10 minute cycles, and a Carbon 18 solid phase column was 
specifically used for its ability to separate metabolites into separate peaks. 
Results were evaluated using Light sight metabolite I.D. software. HPLC 
excluded material outside the chosen molecular weight (MW) boundaries, 
and molecules of MW 50-200kDa passed into the MS-MS. 
An AB SCIEX Q Trap 5500 LC-MS/MS was used to process the samples. 
The machine was calibrated and prepared for use by flushing tubes and 
syringes with a weak H2O solvent. The temperature was set at 20°C and a 
mobile phase solvent was prepared using 65% H2O and 35% MeOH. 
 
3.2.3 HPLC 
Samples for HPLC were mixed with the internal standard (20 µg/ml 11 α- 
hydroxyprogesterone in methanol) and extracted with dichloromethane 
before they were resuspended in 30% MeOH and analysed by Dr Philipp 
Treskes and Dr Helen Grant with an Eclipse XD8-C18 3 µm 3 x 100mm 








3.2.4 Polymerase chain reaction 
C3A and HepaRG ™cells from one well of a 6 well plate were scraped in cold 
PBS and aliquoted in RNAlater for further RNA extraction. Aliquots were then 
stored in -80°C. RNA extraction was performed as per section 2.6.1 in 
Chapter 2. 
The concentration of RNA obtained from both fresh and stored cells was 
nearly 100ng/µl, with a 260/280 ratio 2.03 for a total of 3µg. Concentration of 
DNA was 50ng/µl, 260/280 ratio was 1.82 for a total of 1.5µg.  
Samples collected from above were electrophoresed on a 1.5% agarose gel 
and run for up to 30 minutes. Gel was exposed to UV light and picture was 
taken with gel documentation system. 
3.2.5 Flow Cytometry 
Integrin expression was compared in C3A, HepaRG™ P and fully 
differentiated HepaRG™ cell lines. This allowed assessment of integrin 
expression in C3A cells, known to express foetal markers (eg alpha-
fetoprotein), with both the HepaRG™ P (hepatoblast-like) progenitors, and 
their derivatives (HepaRG™), as comparators. To assess expression of 
integrins, single cell suspensions were enzymatically recovered using xeno-
free Tryple (Life Technologies) – which protects cellular surface proteins, 






albumin (BSA) and 0.1% sodium azide), for simultaneous staining with a 
panel of fluorochrome-labeled integrin antibodies: CD29-BV510, CD49f-
BV451, CD49d-FITC, CD49c-PE, CD49a-APC-Vio770, CD49b-PE-Vio770, 
CD49e-APC, (all Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were 
incubated with antibodies at 4ºC for 20min, washed twice and re-suspended 
in FACS-PBS. Unstained cells were included as controls, whilst dead cells 
and debris were excluded from the analysis based on scatter characteristics. 
Data for at least 10,000 live events per sample were acquired using a 
MACSQuant Analyzer (Miltenyi Biotec) and was analyzed using FlowJo 
version 9.6.7 software (FlowJo LLC). Data is presented as percentage 
positive staining. 
3.2.6 Statistical analysis 
Differences between the different culture conditions (with or without 
treatment) were detected applying a one way Anova. Results were 








3.3.1 Presence of CYP enzymes confirmed by 
immunocytostaining and PCR 
Phase microscopy showed that both HepaRG™ and C3A cultures were 
healthy and had grown to desired threshold of confluency before 
experimentation.  
HepaRG™ cells formed terminally-differentiated in vivo-like hepatic cords and 
cholangiocyte-like cells (Figure 3.1 A). C3A cells were grown to 80% 
confluence as per manufacturers instruction (Figure 3.1 B) Functional 
polarity can be seen in the HepaRG™ culture as evidenced by punctate 
staining of F-actin bands indicative of bile-canalicular structures [phalloidin-
staining] and showcased a level of CYP3A4 indicated in GFP staining 
(Figure 3.1 C). C3A cells were also stained with F actin and CYP3A4 
antibody. However, this culture lacks the cholangiocytes seen in HepaRG™s 
and shows little to no presence of CYP3A4. (Figure 3.1 D) In contrast, high 
CYP3A4 activity with strong expression of CYP2E1, CYP1A2, and CYP3A4 
genes, was evident only in HepaRG™; indicative of high metabolic 









Figure 3.1 Morphological and phenotypic assessment of HepaRG™ vs 
C3A cells A) Phase contrast microscopy of HepaRG™ cells showing bile canaliculi 
indicated by yellow arrows and hepatocyte islands indicated by H. Population of biliary cells 
with endothelial morphology indicated with B. B) Phase contrast microscopy of C3A cells 
showing a near confluent culture of purely hepatic cells. Immunostaining of F-actin 
cytoskeleton (Red), nuclei (blue) and CYP3A4 (green) for HepaRG™and C3A C) & D) cells. 
Immunocytostaining materials and methods undertaken as detailed in Chapter 2 section 2.3 
E) End point PCR produced by Dr. Mai Abd El-Aziz showing positive expression of GAPDH 
for HepaRG ™and C3A cells for use as positive control. Presence of CYP3A4, 1A2 AND 2E1 
can be seen in HepaRG™ cells indicated through the white bands. C3A cells show presence 
of CYP3A4, but no presence of CYP1A2 or 2E1 indicating lower overall CYP activity in C3A 







3.3.2 Induction/inhibition of CYP activity 
Assessing induction of CYP activity using the Promega assays (Chapter 2, 
2.5.2 and 2.5.3), prior to using model inhibitors, demonstrated that 
HepaRG™ cells respond specifically to induction and inhibition while C3As 
do not.  
Induction of CYP1A2 by OMP in HepaRG™ was significantly higher 
(p<0.00001) than that seen in C3A, which was negligible (Figure 3.2 A). 
Addition of the inducer (OMP) with its inhibitor fluvoxamine significantly 
reduced (p=<0.00001) the level of CYP1A2 in HepaRG™, but was 
unchanged in C3A, suggesting that CYP1A2 was not induced in C3A cells by 
treatment with OMP and the level measured was background. 
RIF induced a high level of CYP3A4 activity in HepaRG™ cells, which was 
significantly inhibited (p<0.0001) by addition of its inhibitor ketoconazole. 
CYP3A4 was not detected in C3A cells treated with RIF, suggesting that no 
induction of CYP3A4 took place within this culture (Figure 3.2 B). 
The total concentration of CYPs was higher in both induced and inhibited 
HepaRG™ cells compared to C3As. There were significant differences when 









Figure 3.2 Induction and Inhibition of CYP3A4 and 1A2 in HepaRG™ and 
C3A cells. A) Comparison between HepaRG™ and C3A cells cultured with CYP1A2 
inducer Ompeprazole (OMP), and compared to HepaRG™ and C3A cells cultured with OMP 
and inhibitor fluvoxamine (Fluvox) (n=3)(p<0.00001) or B) with CYP3A4 inducer Rifampicin 
(Rifamp), as well as with rifampicin and CYP3A4 inhibitor ketoconazole(Keto). After 
normalisation to the untreated control, whereby the relative value of the control was 
subtracted from treated samples, HepaRG™ cells show high induction and significant 
inhibition for both CYP3A4 and CYP1A2. Whereas, little to no fluorescence within the C3A 
culture was observed for either induced or inhibited cultures. All data is displayed as the 
mean of 3 experimental replicates, with eight technical replicates each experiment. Materials 
and methods are detailed in section 3.2.1. 
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3.3.3 Metabolism of parent compounds 
Compounds phenacetin and testosterone were chosen as model compounds 
to assess metabolic competency of C3A and HepaRGs™ as they are known 
to be metabolized by CYP3A4 and CYP1A2 respectively. Their turnover and 
ratio of analyte to metabolite were assessed using HPLC and LC:MS/MS. 
3.3.3.1 Phenacetin 
LC:MS/MS showed HepaRG™ cells yielded a higher turnover of phenacetin 
and gave a clear yield ratio of analyte to metabolite via end-point analysis 
(Figure 3.3) compared to C3As. HepaRG™ cells metabolized approximately 
30% of the parent compound phenacetin compared to less than 20% in C3A 
cells. Likewise, HepaRG™ cells metabolized almost 60% of testosterone 











Figure 3.3: Relative turnover of parent compounds phenacetin and 
testosterone Liquid Chromatography alongside tandem mass spectrometry 
(LC:MS/MS) shows the relative turnover of parent compounds based on 
initial quantity vs quantity after 24 hours exposure. This allows for a 
percentage of turnover to be calculated giving the overall amount of parent 
compound metabolised. HepaRG™ and C3A cells were treated with 
phenacetin and testosterone and total percentage turnover was calculated 
based on LC:MS/MS using 3 experimental replicates with 3 technical 
replicates each experiment (n=3). HepaRG™ cells show a significant 
increase in turnover of both phenacetin (p=0.0024) and testosterone 
(p<0.0001) compared to C3A cells. Materials and methods listed in section 








Figure 3.4 Phenacetin metabolites as seen on Light Cycler alongside 
diagram of phase I and II metabolites and graphical representation of 
methylation detected using LC:MS/MS: A) Representative chromatograph 
extracted from Light Sight software showing peak of parent compound phenacetin at its 
unique m/z ration 180.0. B) Schematic diagram showing Phase I and Phase II metabolism of 
phenacetin. C) Representative chromatograms of mono-, di- and tri- demethylation. D) 
Comparison of mean % turnover of mono-, di- and tri- demethylation between HepaRG™ 
and C3A cells (HepaRG™ represented in black and C3A represented in white).(Figure 









The data gathered from Light Sight software allowed us to identify the unique 
m/z ratio of phenacetin (Figure 3.4 A) Phenacetin is metabolised to 
paracetamol and its tertiary metabolites (Figure 3.4 B) through 
demethylation. It was also possible to characterize demethylation of our 
substrate, phenacetin, by observing separate signatures for demethylation, di 
demethylation and tri demethylation of the parent metabolite into paracetamol 
(Figure 3.4 C) and to quantify and compare the overall demethylation 
between C3As and HepaRG™s (Figure 3.4 D).  
 
3.3.3.2 Testosterone 
HPLC was used to analyse the relative turnover of testosterone substrate by 
hydroxylation (Figure 3.5). Comparing C3A cells to HepaRG™s shows 
pronounced presence of 6 Beta hydroxytestosterone, the main metabolite of 
testosterone, in HepaRG™ cells, while no trace of this metabolite can be 
seen in C3A cells.  
Analysis showed HepaRG™ cells metabolised more than 50% of 
testosterone and demonstrated evidence of major metabolite 6 Beta hydroxyl 
testosterone as well as a panel of other secondary metabolites, whilst C3A 
cells only showed presence of the minor metabolites 16 alpha and 
androstenedione, and relatively small turnover of the parent compound 








Figure 3.5 Metabolites of testosterone: Drug metabolite profiling of testosterone 
(CYP3A4) using HPLC. Metabolism of testosterone in A) HepaRG™ or B) C3A cells. on 
culture day 8. HepaRG cells showed a significant level of the major secondary metabolite 
6-beta-hydroxytestosterone and a wider range of secondary metabolites. Data presented 









Figure 3.6 Flow cytometry profiling of integrin expression in C3A, 
HepaRG™P and fully differentiated HepaRG™ cells. Flow cytometry 
histograms comparing integrin expression (CD49a-f: α1–α6) and CD29 (integrin β1) between 
C3A, HepaRG™ P and HepaRG™ fully differentiated cell lines (dark lines), and isotype 
controls (grey lines). CD49d was not expressed by any line. Expression of CD49a, CD49b 
and CD29 was comparable between all 3 cell lines, though downregulated on a proportion of 
HepaRG™ fully differentiated cells. Expression of CD49e absent from C3A cells was 
detected on HepaRG™ P cells and maintained on HepaRG fully differentiated cells. This was 
also true for the expression of CD49c, except that there was some down-regulation of 
expression by HepaRG™ fully differentiated cells. Conversely, C3A expressed CD49f, whilst 






3.3.4 Flow cytometry 
There is very little information associating cell type with specific integrin 
expression. Expression of integrins CD49a-f (α sub-units 1-6) and CD29 (β1 
sub-unit) by C3A, HepaRG™ P and HepaRG™ cells is shown in Figure. 3.6. 
C3A cells expressed CD49a, CD49b, CD49f and CD29 but showed no 
staining for CD49c-e. The immature/undifferentiated hepatoblast-like cell line 
HepaRG™ P, showed a comparable phenotype, expressing CD49a, CD49b, 
CD49f, although the frequency and level of expression of CD49f was lower 
than seen for C3A. In addition HepaRG™ P cells expressed CD49e, which 
was absent from C3A cells. HepaRG™ differentiated cells show hepatocyte, 
biliary and epithelial morphologically (Figure. 3.6). Looking at cellular 
morphology there is a clear difference between C3A and HepaRG™ cell 
cultures. It is clear that the HepaRG™ cell culture comprises two different cell 
types. Using integrin expression to see if there was a difference between the 
two cell types we start to see the differences described above. There is a 
difference in modulation of integrin expression between C3A and HepaRG™ 
cells where there are clearly two different cell populations in the fully 
differentiated HepaRG™ cells as shown in CD49a, b and c and CD29 (Figure 
3.6). This is possibly due to the differentiation process and time in media 






However, more work is needed to demonstrate integrin modulation is an 
indicator of differentiation and a key to defining the two cell types seen in 
HepaRG culture.  
 
3.4 Discussion 
Appropriate in vitro human models are urgently required to help reduce high 
drug attrition rates in clinical trials by detecting toxicity at earlier stages and 
improving predictive outcomes. This may also reduce the reliance on 
subsequent animal testing in drug development. Here the human hepatic cell 
lines C3A and HepaRG™ were assessed in terms of intrinsic CYP enzyme 
activity, metabolic competency, and integrin expression to determine which 
cell line is best suited in pharmaceutical applications.  
Compared with C3As, HepaRG™ co-cultures, exhibit a more organotypic 
phenotype, including evidence of hepatic polarity with strong expression of 
CYP3A4 (Figure. 3.1), the major isoform involved in the metabolism of over 
60% of marketed drugs (Newsome et al., 2000, Tsiaoussis et al., 2001). 
Using immunocytostaining, cytochrome P450 assays, LC:MS/MS and flow 
cytometry we show HepaRG™ cells to be a superior model to C3A cells for  
in vitro applications and pre-clinical toxicity testing. 
Major CYP enzymes CYP3A4, 1A2 and 2E1 are more abundant in 
HepaRG™ cells compared to C3A (Figures 3.1 & 3.2) This shows a more 






PHHs. Furthermore, HepaRG™ cells show a specificity of CYP activity 
induction and inhibition, not seen in C3A cells. (Figure 3.2). This could, in 
part, be due to the phenotype of the HepaRG™s. HepaRG™s were isolated 
from a mature female in her 30’s while C3A cells were isolated from a teen. It 
is speculated that HepaRG™s mature differentiated function and phenotype 
is due to the donors exposure to compounds such as ethanol, paracetamol, 
ibuprophen and other over the counter or prescribed meds that a younger 
donor would not have necessarily been exposed to. 
HepaRG™s mature function can also be seen in the turnover of phenacetin 
and testosterone. LC:MS/MS is used for a variety of applications to identify 
and quantify compounds and metabolites. Here it is employed to analyse the 
turnover of phenacetin and testosterone and to discover if the cell lines are 
metabolizing the parent compound into secondary or even tertiary 
metabolites. 
The results of LC:MS/MS within this study supports preferential usage of 
HepaRG™ cells over C3A in terms of metabolic proficiency of phase I 
metabolites. Adding to this the HepaRG™ cells reproducibility and stability in 
culture for >28 days, make it an attractive model which would give a more 
detailed analysis of drug metabolism and exhibit CYP activity comparable to 
PHH. This level of CYP activity would normally have to be engineered into 
other cell lines. Metabolism and turnover of phenacetin and testosterone 






compound than C3As (Figures 3.3, 3.4 and 3.5). While we show no 
presence of CYP1A2 in C3A cells using end point PCR (Figure 3.1) we also 
show that there is roughly a 20% turnover of phenacetin using LC:MS/MS 
(Figure 3.3). While this project was focusing on one of the major enzymes, 
CYP1A2, involved in the metabolism of phenacetin, there are other CYP 
enzymes which are also responsible for metabolism (CYP2E1 and CYP3A4) 
of this compound which may explain turnover of phenacetin in LC:MS/MS 
(Kobayashi et al., 1999). The major metabolite of testosterone, 6 Beta 
hydroxytestosterone, is only seen in HepaRG™ cells. Given that hepatic 
clearance of drugs depends on the activity of transport proteins located on 
the bile canalicular membranes, the unique property of bipotency in HepaRG 
cells, which gives rise to a representative split of hepatocytes and biliary 
cells, may permit focused approaches for cholestatic DILI studies.  
 
This is in agreement with other reports which show HepaRG™ cells to exhibit 
superior Phase I-III metabolism when compared to C3A and PHHs (Gerets et 
al., 2012). Using real time impedence biosensing with various CYP450 
assays containing prototypical inducers, Gerets et al., (2012) found 
HepaRG™ cells to be the most inducible model, and metabolically more 
closely related to PHHs than HepG2. When comparing gene expression of 
Phase I, II and III mRNA between HepG2, HepaRG™ and PHHs cells, they 
also found that HepG2 cells expressed the lowest mRNA values for almost 







Flow cytometric analysis was also performed to compare the expression 
profile of cell surface integrin receptors. Integrin-mediated cell adhesion sites 
link the actin cytoskeleton with the extracellular matrix, and are important 
modulators of cell behaviour including growth and survival, differentiation, 
and polarity (Giancotti and Ruoslahti, 1999). Several integrins were assessed 
to determine if we would see two separate populations of cells in the 
HepaRG™ fully differentiated cell culture. While these integrins are not 
definitive of cell type, understanding how they respond to their environment 
can be informative. Integrins are best known to be involved in migration and 
homing with the best example being the hematopoetic system (Magnon and 
Frenette, 2008, Yu,et al., 2002) Expression profiling reveals that 
differentiated HepaRG™ cells have markers associated with hepatocyte, 
biliary and epithelial morphology and modulate integrin expression as 
compared to progenitors (Figure 3.6). Expression of CD49a, CD49b, CD49c 
and CD29 was comparable between all 3 cell lines, though downregulated on 
a proportion of HepaRG™ fully differentiated cells. This may indicate two 
distinct populations within the HepaRG™ fully differentiated culture. In 
contrast, the C3As, notably express the most abundant hepatocyte integrin 
a5 (the fibronectin receptor, a5b1), important in development and cell 
differentiation processes. Therefore, HepaRG™ cells may represent a 
valuable model in which to study hepatic cell-cell and cell-matrix interactions. 






delineate the HepaRG™ co-culture into its two separate populations. This 
could have a significant impact on future experimentation and the ability to 
identify damage and characterise toxicology profiles by cell type. 
	
C3A cells have been utilized in tissue engineering and cell therapeutic 
applications, such as the extracorporeal liver assist device (ELAD) system, 
which failed to meet expectations in clinical trials (Ellis et al., 1996). It is well 
known that detoxification capacity and mixed function oxidase activity is very 
poor (Yu et al., 2012) in C3A cells, that require various manipulations, 
including transfection, to stimulate CYP450 activity (Vermier et al., 2005) and 
functional suitability for BALs, drug safety or pharmacological experiments. 
The present study shows C3As exhibit a lack of specific liver function 
(CYP450 activity/ metabolism) and potentially miss significant toxic effects 
(secondary metabolites) of candidate compounds under investigation, while 
HepaRG™ cells basal level of CYP expression, Phase I, II and III metabolism 
and longevity in culture show differentiation and function comparable to PHH. 
 
3.5 Conclusion 
In conclusion, comparison of C3A and HepaRG™ cell lines supports human 
HepaRG™ cells as a more relevant organotypic in vitro human model, which 
may permit more predictive pre-clinical screening of drugs and could 
potentially reduce drug attrition, DILI and animal testing, leading to lower 







Chapter 4 Optimisation and assessment of 










It has been shown that tissue culture substrates play an important role in the 
development and maturity of a cell culture, especially those which retain 
some form of plasticity. Traditional culturing methods to differentiate the 
HepaRG™ –P cell line involve a 4 week protocol of proliferation and 
differentiation that uses a variety of media including DMSO in the later 2 
week phase of differentiation. Alternative substrates that have been shown to 
promote differentiation in stem-like cell cultures have been proposed. 
However, there is currently no data on the ability of NPS to promote 
proliferation and differentiation in hepatic cell lines, therefore this will be 
investigated in detail in this chapter.  
 
4.1.1 Cell differentiation and use of DMSO in hepatic cell 
culture 
HepaRG™ cells are a surrogate of PHHs for use in pharmacological 
applications. Maintaining phase I and II metabolism and superior CYP activity 
to C3A cells makes the HepaRG™-P cell line attractive and more 
physiologically relevant for evaluating the toxicity of compounds. NPS have 
increasingly been used in tissue engineering because they do seem to 






al., 2004). For this reason, HepaRG™-P cells, known to retain some stem-
like properties are an attractive cell line for assessing whether differentiation 
and enhanced function can be achieved using NPS.  
HepaRG™-P cells are a bipotent progenitor culture consisting of 
fibroblastic cholangiocyte-like cells which normally mature into a co-culture of 
hepatocyte and cholangiocyte-like cells 14 days after addition of DMSO to 
culture medium (Figure 4.1). DMSO is traditionally used in many cell cultures 
to promote differentiation by pushing cells already committed to a specific 
lineage and to maintain and stabilise a differentiated phenotype (Pal et al., 
2012, Czysz, Minger and Thomas, 2015)  
While the effect of DMSO creates a stable co-culture of hepatocytes and  
cholangiocyte-like cells within the HepaRG™-P cell line, in toxicity assays 
DMSO’s induction of CYP pathways could mask specific drug-induced CYP 
activity or cause other unintended inductions or inhibitions (Park, 1988). 
Therefore, it has been suggested in toxicology studies, testing for the 
presence of phase I metabolism, that DMSO be kept below 0.5% to allow the 
detection of toxic effects of the tested drug (Schevchenko, 2014). Whereas, it 
is recommended to increase the concentration of DMSO when looking for 
toxic secondary metabolites, as DMSO induces pathways which increase 
production of secondary metabolites (Schevchenko, 2014). At low DMSO 
concentration direct effects of the drug are seen, and at high concentration, 
increased production of secondary metabolites can be seen. Finding a 






chords and maintain a stable ratio between hepatocytes and cholangiocytes, 
without the need for DMSO-induced differentiation, in drug toxicity studies 
would eliminate its secondary concentration dependent effect on either phase 
1 or phase 2 metabolism.  
Timing of the addition of DMSO is also important. Added too early, DMSO 
can cause a decrease in cell mass as some non-committed cells die off. 
However, induction of CYP activity by DMSO in cells committing to 
hepatocyte lineage appears to enable detoxification pathways allowing 
survival of committed cells. It is speculated that this promoted differentiation 
is due to a ‘survival’ mechanism within the cells (Guguen Guiliozo, 2014) and 
cues undifferentiated cells to become hepatocytes to further ‘filter’ their 
environment of toxins.  
DMSO is also reported to induce several CYP pathways including CYP3A4 
which is key in removing toxic substances. A study carried out by Kanebratt 
and Andersson (2008) showed a correlation between DMSO and the 
induction of CYP enzymes 2C9, 3A4, and 7A1. It also showed an increase in 
phase II enzymes and efflux transporters further supporting the theory that 
DMSO induces a detoxifying mechanism of survival. While HepaRG™-P cells 
do not need DMSO to initiate the differentiation process, it is required to 
sustain this process and to produce a confluent culture comprised of  
hepatocyte and cholangiocyte-like cells which is maintained for 4 weeks + in 






Finding a NPS that would advance the timing of differentiation of HepaRG™-
Ps without the need for DMSO would be more cost effective, and eliminate 
the variable, or bias, that DMSO lends to experimentation with potential 
pharmaceuticals or compounds. 
 
Fi
gure 4.1: HepaRG™ progenitor timeline: Timeline of HepaRG™ –P cells showing 
a distinct proliferation and differentiation phase, separated by a media change at day 14 with 
media containing DMSO supplementation required for induction and sustained commitment 
of hepatocytes.  
 
 
4.1.2 Outline of experimental work  
This chapter will examine the HepaRG™-P cell line on NPS developed by the 
UoG to assess if there was a change in growth, viability or function. Culturing 
multipotent cells on NPS is a trial and error process. Initially, it was unknown 
whether HepaRG™-P cells would adhere to the NPS and grow into a viable 
culture.  The first stages of this study assessed HepaRG™-P cells by 
studying morphology when grown on NPS vs those grown on TCP to assess 
adherence to NPS. Secondly, it was important to assess cell viability and to 
identify a NPS that may give rise to earlier hepatic differentiation without the 






inducing earlier the hepatic morphology as assessed by microscopy, we 
studied a number of genes of interest (GOI) to assess in depth differentiation. 
In order to adhere to the minimum information for publication of quantitative 
real-time PCR experiments (MIQE) guidelines we assessed a panel of stable 
reference genes (RGs) for use in normalisation of GOI for molecular analysis 
of this study, that would be used to assess phenotype. Where cells go 
through a maturation process with changes in the cytoskeleton and gene 
profile, it may be difficult to determine a panel of appropriate RGs as these 
may change as culture conditions and cell maturity are altered. This also 
raises questions as to whether traditional RGs may become GOI. For 
instance, traditional RGs such as the cytoskeleton protein B-actin may be a 
GOI under tissue engineering experimental conditions (where cell 
morphology is expected to be modified). For this reason, MIQE guidelines 
established strict criteria for assessing GOI by ensuring that the RGs used to 
normalise data are appropriate across all experimental conditions (Bustin et 
al., 2009). This is particularly relevant to HepaRG™-P cell line which retains 
a stem-like plasticity.  
The next step evaluated the phenotype of cells grown on specific NPS vs 









The specific aims of this chapter are 
1. To evaluate HepaRG™-P cell adhesion and proliferation on NPS  
2.  To investigate whether or not cell viability on NPS is stable compared 
to internal unpatterned control (UP) and standard tissue culture plastic 
(TCP) routinely used in HepaRG™ differentiation process.  
3. To evaluate a number of RGs against all of our experimental 
conditions to acquire an appropriate set of RGs for use in normalising 
GOI in accordance with MIQE guidelines.  
4.  To identify a promising specific nanopattern likely to promote earlier 
hepatic morphology in HepaRG-P cells without using DMSO which is 
known to promote and sustain differentiation of HepaRG cells in 
culture. To use biochemical, molecular and immunostaining 
techniques to assess in depth maturation and function to ascertain if 
differentiation can occur on NPS via only biomechanical cues that 
NPS provides.  
Rationale: Having shown that HepaRG cells are a surrogate to PHH in DILI 
studies (Chapter 3), here we assess the effect of surface pattern and 
treatment on proliferation and differentiation of HepaRG-P cells. Finding an 
NPS which would differentiate HepaRG-P cells without the use of media 






these cells for use in DILI studies and also exclude any toxic or metabolic 







4.2 Materials and methods 
4.2.1 Nanopattern plates  
NPS for this study were produced by UoG Bioengineering Department, 
based on the nano-architecture used by Dalby et al. (2007) using EBL a 
patterned silicon chip was manufactured in the UoG clean room. A nickel 
shim was created based on this chip and used at high pressure to print the 
various nanopatterns onto a molten polymer (Figure 4.2). Once hardened 
this polymer was fixed within a plate framework and treated with oxygen 
plasma before arriving at UoE. Twenty-four wells accommodated 21 different 
patterns with replicates of DSQ50 and Near 50 making up the 3 final wells. 
The names given to the patterns were based on how far apart the pits were 
in relation to one another. For example, on the DSQ10 pattern nanopits were 
10nm apart, pits on DSQ20 were 20nm apart, DSQ30’s nanopits were 30nm 
apart, and so on. It is important to mention that the polymer used as support 
medium for nanopatterning was also included as an internal planar control or 
unpatterned (UP): the wells on the UP control were of the same size and 
dimensions and received the same surface treatment, however, there was no 
nanopattern. Very few published papers on NPS consider a planar control. 
Here we will use the UP to normalize for the surface chemistry treatment 
where necessary, but also as a comparison of non-patterned oxygen plasma 









Figure 4.2 Nanopattern nickel shim and graphical illustration of all 24 
patterns A) Nickel shim designed in Glasgow and produced in Germany showing the ¾ 96 
well format of the various 24 well patterns. 
B) Visual representation of 24 well nanopattern array DSQ signifies disordered square 
patterns and corresponding number indicates the distance in nanometers between each pit. 
Hex stands for hexagonal pattern while SQ stands for ordered square array. Control well 
was oxygen plasma coated alongside wells containing nanopits, but does not have any 








4.2.2 Coating of nanopattern substrates 
There are various surface treatments available to create an adhesive 
hydrophilic surface. The two main types of treatment are oxygen plasma and 
corona treatments, both discussed in Chapter 1, section 1.2.2.5. In this study, 
oxygen plasma treatment was the treatment of choice because it was done 
under controlled conditions with high reproducibility. Corona treatment of 
plates was also possible. However, this is currently done manually using a 
hand held device resulting in variability between plate treatments. We also 
trialled non-coated plates to see if nanopatterns had an effect on adhesion 
without surface chemistry treatment. 
4.2.3 Seeding HepaRG™-P cells on nanopattern substrates 
Prior to seeding the HepaRG™-P, the NPS were wetted with 100µl of media 
at room temperature for 1 hour. This ensured better adherence of cells to the 
surface substrate, and also confirmed that there was no leakage on the plate. 
 
Cells were seeded, as described in Chapter 2, 2.2.2.1. The first batch of 
plates was used to identify nanopattern wells that supported normal growth 
and adherence of HepaRG™-P cells. Once this had been established cells 







Cells were kept in 711 growth media (DMSO negative) for the duration, and 
media was changed every other day. Phase microscopy on the EVOS Flo 
Auto was used to assess cultures on a daily basis and pictures were taken 
across a variety of time points.  
 
4.2.4 Surface treatment 
 
4.2.4.1 Quality control of C3A cells grown on oxygen plasma treated 
plates 
Initially C3A cells were used to test various surface treatments as they were 
a more cost effective way to investigate adhesion. Two batches of 
nanopatterned plates were used for assessment in comparison to TCP. 
Batch 1 was untreated and batch 2 was treated with oxygen plasma. 
C3A cells were seeded at 25k cells per well on NPS batch 1, batch 2 and 
TCP 96 well plates.  
4.2.4.2 Assessment of cell viability, confluency and morphology using 
EVOS Auto flo microscopy 
The EVOS flo auto™ has the ability to set a ‘beacon’, a customized focal 
point that can be saved as a routine so the microscope can return to the 
same spot to take consecutive pictures over time. The routine is saved and 
can be run automatically or manually. Two beacons were set per well, at 






C3A cells were cultured in MEME+ for 5 days with media changes on Day 1, 
Day 2 and Day 4.  PrestoBlue™ was used on day 4 to assess cell viability.  
 
4.2.4.3 Testing oxygen plasma surface treatment with HepaRG™- P 
cells 
Each NPS required oxygen plasma treatment to create a hydrophilic 
substrate that would allow cells to adhere to the surface. This treatment was 
applied across the whole plate (21 different patterns, repeated patterns and 
UP control). 
As no standard oxygen plasma treatment had previously been used, it was 
decided that various wattages over time should be assessed to determine the 
best treatment for use with HepaRG™-P cells. Plates were treated with 
oxygen plasma at UoG before being sent to UoE for use.   The wattages and 
times chosen were; 40W oxygen plasma 30s, 40W oxygen plasma 60s, 40W 
oxygen plasma 120s, Corona treatment, 80W oxygen plasma 30s, 80W 
oxygen plasma 60s, 80W oxygen plasma 120s.  Two plates were used per 
treatment.  
Once the plates arrived in Edinburgh they were gamma sterilized using a CIS 
bio international IBL 637 gamma steriliser for 5 minutes on the bottom shelf, 
which equates to 10 greys of gamma irradiation.    
For this experiment, HepaRG™-P cells were seeded at 20k cells per well on 
plates receiving oxygen plasma and corona treatment and viability assessed 






4.2.5 Viability assays 
PrestoBlue™ and total ATP assays were carried out in accordance to the 
materials and methods described in Chapter 2, 2.5.1 & 2.5.3. 
4.2.6 Pierce BCA total protein analysis 
Pierce™ BCA protein assay kit (ThermoFisher catalogue number 23225) was 
used to measure total proteins of HepaRG-P™ day 7 cells grown on TCP, UP 
and DSQ120 cell culture substrates. This kit uses a detergent reagent which 
quantitates a total protein concentration when compared to a protein 
standard. Standards were made according to manufacturers specifications 
using an albumin standard (BSA). Cells were washed once with PBS+ before 
addition of lysis buffer (100µl per well). After addition of lysis buffer, cells 
were put onto a cell shaker for 30 minutes. After 30 minutes in lysis buffer, 
25µl of each sample was added to a clear 96 well plate, 200µl of working 
reagent was added to wells before incubation at 37°C for 30 minutes. This 
reaction measures proteins through the colorimetric detection of copper by 
bicinchoninic acid. Known as the ‘biuret reaction’, amino acids form a blue 
coloured complex when they react with cupric ions. Bicinchoninic acid (BCA) 
is then added to develop the colour further so it can be read at 562nm. 
Binding of 2 BCA to 1 cuprous ion intensifies the colour from a light blue to 
an intense purple which is more readily detected. Absorbance was measured 







4.2.7 Materials and methods of molecular analysis 
In accordance with MIQE guidelines a record of RNA integrity and quantity 
was stored. (Further evidence can be found in Chapter 7 Supplementary 
data), RNA samples were stored in -80°C and cDNA samples were stored at 
-20°C until processed.  
RGs are crucial as a control in interpreting fold changes and analysing GOI. 
Appropriate RGs are especially important in tissue engineering applications 
where a cell line retains progenitor or stem cell-like properties and moves 
through various stages of development.  
Within this tissue engineering experiment, the RG analysis was repeated 
independently three times using HepaRG™-P cells synchronized at a specific 
passage. Thawed cells were plated separately in order to create 3 
independent technical replicates (n=3, technical variability: the results from 
one separately set-up plate are independent). As this experiment was carried 
out 3 times, the total independent replicates were 9. 
 
Based on current literature (Celeen et al., 2001, Hart et al., 2010) and 
personal preference 12 RGs were selected, for use in normalising GOI for 
experiments using HepaRG™-P grown on NPS. All samples were run against 
12 RGs; UBC, YWHA, SDHA GAPDH EIF4A1, B2M, TOP1, RPL13A, 







Table 3: Tested reference genes with names and functions 
Abbreviation Name Function 
18S 18S ribosomal RNA subunit Component of 
eukaryotic ribosomal 
subunit 40S 
ATP5b ATP synthase subunit 5b Encodes a subunit of 
mitochondrial ATP 
synthase 
β-Actin Beta-actin Isoform of actin 
proteins – part of 
cytoskeleton 
B2M Beta-2microglobulin Encodes a protein 
found in major 
histocompatibility 
protein (MHC) 1 
CYC1 Cyclin D1 Encodes a subunit of 
the mitochondrial 
transport chain 
EIFa2 Eukaryotic initiation factor 4a2 A component of a 
complex which 
facilitates recruitment 








Important enzyme for 
ATP production  
RPL13a Ribosomal protein L13a Ribosomal subunit 
SDHA Succinate dehydrogenase complex, 
subunit A 
Subunit of succinate 
dehydrogenase that 
plays a role in energy 
conversion within 
mitochondria 
TOP1 Topoisomerase 1 Encodes an enzyme 
responsible for the 
breaking and 
subsequent joining of 
DNA during 
transcription 
UBC Ubiquitin C Encodes a 
polyubiquitin precursor 
which helps regulate 
and modify various 
effects within the cell  
YHWAZ Phospholipase A2 Adapter protein which 
binds other protein 







The geNorm output ranked the candidate reference gene according to their 
expression stability (M). 
All primers were obtained from, and validated by, Primer Design.  
Biogazelle geNorm software was used to analyse M and V values which are 
an indicator of RG stability.  
 
4.2.7.1 Experimental design for reference gene validation 
HepaRG™-Ps were seeded on NPS as outlined in chapter 5. Cells were 
collected on day 7 for RNA extraction.  
4.2.7.2 Total RNA preparation and reference gene selection 
In brief, RNA extraction was undertaken using Life Technologies 
RNAqueous™ kit and RNA purity/quantity was measured using Thermo 
Fisher nanodrop and Agilent chip technology. Every sample was assessed 
on nanodrop and a selection of samples at random were assessed on the 
Agilent chip (Further information can be found in Chapter 7 Supplementary 
data).  
4.2.7.3 cDNA synthesis and qRT-PCR analysis 
cDNA was prepared using PrimerDesign nanoScript to RT kit and qRT-PCR 
was performed using PrimerDesign-validated primers and master mix on a 
Roche light cycler 96 system. As previously mentioned, 12 candidate genes 






which uses raw Ct values taken from the Light Cycler 96 to rank RGs in order 
of stability by assigning an M value to represent stable expression and V 
values to suggest how many RGs should be used to create a geometric 
mean that gives the best stability throughout all experimental conditions. 
Graphpad Prism software was used for performing statistical analysis. A one 
way Anova and Tukey test were used to assess statistical significance 
between genes of interest. 
 
4.3 Results 
4.3.1 NPS surface treatment 
Initially untreated and treated surface were compared. Significant 
discrepancies between batch 1 (untreated) and batch 2 (oxygen plasma 
treated) were observed. When grown on untreated NPS, C3A cells exhibited 
a different morphology than those seen on treated or TCP (Figure 4.3).  Cells 
grown on the TCP grew to confluency and started differentiation around the 
same time as those grown on the treated NPS. These cells formed a typical 
polygonal morphology reproducibly seen in C3A cultures. The TCP 
resembled a normal culture and no abnormalities could be seen.  However, 
cells grown on untreated NPS did not grow to confluency. These cells 
struggled to adhere to the NPS in the first 48h of culture and then started 
moving towards other cells in the area via elongated filopodia-like 






gaps could be seen across the culture wells. Cells aggregated into spheroid 
like balls with ragged edges. Around day 7 these aggregated structures 
disappeared and cells that were congregated together started growing 
upward through the z plane. Cellular debris was observed on the NPS and 
remaining cells had a ragged and unhealthy appearance. Cells grown on 
oxygen plasma treated substrate grew to confluency and exhibited typical 
C3A morphology. Further confirmation of this assessment of cell viability was 
carried out using the PrestoBlue™ assay (Figure 4.4). Cells grown on 
untreated plates showed a negative viability due to subtraction of no cell 
control. Cells grown on treated plates showed viability, though it was variable 
by pattern. 
 
When surface treatment was assessed the UP well on untreated and treated 
plates, UP well was observed first to remove the variable of patterning from 
the experiment. However, all wells were viewed and taken into consideration 
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Figure 4.3 Comparing untreated and treated NPS plates on day 1 and 
day 2: A&B Batch variation of nanopattern plates: C3A cells grown on untreated and 
treated NPS plates (unpatterned well), show significant morphological changes between 
batches. Pictures were taken at days 1(a) and 2(b) at x20 on an EVOS autoflo microscope. 
Beacons were picked at random, but once picked, were used consistently for assessment 
across days 1 and 2. (not all data shown)  Major discrepancies were seen between untreated 
and treated plates. Cells grown on untreated plates were not confluent, were ragged in 
appearance and culture contained excessive debris compared to treated. C3A cells grown 
on treated plates grew to confluency and showed clearly defined cells. 
 
Untreated Treated  Day 2 
DSQ100/Beacon 28  
DSQ50/ Beacon 38  

































































































-5 0 0 0 0
-4 0 0 0 0
-3 0 0 0 0
-2 0 0 0 0
-1 0 0 0 0
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0
5 0 0 0 0
6 0 0 0 0
7 0 0 0 0
8 0 0 0 0
9 0 0 0 0
1 0 0 0 0 0
1 1 0 0 0 0
1 2 0 0 0 0
1 3 0 0 0 0
1 4 0 0 0 0
1 5 0 0 0 0
1 6 0 0 0 0
1 7 0 0 0 0
1 8 0 0 0 0
1 9 0 0 0 0
2 0 0 0 0 0
P re s to B lu e  a s s a y  c o m p a r in g   C 3 A  c e lls  o n  u n tre a te d  v s  t re a te d  n a n o p a tte rn  p la te s




















U n tre a te d  p la te
T re a te d  p la te
 
Figure 4.4: Viability of C3A cells grown on untreated and treated NPS 
plates Quantitative fluorescent measurement of cell viability using PrestoBlue™ resazurin 
based assay comparing C3A cells plated on untreated and treated nanopattern plates. Data 
normalized to unpatterned control on each plate. Data shows cell viability at Day 4 (n=1 One 









4.3.2 Surface chemistry treatments 
Basic cell morphology highlighted the importance of surface chemistry in 
preparing NPS for cell culture, as major discrepancies could be seen 
between untreated and treated NPS. Once it was confirmed that cells could 
not remain viable on untreated NPS, various types of oxygen plasma were 
trialled to determine the best surface chemistry for the duration of the project. 
For this stage of the project HepaRG™-P cells were used to assess 
morphology and adhesion.  
As oxygen plasma treatment is a combination of wattage for a set time, 
seven different concentrations of oxygen plasma were trialled (Figure 4.5). 
Corona treatment was also included for comparison. Microscopy showed that 
cells grown on low wattage treatments for a short time displayed a 
morphology of healthy, well defined cells which grew to confluency within a 








Figure 4.5: Comparing HepaRG™ progenitor cells grown on various 
oxygen plasma and corona surface treatments Day 6 of HepaRG™-P cells 
grown on a variety of oxygen plasma and corona treated plates and compared to industry 
standard 96 well Corning. Only the planar control of the nanopatterned plate was used in this 
experiment as we wished to compare like for like between the various treatments. Oxygen 
plasma treatments of 40W 30s, 40W 60s and 40W 120s (A1, A2, C5 and C6) were trialled 
alongside manual corona treatment (D7) and higher wattage oxygen plasma of 80W 30s, 








4.3.3 Morphology on NPS 
While assessing HepaRG-P™ cells on each pattern of the NPS, it was noted 
that cells grown on DSQ120 regularly formed a more cuboidal and bi-
nucleated morphology around day 7 compared to other patterns or TCP. The 
ratio of hepatocytes to flat cholangiocyte-like cells was above average. It was 
estimated that on DSQ120 there was an 80:20 split of hepatocytes to 
cholangiocyte-like cells. As hepatocytes make up around 80% of the human 
liver with the remaining 20% made up of cholangiocytes, stellate cells, 
Kupffer cells and other, it was thought that this pattern could be a more 
clinically relevant model (Wisniewski et al., 2016) 
 
Repeated observation of HepaRG™-P cells grown on DSQ120, UP and TCP 
also showed confluency alongside the emergence of cuboidal, hepatocyte 
like cells ~ days 6 and 7 (Figure 4.6) Cells grown on TCP were not confluent 
at day , and still showed only fibroblastic morphology, and did not show any 
cuboidal hepatocyte-like cells. Cells grown on the UP substrate were 
confluent and showed signs of committing to hepatocyte lineage, acquiring a 







Figure 4.6 Morphological assessment of HepaRG™-P cells on TCP, UP and 
DSQ120 at day 6. Phase contrast microscopy from EVOS Flo Auto (x20, line measures 
200µm) showing HepaRG™-P cells at day 6. Cells grown on TCP (96w Corning) UP 
(unpatterned control on nanopattern slide) and DSQ120 (nanopattern substrate).Cells grown 
on TCP are not confluent. Cells grown on UP are smaller and more confluent than TCP, 
while cells grown on DSQ120 are confluent and signs of a cuboidal morphology indicative of 








4.3.3.1 Selection of reference genes 
As sections 4.3.5 and 4.3.6 show results of molecular investigations of GOI, 
the process whereby a set of RGs was established is described below.  
 
 
4.3.3.2 RNA preparation and quality 
Nanodrop 260/280 was used to assess RNA purity. A nanodrop 260/280 ratio 
of 2 is considered to be uncontaminated with genomic DNA and of good 
quality (260/280 ratios: 1.8-2.0) and RNA integrity. Further materials and 








Figure 4.7: Selection of nanodrop analysis of mRNA. Screen shot of mRNA 
analysis by nanodrop spectrophotometer across all cell culture substrates (corning (TCP), 
planar or untreated control (UP) and DSQ120. Nanodrop records ng/ul and assesses purity 
of sample. A 260/280 ratio of sample purity ranged from 2.1-3.6 where 1.8 and above is 








4.3.3.3 Standard deviation, M and V values in reference gene selection 
Standard deviation (SD) has traditionally been used to assess stability 
between Ct values for individual sample assessment (Figure 4.8). Here we 
calculate SD alongside analysis performed using geNorm software to gauge 
robustness of individual gene expression (SD) and how stable each gene is 
across all experimental conditions. geNorm software calculates the gene 
expression stability (M value) for a reference gene by using the average 
pairwise variation (V value) for that gene against other tested reference 
genes across all experimental conditions (Vandesompele et. al, 2002). Low 
SD and M values suggests high stability.  
Within the tissue engineering experiment, mean SD was 0.3 with a range 
from 0 to 0.5 in individual samples showing high stability. However, tissue 
engineering M values show low stability when individual samples are 
assessed across all experimental conditions (Table 2). V values assess the 
optimum number of RGs needed for normalization of data. Within the NPS 
study the V values indicating variability between sequential normalization 
factors is relatively high (geNorm V > 0.15) and at least 7-8 RGs were 
recommended to normalize GOI (Figure.9).  
 
It is advised that genes with an M value higher than 1 are not stable enough 






M value ranking less than 1, SDHA and 18S M values ranked between 1 and 
1.2, and UBC, EIF4A1, GAPDH and ATP5B ranked between 1.2 and 2.5. 
This confirms that the selection of the set of 7 reference genes should be 
considered for HepaRG™-P transcriptional profiling across all conditions as 
confirmed in the V values generated from geNorm software.  
Though due to the cost of running 7 genes alongside each GOI, it was 
decided that the geometric mean of the top three genes would be used as 








Table 2: Reference gene ranking for nanopattern project Ct and M Values 
generated by geNorm software Reference genes for tissue engineering/nanopattern project 




Figure 4.8: Average Ct values for tissue engineering/Nanopattern 
substrate reference gene selection: Graphical representation of average Ct values 
are shown for all 12 genes used in validating optimal reference genes. SD shown in error 







Figure 4.9 V values generated by geNorm software for Nanopattern 
project: The optimal number of reference genes is determined by pairwise 
variation known as a V value. The lower the V value the more optimal the 
number of reference genes for use in nomalisation. In this study a 
combination of 7/8 reference genes is suggested for use in normalising 









4.3.4.1 Zonula occludens 1 as a marker of polarity 
One of the basic indications that a cell is a mature hepatocyte is the 
exhibition of polarity. ZO-1 is a membrane bound protein that stabilizes tight 
junctions by interacting with the F-actin portion of the cytoskeleton. As 
hepatic epithelial cells establish bile canaliculi (BC) at sites of intercellular 
contact separated by tight junctions from basolateral domains, the presence 
of ZO-1 localized within the membrane at cell-cell junctions would represent 
polarity. 
Here we see distinct membrane bound positive staining for ZO-1 on UP and 
DSQ120 at day 7 (Figure 4.10). Because of the known bipotent nature of this 
cell line a positive ZO-1 staining localised to the cellular membrane indicates 
that this population of cells has reached maturity. Therefore, it is most likely 
that these cells are differentiating towards a hepatocyte lineage.  
Staining is backed up by qRT-PCR for expression of TJP1 a gene encoding 
for ZO-1. Significant fold increases can be seen on DSQ120 and UP on day 







Figure 4.10 Primary staining of Zonula Occludens 1, a marker of cellular 
polarity: HepaRG™-P cells were grown for 7 days on UP, DSQ120 and TCP. Cells were 
fixed and stained on day 7 with primary antibody of Hepatic polarity marker Zonula 
Occludens 1 (ZO-1) (See materials and methods chapter 2). ZO-1is shown in green 
alongside blue Hoescht nuclei staining. Images were taken on an EVOS Flo Auto at x20 
magnification. Day 7 TCP immunocytochemistry shows ZO-1 un-localized in the cytoplasm 
of cell, while UP and DSQ120 shows localized membrane bound ZO-1 (‘chicken wire’ 
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Figure 4.11 qRTPCR of TJP1 (ZO-1) Fold change (±SD) in mRNA expression of 
tight junction protein 1. Quantitative Real Time PCR showing presence of Tight Junction 
Protein 1, the gene encoding for ZO-1, on day 7 of HepaRG™-P culture. qRT-PCR 
correlates little TJP1 at Day 7 on TCP with previous and significant fold increases of TJP1 
Day 7 on UP and 120. Results are presented as fold-changes in gene expression relative to 
untreated control calculated with the ΔΔCq method. (n=3, representing 3 independent 








4.3.4.2 SOX9/HNF4α reciprocal expression 
SOX9 is found in various tissues. However, it is a known marker of a cell 
committing to the cholangiocyte lineage. Mature hepatocytes should stain 
negative for SOX9. Therefore, within this bipotent culture, the presence of 
SOX9 shows a population of cholangiocyte-like cells.  
 
Although hepatocyte nuclear factor 4 α (HNF4α) is found in tissue other than 
the liver, within this bipotent culture it is used as a marker of a mature 
hepatocyte. Positive staining of HNF4α is indicative of a mature hepatocyte 
culture. Here we show reciprocal staining of SOX9 and HNF4α.  
 
When cultured on UP substrate, expression of SOX9 is bright and well 
defined by day 6, becomes diffuse by day 14 and increases again by day 28. 
On the DSQ120 substrate SOX9 expression follows that seen on UP up to 
day 14, but is much lower by day 28 and is also lower than that seen in TCP 
(Figure 4.12). 
 
Low levels of HNF4α are expressed by day 14 on TCP and maintained to 
day 28. Expression is localized to areas of culture which have committed to 






substrate. Using DSQ120, diffuse staining is seen at day 6, becoming more 
localized by day 14 and is maintained at day 28. 
 
SOX9 expression is present and clearly detectable until around day 14 where 
it becomes diffuse. HNF4α is either absent or un-localised until ~ day 7 
where some emergence is seen on UP and DSQ120. High levels of HNF4α 



























Figure 4.12 Phenotypic staining of progenitor protein SOX9 and mature 
hepatic marker HNF4α: All conditions showed reciprocal staining of SOX9 and HNF4α 
throughout a 28 day culture period.Sox9 can be seen at days 2 and 6 on all substrates as 
localised green staining within the cytoplasm. HNF4α is also a cytoplasmic stain which 
becomes more localised as cells mature, between day 6 and 14. Pictures taken on EVOS fl 
Auto at x20 A) Reciprocal staining of SOX9/hnf4a on DSQ120   B) Reciprocal staining of 
SOX9/hnf4a on UP control C) Reciprocal staining of SOX9/HNF4α on TCP. Scale bars 
representative of 160µM. Background fluorescence subtracted across all images equally 










qRT-PCR analysis of SOX9 showed no presence at any time under any 
condition. This analysis was repeated 3 times with 3-4 technical replicates 
each time. HNF4α is present in all conditions on day 7 and 14 (Figure 4.13). 
High expression of HNF4α mRNA is seen when proteins are starting to be 
detected through immunostaining. HNF4α gene expression is lower at day 
































Figure 4.13 qRTPCR data for HNF4α day 7: A) There was no expression of 
SOX9 under any condition (n=6). B) mRNA expression of HNF4α. qRTPCR data shows 
mRNA expression of HNF4α on day 7 for TCP, UP control and DSQ120. Both UP and 
DSQ120 showed higher levels of mRNA expression on day 7 than TCP. Results are 
presented as fold-changes in gene expression relative to untreated control calculated with 










4.3.5.1 Viability assays 
Total ATP and metabolic competence was measured at day 7. Total ATP 
data shows a significant difference between DSQ120 and UP compared to 
TCP. However, no difference was seen at day 7 in the PrestoBlue™ assay 
which measures metabolic competence (Figures 4.14 & 4.15).  
A comparison was then made between DSQ120 and UP day 7 and TCP day 
14. No statistical significance was seen suggesting that by day 7 total ATP 
and metabolic competence of cells grown on DSQ120 and UP are 
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Figure 4.14 Measuring total ATP in HepaRG™-P cells at day 7 across 
cell culture substrates: Measurement of total ATP in relative fluorescent units on day 
7 showed a statistically significant difference between HepaRG™-P cells grown on TCP and 
HepaRG™-P cells grown on both unpatterned (p<0.0008) and nanopatterned (p<0.007) 
substrates. There was no statistically significant difference in total ATP when comparing cells 
grown on unpatterned control and DSQ120 patterned oxygen plasma treated surfaces (n=3, 
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Figure 4.15 Measuring metabolic competency in HepaRG™-P cells at 
day 7 across cell culture substrates: Results of PrestoBlue™, resazurin based 
assay, in relative fluorescent units on day 7 showing no difference of metabolic proficiency 
between TCP and cells grown on both unpatterned (UP) and nanopatterned substrate 
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Figure 4.16 Pierce BCA total protein analysis of HepaRG™-P cells at 
day 7 across all cell culture substrates: Results of Pierce total protein assay was 
performed on HepaRG™-P cells across TCP, UP and DSQ120 cell culture substrates on day 
7 to quantify the levels of protein in cells grown on each substrate. There was no statistical 
difference in the amount of protein between UP and DSQ120 or TCP and DSQ120. There 
was some significance between TCP and UP, with TCP expressing the highest levels of 
protein (p=0.25). Data comprises 3 experiments with 2 technical replicates each experiment. 









Figure 4.17: Comparing total ATP of HepaRG™ cells at day 14 on TCP to 
day 7 on UP and DSQ120 Measurement of total ATP in relative fluorescent units 
comparing HepaRG™-P cells grown on oxygen plasma treated substrates UP and DSQ120 
at day 7 to HepaRG™-P cells grown on TCP at day 14. There is no significant statistical 
difference between HepaRG™-P cells grown on oxygen plasma treated substrates at day 7 
vs HepaRG™-P cells grown on TCP at day 14 (n=3, representing 3 independent 








Figure 4.18 : Comparing metabolic proficiency of HepaRG™ cells at day 
14 on TCP to day 7 on UP and DSQ120: Measurement of metabolic proficiency in 
relative fluorescent units comparing HepaRG™-P cells grown on oxygen plasma treated 
substrates UP and DSQ120 at day 7 to HepaRG™-P cells grown on TCP at day 14. There is 
no significant statistical difference between HepaRG™-P cells grown on oxygen plasma 
treated substrates at day 7 vs HepaRG™-P cells grown on TCP at day 14 (n=3, representing 
3 independent experiments with 3 technical replicates each experiment)  
 
4.3.5.2 Transferrin 
Transferrin is required for transport of iron into hepatocytes and is therefore a 
marker of a functional hepatocyte (Hine and Martin, 2016). At day 7 localized 
transferrin expression is seen most abundantly on cells grown on UP, and 
there is also expression on cells cultured on DSQ120. On TCP, cells show 
some diffuse and un-localised transferrin staining suggesting the protein is 









Figure 4.19 Transferrin primary antibody staining: A)Primary antibody staining 
of HepaRG-P™ cells with transferrin (green) shows localized staining on UP at day 7. TCP 
and DSQ120 showed diffuse staining throughout with little to no localised staining. B) Same 
images as panel A showing Hoescht nuclear staining overlay (X20 magnification on EVOS 
Auto-fl microscope. Images acquired in GFP and DAPI channels channels (scale 160µm). 
Images representative of n=2 biological with 3 technical replicates. Background fluorescence 









4.3.5.3 CYP3A4 activity 
Mature cytochrome P450 enzymes also show functionality of hepatocytes. 
On day 7 CYP3A4, one of the major CYP enzymes in the metabolism of 
xenobiotics, is detected on all three substrates. However, UP and DSQ120 
shows an abundance of CYP3A4 not normally seen without the addition of 
DMSO. (Figure 4.20) qRT-PCR showed a 70 fold increase of CYP3A4 
mRNA expression between UP and TCP. DSQ120 had a high fold increase 







Figure 4.20 Assessing functionality of CYP3A4 through 
immunocytostaining: HepaRG™-P cells were grown on various substrates and 
stained for CYP3A4 (green) on day 7 A) Primary antibody staining of HepaRG™-P cells 
show little to no localized staining on TCP,and clear and abundant staining localised to 
cytoplasm in UP and DSQ120. B) Same images as panel A showing Hoescht nuclear 
staining overlay (X20 magnification on EVOS Auto-fl microscope. Images acquired in the 
GFP channel (scale 160µm). Data representative of n=2 biological and 2 technical 
replicates. Background fluorescence subtracted across all images equally using Volocity 
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Figure 4.21 Fold changes of CYP3A4 on various substrates using qRT-
PCR: mRNA expression of CYP3A4 in the HepaRG™ cells comparing Day 7 TCP, UP and 
DSQ120 substrates. There is significant upregulation of CYP3A4 on UP and DSQ120 
compared to TCP. Results are presented as fold-changes in gene expression relative to 
untreated control calculated with the ΔΔCq method. (n=3, representing 3 independent 










4.3.5.4 Glutamine synthetase/Carbomyl Phosphate Synthetase 
Glutamine synthetase (GS) and Carbomyl phosphate synthetase (CPS) were 
investigated to assess the cells ability to regulate and detoxify ammonia. 
Using immunocytochemistry, HepaRG™-P cells were observed on all three 
substrates (DSQ120, UP and TCP). There was no expression of CPS in any 
sample (Figure 4.22). GS was visible in all samples, however, it was more 









Figure 4.22 Carbomyl phosphate synthetase antibody staining.  
Immunocytochemistry showing negative staining for carbomyl phosphate synthetase across 
all substrates on day 7. X10 magnification on EVOS Auto-flo microscope. Image acquired in 
the GFP channel (scale 400µm) However, the experimental results of CPS need to be 
interpreted with caution in the absence of a positive control and low n number. Data 







Figure 4.23 Presence of glutamine synthetase at day 7: HepaRG™-P cells 
were grown on TCP,UP and DSQ120 substrates for 7 days before fixing and staining with 
glutamine synthetase (GS) (shown in red, RFP channel) Detection of GS on TCP is present, 
but diffuse. Presence of GS on UP and DSQ120 is more localized, clustered and more 
abundant that TCP. Images taken on the EVOS fl Auto x10 Images acquired in the RFP 
channel (scale 160µm). Data representative of n=1 with 2 technical replicates. Background 








4.4.1 Types of patterns used 
Previously, mesenchymal stem cells grown on nanopattern topography at 
UoG differentiated into bone fragment without the use of additional chemicals 
or nutrients in the cell media (Dalby et al., 2007). The conclusion from this 
study suggested that stem/progenitor-like cells grown on certain patterns 
may be directed into specific lineages without the need of supplements to 
stimulate differentiation. Schernthaner (2012) also showed evidence that the 
orientation of patterned surfaces resulted in morphological changes and 
directional cell alignment along wall like structures. Other studies 
used nanopatterns to direct cell migration by altering the likelihood of cell 
adhesion by modifying the form of nanopattern (Qian and Wang, 2010).  
For this reason, we grew HepaRG™-P cells on 21 
different nanopattern topographies and UP control to determine if lineage 
specific commitment could be directed by the pattern alone.  
4.4.2 Surface treatment  
C3A cells grown on untreated nanopattern plates exhibited very different 
morphology to those grown on oxygen plasma treated plates (Figure 4.3) or 
TCP. C3A cells grown on untreated plates were ragged, congregated into 
spheroid like balls and were not sustainable for more than a week. The 
PrestoBlue™ assay (Figure 4.4) showed a significant difference in cell 






no cell/prestoblue only control, it was clear that untreated performed less well 
than treated.   Untreated plates showed relative fluorescent units in the 
negative due to subtraction of background fluorescence and normalisation to 
the no cell control.   
 
After confirming the need for a surface treatment we set out to determine the 
parameters causing variation in adhesion and morphology and to understand 
the technical mechanisms used in coating plates so that we could ensure 
quality control and reproducibility between experiments.  To choose the 
surface treatment most suited to the HepaRG™-P cells, we tried various 
concentrations of oxygen plasma treatment and compared this to TCP 
control (Figure 4.5).  
 
Further to the descriptions of oxygen plasma treatment and corona treatment 
described above in Results section 4.3.2, several oxygen plasma treatments 
and one corona treated plate were trialled and compared to TCP. Only 
growth on the UP well of these oxygen plasma treated plates was compared 
to TCP. This allowed us to remove the variable of the pattern surfaces so that 
only the effect of oxygen plasma or corona treatment was observed. 
Higher wattage and long exposure time of oxygen plasma may cause 
damage to nanopatterned substrates which would not be visible using light 
microscopy, and would be difficult to quantify.  It was therefore decided to 






we narrowed our choice of parameters further to plates treated with 40W 
oxygen plasma for no more than 30s.   
Cell morphology was also a factor, and cells grew similar to TCP plates on 
A1 and A2 configuration of 40W 30s (Figure 4.5) confirming further that the 
lowest wattage and shortest duration of oxygen plasma treatment was ideal.   
There was also a corona treated plate used for comparison.  This treatment 
is similar to current industry standard TCP, but corona treatment can only be 
applied at the UoG by hand. Hand coating plates introduces high variability, 
and it was decided that the corona treatment would not be reproducible until 
an automated machine is built that can evenly coat plates, and so this 
treatment had to be discarded from the experiment, again, due to issues with 
reproducibility.  
This left us with A1 and A2 configuration which were treated with 40W 
oxygen plasma over 30s.  While this method was used throughout the rest of 
the study, a lower wattage time could be trialled in future to further optimise 
this process.  
From assessing growth and viability of HepaRG™-P cells cultured on a 
variety of surface chemistry treated patterned and unpatterned wells, it 
became clear that surface chemistry has as much effect on morphology as 
does growth on nanopatterned substrates. Therefore, instead of using UP as 
an internal control for experiments, it was used as a test of surface chemistry 






4.4.3 Reference gene selection for normalising genes of 
interest 
After selection of surface chemistry a protocol was established for analysing 
the molecular profile of HepaRG™-P cells grown on the NPS. The practice of 
using one untested RG can lead to inaccurate findings (Marx, 2013, Bustin et 
al., 2009). This is especially applicable within tissue engineering applications 
where use of one RG or an untested set of RGs can cause wildly varying 
results. This is because genes typically stable in a normal 2D culture can be 
up or down regulated by the very act of tissue engineering. This can make 
traditional structural RGs such as β-actin, a GOI in tissue engineering 
applications. For this reason, it is essential to validate a wide panel of RGs 
that consider proteins involved in many different basic cellular processes.  
High reference target stability (average geNorm M ≤ 0.5) is typically seen 
when evaluating candidate RGs on a homogeneous set of samples (e.g. 
untreated cultured cells, or treated cultured cells upon one type of 
condition)(Bustin et al., 2009). While SD was low between our individual 
sample sets, the overall stability (M value) of RGs across all experimental 
conditions was high (Table 4). This demonstrates the importance of 
evaluating samples across all conditions before deciding on the set of RGs 
which should be used within a given experiment.  
While there were benefits to using the HepaRG™-P cells within the tissue 






progenitor state of these cells it was difficult to extract adequate quantities of 
RNA. While RNA of 5 individual experiments was pooled for analysis, the 
quantity of RNA was still quite low. However, RNA integrity, or quality, was 
high.  
GeNorm software advised the use of 7/8 RGs to normalise GOI within the TE 
experiment. Due to the costs involved in running 7/8 RGs and the limited 
quantity of RNA, it was decided that the minimum requirement within MIQE 
guidelines of 3 RGs would be adhered to.  
 
4.4.4 Using nanopatterned substrates to alter HepaRG™-P 
form, phenotype and function 
After a blinded assessment of morphology, DSQ120 was identified as a NPS 
on which HepaRG™-Ps grew to confluency and acquired a morphological 
hepatic phenotype by day 7 without the addition of DMSO (Figure 4.6). 
However, biochemical and molecular assessments were carried out to 
ensure viability and function.  
Assessment of the effect of DSQ120 vs UP/TCP was carried out across three 
parameters using specific markers. Form (Morphology and tight junction 
assessment of polarity), phenotype (immature cholangiocyte marker SOX9 







4.4.4.1 Form  
4.4.4.1.1 Morphology 
First, it was important to distinguish the morphology of both cell types within a 
normal culture. Normally, cholangiocytes are elongated, thin cells, with 
singular nuclei compared to hepatocytes where form is more cuboidal, bi-
nucleation is seen, and cells take on a more granular appearance. Since it 
was hypothesized that an early change in morphology would be directed by a 
NPS, particular interest was paid to the first week of culture where mature 
hepatocytes seemed to be forming in DMSO negative media on several 
patterns. However, morphology was assessed by phase microscopy between 
day 1 and 14 to identify any effects NPS may have on the cells in week 2 of 
culture. 
On 2 separate occasions, a blind test was carried out to assess the top 3 
patterns for establishing an early hepatocyte culture, without the addition of 
DMSO. Day 7 was chosen as the time point for this investigation as it 
indicated the earliest day where we would see a culture resembling 
hepatocytes. Unanimously, 3 separate scientists concluded that cells grown 
on DSQ120 were the most confluent, mature and looked the healthiest of 
cultures across all patterns. 
4.4.4.1.2 Immunocytochemistry of Zonula Occludens 1 
Once ideal parameters of time and pattern were identified we began 






occludens 1 (ZO-1) as a marker of polarity. ZO-1 is part of a membrane 
bound complex which regulates signal cascades of the tight junctions. Tight 
Junction Protein 1 (TJP1) is the gene encoding for ZO-1. Tight junctions are 
important cellular constructs that regulate passage of molecules from the 
apical to the basal membrane. Figure 4.10 shows presence of ZO-1 under all 
conditions. However, it is important to note where this protein is congregated 
within the cell to assess it as a marker of polarity. In TCP, ZO-1 is clearly 
present, but remains mostly cytoplasmic and irregular in expression. This is 
typical of a protein undergoing translation as it migrates to its point of 
function. In both DSQ120 and UP, ZO-1 can be seen clearly within the 
membrane where ZO-1 is functional. qRT-PCR supports this pattern showing 
significantly higher expression of TJP1 in UP and DSQ120 than TCP (Figure 
4.11). As polarity is a sign of a mature cell, this marker was used to satisfy 
the criteria that we had the morphology of a mature hepatic culture containing 
polarised cells and the beginnings of formation of bile canaliculi. 
4.4.4.2 Phenotype 
 
4.4.4.2.1 SOX9  
SOX9 is an ubiquitous protein found in a variety of cell types and is known by 
several different names (CMD1; SRA1; CMPD1; SRXX2; SRXY10; 
SRYBOX9) (National Center for Biotechnology Information) For the purposes 
of this study, we evaluate SOX9 in its role as an early marker of a 






the knowledge that the HepaRG™-P cell line will only differentiate into a 
cholangiocyte or hepatocyte gives confidence that SOX9 will be associated 
with an early stage cholangiocyte while HNF4α will only be seen in hepatic 
cells. For this reason, SOX9 was used as a marker of cholangiocytes to 
investigate reciprocal expression of early markers within the HepaRG™ P cell 
culture. Sox9 was seen early in culture across all conditions. However, it 
reappears between day 21 and 28 across all conditions. Personal 
communication with Christophe Chesne (2017) confirms that this has also 
been seen at Biopredic International where the cells have been fully 
characterised. While SOX9 is known to be a marker of an early cholangiocyte 
lineage, it is possible that this gene has many other functions. It is believed 
that many genes have a degree of pleiotropy, or the ability to multitask 
(Guillaume and Otto, 2012). It is possible that while SOX9 is a marker of 
early phenotype, it may also have other functions at a later stage of cellular 
development especially since it is so well conserved across a variety of 
tissues. 
4.4.4.2.2 HNF4α 
HNF4α is part of a nuclear receptor family of transcription factors found in 
digestive tissue such as gut (Ahn et al., 2008, Babeu et al., 2014) and liver 
(Bonzo et al., 2012). It is responsible for downstream regulation of many 
metabolic processes such as bile acid synthesis, lipid and glucose 






Matsuo et al., 2015). Loss of function studies using HNF4α knock out mice 
results in mortality (Bonzo et al., 2012). Furthermore, acute disruption results 
in hepatosteatosis, and impacts apoptosis, cell cycle and growth factors 
downstream (Bonzo et al., 2012). Therefore, we use HNF4α as a marker of 
hepatocytes when assessing the HepaRG™ and distinguishing between 
hepatocytes and cholangiocytes.  
4.4.4.2.3 SOX9/HNF4α reciprocal expression 
As previously stated, although SOX 9 and HNF4α are found in a variety of 
tissues within the body, they were chosen for phenotypic characterization 
due to the fact that the HepaRG™-P cell line is bipotent and can only 
differentiate into a cholangiocyte-like cell or a hepatocyte. Therefore, 
phenotype and maturity of hepatocytes within this culture can be determined 
by the presence of HNF4α and the absence of SOX9. However, where SOX9 
is present and HNF4α absent, it can be assumed that a population of early 
cholangiocytes are present. 
To establish reciprocal expression, one would expect to see clear indication 
of SOX9 early in the culture (week 1-2) and no, or diffuse expression in later 
weeks. Whereas, HNF4α should not be present early in the culture or should 
not be well established until the cells following the hepatocyte lineage 
become committed. At this stage it would be expected that HNF4α would 






Under all conditions (DSQ120, UP and TCP), SOX 9 is present and localized 
in cytoplasm with a sharp and clear appearance on days 2 and 6. This would 
be expected in support of the hypothesis of reciprocal expression. Around 
day 14 staining for SOX9 becomes more diffuse. More interestingly, qRT-
PCR data suggests that there is no SOX9 expression at any time point on 
any condition. This experiment was performed on 3 separate experimental 
samples with 3-4 technical replicates for each experiment. As qRT-PCR data 
gives quantity of total mRNA of specific genes, in this case SOX9, we could 
speculate that the gene has already been transcribed into the protein seen in 
immunocytochemistry. However, to add credence to this analysis we would  
need to validate our primer for SOX9 against a cell line or tissue known to 
express high levels of SOX9. This analysis would show us that the SOX9 
primer is working and that there was no expression within our experimental 
parameters. As we show SOX9 staining clearly in all samples, this would 
indicate that further work needs to be done to validate our SOX9 primer 
before further experimentation takes place. 
HNF4α is either not present or extremely diffuse on day 2, suggesting the 
protein is absent or not completely translated. At day 6 HNF4α starts to 
emerge on DSQ120 with clear cytoplasmic staining on a representative 
group of cells (Figure 4.12). This emergence is not seen to the same extent 
on TCP or UP, though some expression of HNF4α is present on these 
conditions. In relation to qRT-PCR data, where TCP was used as a control, 






however both contain significantly higher expression than TCP (Figure 4.13). 
On day 14 HNF4α staining emerges as clear and localized expression of the 
protein, however, qRTPCR data shows a decline in expression. Considering 
qRTPCR gives a quantitative expression of mRNA and Immunocytochemistry 
shows downstream translation of the protein, it is understandable that mRNA 
expression for HNF4α would be high on day 7 when the protein is starting to 
emerge and would be lower on day 14 when the protein has been further 
translated.  
4.4.4.3 Function 
We have established that HepaRG™-Ps grown on DSQ120 show 
morphology and phenotype around Day 7 that would suggest commitment to 
a hepatocyte lineage without the use of media containing DMSO. After 
establishing form and phenotype of cells grown on this condition, we further 
investigated whether there is cell functionality as a mature hepatocyte and 
compared this to UP and TCP controls. From here, we focus on day 7 for 
comparison as this is the earliest day at which hepatocyte morphology can 
be seen and HNF4α is detected suggesting a hepatic lineage is present. 
Metabolic assays PrestoBlue™ and ATP were used to compare day 7 
conditions and also to compare DSQ120 and UP day 7 with day 14 TCP to 
ascertain what the correlation of metabolism and total ATP between cells 
grown on the nanopattern and UP and those at a further stage of 






4.4.4.3.1 Total ATP and metabolic function  
There are many ways to assess the health and viability of a cell culture. 
Some of the most widely available are live/dead staining, resazurin based 
assays such as MTT, or Alamar Blue and through the quantitation of ATP. 
Within this study it was decided that two biochemical assays would be 
employed to assess cell health and viability. The PrestoBlue™ assay was 
used to assess metabolic function of the cells alongside an assay to measure 
total ATP. 
Within the PrestoBlue™ assay resazurin is reduced to resarufin which emits 
fluorescence and can be measured quantitatively. As PrestoBlue™ is not an 
end point assay, the Promega cell titer glo assay was used directly after 
PrestoBlue™ on the same population of cells to measure total ATP.  
 
The Pierce BCA total protein kit was also used to quantify total protein which 
would correlate cell number between conditions. This would allow us to see if 
there was a statistical difference between total protein and if one condition 
prompted more proliferation than the others. It also allowed for a direct 
comparison of metabolic proficiency assuming there was not statistical 
difference. 
 
Total ATP was measured on day 7 and day 14 across all conditions. On day 
7 there is a significant increase of fluorescence related to total ATP on 






and UP are more viable. However, there was no statistical difference on day 
7 measurement of metabolic proficiency (Figures 4.14 & 4.15). Here we can 
postulate that cells are viable and equally metabolically active across all 
conditions, but cells grown on DSQ120 and UP contain significantly higher 
ATP. This is especially significant when we consider the Pierce total protein 
assay which shows a significant difference in the level of protein on day 7 
between TCP and UP. This shows that more proteins are present in TCP, but 
metabolic proficiency is higher in UP and DSQ120 suggesting that there may 
be fewer cells on UP and DSQ120, but they are more metabolically active 
especially in production of ATP. 
Comparing day 7 total ATP and PrestoBlue™ on DSQ120 and UP against 
day 14 TCP we see there is no statistical difference. This comparison was 
done using day 7 data of UP and DSQ120 vs day 14 TCP. Showing no 
statistically significant difference between day 7 DSQ120/ UP to day 14 TCP 
shows that at day 7 HepaRG™-Ps grown on the NPS and UP well show 
metabolic proficiency and total ATP comparable to day 14 TCP without the 
addition of DMSO (Figures 4.17 & 4.18). Unfortunately, there was not a total 
protein assay carried out at day 14. While we can speculate that there is no 
metabolic differences between day 14 TCP and day 7 UP and DSQ120, 
further experiments measuring total protein or cell counting using flow 
cytometry would lend more information to this model, normalise the data and 







Transferrin plays an important role within the liver where it is needed for the 
metabolism and uptake of iron from red blood cells (RBCs). Iron is needed 
for many processes in the body and the absence of iron can cause anemia. 
Anemia is a disease state where the body lacks healthy RBC. As hemoglobin 
in RBCs binds oxygen, if healthy RBCs are diminished, hemoglobin will be 
insufficient and the binding of oxygen will be insufficient. Therefore, a 
functional hepatocyte should show presence of transferrin. 
On day 7 diffuse transferrin is shown by immunocytostaining on TCP and 
within clusters of cells on DSQ120 and UP, however, DSQ and UP are the 
only two conditions where localized and clear staining was observed on this 
early time point (Figure 4.19).  
4.4.4.3.3 CYP3A4 
Within the liver over 50 different isoforms of cytochrome P450 enzymes 
responsible for metabolism, can be found. Of these, CYP3A4 is responsible 
for the metabolism of most xenobiotics. Normally for the HepaRG™ culture to 
produce a high level of CYP3A4, it must be induced with DMSO (Guguen-
Gouillozo, Corlu, and Gouillozo, 2010). As such, HepaRG™ cells staining 
positive for CYP3A4 within a system where DMSO is not used, would be 
indicative of a functional cell capable of metabolic enzymatic activity not 






Here we show high CYP3A4 expression and activity through 
immunocytostaining and qRT-PCR on day 7 in DSQ120/UP compared to 
TCP (Figures 4.20 & 4.21). Diffuse staining is seen on TCP at day 7 
indicating that CYP3A4 is not as abundant on TCP as DSQ120/UP. 
Abundant localized staining can be seen on DSQ120 at day 7. However, 
highly localized staining is seen on UP on day 7 compared to both DSQ120 
and UP. This suggests that, in terms of CYP3A4 activity, UP outperforms 
both DSQ120 and TCP. 
4.4.4.3.4 Urea cycle: Glutamine synthetase/Carbomyl Phosphate 
Synthetase 
Carbamoyl phosphate synthetase (CPS) and glutamine synthetase (GS) are 
enzymes used in the regulation and detoxification of ammonia. GS is 
regulated by the amount of ammonia within the body and plays a role in 
converting nitrogen to ammonia. CPS is one of the main metabolic enzymes 
responsible for the conversion of ammonia into urea. These enzymes are 
found in specific zones of the liver.  
The liver is made up of functional units called liver lobules. Each lobule 
consists of acini which run from the portal triad (periportal) to the central vein 
(pericentral). The portal triad consists of a bile ductile, portal vein and hepatic 
artery. The pericentral end of this structure is where blood leaving the liver 
enters the central vein. The acinus is split into 3 zones correlated to the 








Figure 4.24 Representation of liver zonation Figure adapted from Birchmeier,W. 
2016 Schematic representing the functional gradient of the liver acinus showing 










The zones have been described as both having a gradation and being 
compartmentalized (Christoffels et al., 1999). Within the gradient of the acini, 
each cell can express the same genes, but the expression level of these 
genes is determined by the position of the hepatocyte along the gradient. As 
zones follow a gradient there can be overlap between enzymes found within 
the acini. This gradient is structural and functional for liver microcirculation 
and plays a key role in liver homeostasis including processes such as β 
oxidation, gluconeogenesis and glycolysis which are specific to a zone within 
the acinus. 
Markers such as CPS and GS may overlap in one zone, but are also 
restricted to, or absent from, other zones (Christoffels et al., 1999). For 
example, CPS is found mainly in zones 1 and 2 and GS is found in zones 2 
and 3 specifically. Therefore, these markers can be used to determine a zone 
1 vs zone 3 hepatocyte by the presence or absence of either marker 
(Christoffels et al., 1999). A further analysis of these two markers can be 
made by describing them as either dynamic or stable. A dynamic marker 
would be categorized by adaptive changes in response to a metabolic or 
hormonal state that then has a direct impact on gene expression.  CPS is 
one such gene. A stable marker would be characterized by the total absence 
of the gene in certain zones despite metabolic or hormonal changes. This 






GS as compartmentalized markers of liver zonation with CPS being a 
dynamic marker and GS being a stable marker. Using the combination of 
these markers, knowing their characteristics and where they are found along 
the acini, we can build a picture of the type of cell (zone 1, 2 or 3) through 
protein analysis.  
Within this study HepaRG™-P cells were stained with CPS and GS on day 7, 
across all substrates. There was negative staining of CPS and positive 
staining for GS (Figures 4.22 & 4.23). Cells which stain positively for GS and 
negatively for CPS suggest a zone 3 phenotype. Another criteria for zone 3 is 
high CYP3A4 activity which we have also shown on day 7, especially in 
those cells grown on DSQ120 and UP. Taking this alongside the functional 
capabilities and other mature markers of the cells (presence of transferrin 
and HNF4α) it can be theorized that HepaRG™-P cells grown on DSQ120 
and UP show a mature phenotype, functionality and characteristics of zone 3 
hepatocytes. 
While this creates a hypothesis for the zonation of HepaRG™-P cells grown 
on certain substrates, this study of zonation is limited to immunocytostaining 
of proteins. While immunostaining of CPS appeared to be negative, a 
positive control should be used to ensure that the antibody is indeed staining 
for CPS. Once it is proven that the antibody is staining specifically for CPS, 
then we can say that staining was negative and further assessment through 
biochemical assays and mRNA expression of CPS and GS should be 






upstream nuclear regulators, such as the 469 base pair upstream regulatory 
fragment for CPS (Christoffels et al., 2000) and precursors of GS, should be 
considered to ultimately classify the zonation of HepaRG™-P cells when 









Within this study, HepaRG™-P cells were plated on DSQ120 and UP and 
assessed by various experimental techniques to characterize their form, 
phenotype and function vs TCP at day 7. The following conclusions were 
formed: 
1. Morphology on DSQ120 and UP consistently showed a culture of cells 
committed to a hepatic lineage which is supported by morphological 
observations and reciprocal expression of SOX9 and HNF4α, with 
HNF4α emerging as early as day 6. While there was some reciprocal 
expression of SOX9/HNF4α on TCP, there was little evidence of 
morphological criteria of hepatocytes at day 7 when compared to 
DSQ120 and UP. 
2. Immunocytochemistry and qRT-PCR showed presence of polarity 
marker ZO1 on DSQ120 and UP at day 7.  
3. Viability assays assessing total ATP and metabolic proficiency show 
significant differences in cells grown on DSQ120 and UP compared to 
TCP at day 7. Further investigation showed no significant difference 
between day 7 DSQ120/UP viability to day 14 TCP. This suggests that 







4. Both DSQ120 and UP stained positive for functional markers 
transferrin and CYP3A4, on day 7.  Here UP control showed 
significant increases in functionality compared to DSQ120 and TCP.  
5. Cells stained with CPS and GS showed negative CPS and positive GS 
staining on all surfaces. This alone would not constitute a 
characterization of liver zonation, but taken alongside CYP3A4 data 
for DSQ120 and UP, could show a propensity of zone 3 phenotype. 
In summary, UP is a superior substrate to either DSQ120 or TCP and should 
be considered for further investigation, alongside other oxygen plasma 











Chapter 5 Chlorpromazine disrupts structural 
integrity of cell membranes in 










ECIS technology provides a unique opportunity to explore how a cell culture 
responds, in real time, to a challenge of model compounds. By measuring 
impedance and using the innate mathematical modelling built into the ECIS 
Zθ software, it is possible to ascertain if there are any changes in impedance 
to specific parameters i.e. TJs, basolateral adhesion or cell membrane 
integrity (Cm).  
As previously discussed, the fully differentiated HepaRG™ cell line is a 
bipotent co-culture of hepatocytes and cholangiocytes exhibiting 
differentiated functions including CYP activity comparable to PHHs and 
phase I and II metabolism. The fully differentiated HepaRG™s maintain 
stability for up to 4 weeks in culture and beyond, so have become a cell line 
of choice for studies in drug development. 
Chlorpromazine (CPZ) has long been used as an in vitro model of 
intrahepatic cholestasis (IHC) as there is evidence that CPZ causes impaired 
biliary function, though the mechanisms behind this are not fully understood 
and side effects are usually idiosyncratic (Antherieu et al., 2013, Akerboom et 
al., 1991, Zimmerman et al., 1987, Moradpour et al., 1994 and Castell et al., 
2005). Cholestasis is a condition characterized by an impaired ability of the 
bile ducts to secrete bile acids, bilirubin and cholesterol (Antherieu et al., 






cholestasis in vitro before drugs are submitted for pre-clinical trials. 
Investigating the mechanisms behind CPZ toxicity may be informative for 
studies of other xenobiotics known to target the biliary system/cholangiocytes 
and aid in pre-clinical toxicity studies. 
Here we examine the effect of a model cholestatic drug on differentiated 
HepaRG™ cells and investigate the changes in impedance as detected by 
ECIS technology.  
Alongside impedance-based monitoring qRT-PCR will also be used to 
quantify fold changes in GOI that pertain to adhesion, tight junctions, 
inflammatory, adaptive and apoptotic pathways. 
This combined assessment could provide vital clues to the mechanistic 
action of CPZ and produce a model that could be used for high throughput 









1. This study aimed to establish a cholestatic model using CPZ on 
terminally differentiated HepaRG™ cells using the ECIS Zθ impedance 
system. 
2. To gain further insight into the mechanism of action of CPZ in IHC in 
particular in relation to idiosyncratic presentation. 
 
Rationale: Using a novel cell line and model compound which induces 
cholestasis we examine the ability to assess DILI in a real-time, non-







5.2 Materials and methods 
5.2.1 Drug	
Cpz (Chapter 2, 2.1) was stored at room temperature. A stock of 100mM in 
PBS buffer was aliquoted and stored at -20°C. CPZ dilutions were made in 
HepaRG™ Maintenance and Metabolism Medium (ADD620) according to 
dilutions established by Antherieu et al., 2013.	
5.2.2 HepaRG™ cell culture on ibidi 8W10+E plates 
The HepaRG™ cell culture method is discussed further in Chapter 2, 2.2.2. 
Here this method is used for HepaRG™ cells cultured on the ibidi 8 well 10+ 
electrode plate for ECIS ZØ. After establishment of cell culture at day 8 on 
the ibidi 8W10+E plate, cells were treated with CPZ, (0µM, 25µM, 50µM or 
100µM C8138-5G Sigma-Aldrich) in MMM, alongside a no cell control and 
monitored on the ECIS platform for 24 hours. According to Antherieu, (2013), 
CPZ has an IC50 of 80µM after 24 hour exposure. Within his study a range 
of doses were used ranging from non toxic, sub toxic and toxic. Here we 
replicate these doses as follows; non-toxic (25µM), sub-toxic (50µM) and 
toxic (100µM).  
5.2.3 Immunocytostaining 
Immunostaining was carried out in accordance to the materials and methods 







5.2.4 Cell viability assays 
Methods of measuring cell viability assays using PrestoBlue™ and Promega 
Cell titer-glo, total ATP, are discussed in Chapter 2, 2.5.1 and 2.5.3. 
 
5.2.5 Electric Cell-substrate Impedance Sensing (ECIS)– 
Impedance assay	
The ECIS Zθ system was used to measure, in real time, total impedance 
using a multiple frequency model. Using the ECIS-Zθ software’s built-in 
mathematical model we were able to mathematically deconvolve the total 
impedance measurements, through various frequencies, to recognize 
electrical current pathways relating to cell-cell TJ (Rb), basolateral adhesion 
(z-alpha) and cell membrane capacitance (Cm) and extrapolate this into 
quantitative data. HepaRG™ cells were seeded in 8 well 10+ electrode 
(8w10E+) cultureware from ibidi. Differentiation of HepaRG™ cells into a 
stable and confluent co-culture of cholangiocyte-like and hepatocytes was 
monitored using phase microscopy alongside the ECIS–Zθ model (n=3) with 
measurements taken at 180s intervals over a 500Hz to 64kHz frequency 
range. A baseline for confluency, 8 days, had already been established within 
our laboratory (Gamal et al., 2017). At day 8 HepaRG™ cells were 






measurements were normalized to the values at 0 hours and modelled to a 
no cell control.  
 
5.2.6 Molecular analysis   
RGs for the use of normalizing GOI within the CPZ study were assessed in 
the same manner as the nanopattern RGs, Chapter 4, 4.2.5. The same 12 
RGs; UBC, YWHA, SDHA GAPDH EIF4A1, B2M, TOP1, RPL13A, ATP5B, 
CYC1, 18s and ACTB were used on RNA gathered from day 8 cells before 
treatment with CPZ and again after 24 hrs treatment with CPZ. RNA 
extraction, cDNA creation and qRT-PCR analysis was carried out according 




Cell/cell junctions were assessed using immunocytochemistry staining with 
phalloidin for F-actin cytoskeleton and specific tight junction protein Z01.	After 
24 hours exposure, F-actin staining appears intact at untreated and 25µM 
concentrations. At 50µM concentration, some degradation of cell/cell 
membrane and loss of confluency can be seen. While there are still some 
nuclei present at 100µM, evidenced by Hoescht nuclei staining (blue), there 
is little cellular material present and few instances of cell/cell interaction. A 






toxic dose there is ample ZO1 illustrated with green fluorescence localised 
around the cell membrane giving the traditional ‘chicken wire’ appearance. 
Degradation of this appearance is seen at 50µM and little to no cell/cell 








Figure 5.1 Immunocytostaining of HepaRG™ cells showing f-actin 
cytoskeleton after treatment with chlorpromazine: F-actin stain (red) showing 
cytoskeleton at day 9 after treatment with 0, 25, 50 and 100 µM Cytoskeleton indicated with 
arrows. Blue staining represents nuclei (hoescht). X20 magnification on EVOS Auto-flo 
microscope.(scale 160µm) Data representative of n=3 with 3 technical replicates. 
Background fluorescence subtracted across all images equally using Volocity image analysis 


























Figure 5.2 Immunocytostaining of primary antibody ZO1 on HepaRG™ 
cells treated with chlorpromazine: A) Chlorpromazine induced disruption of TJ 
protein ZO1. Green fluorescence represents ZO1 TJ protein, and nuclei are blue (hoescht) at 
0 (Untreated control), 25, 50 and 100 µM. B) Magnified selection of 0µM (untreated control) 
and 25µM showing membrane bound protein. All x20 magnification on EVOS Auto-flo 
microscope, scale bar 160µm. Data representative of n=3 biological replicates with 3 
technical replicates. Background fluorescence subtracted across all images equally using 












5.3.2 Measuring cell viability 
 
5.3.2.1 Total ATP and PrestoBlue™ assays 
CPZ did not compromise HepaRG™ cell viability at sub toxic concentrations 
as evidenced by total ATP and PrestoBlue™ assays where no statistical 
difference in cellular viability between treated and untreated samples was 










Figure 5.3 Measurement of HepaRG™ Cell Viability after treatment with 
chlorpromazine using total ATP and PrestoBlue™ assays: Assessment of 
cellular viability using A) Promega total ATP assay and B) PrestoBlue™ resazurin assay 
quantifying metabolic proficiency after 24 hours.(See materials and methods Chapter 2) 
HepaRG™ cells treated with 25µM, 50µM and 100µM of CPZ. No significant difference was 
detected in total ATP levels or PrestoBlue™ analysis for all conditions. (n=3, representing 3 









5.3.3 Effects of CPZ on Cell to cell junctions and adhesion 
5.3.3.1 ECIS 
Multiple frequency measurements using ECIS Zθ allowed modelling of the 
following parameters: overall impedance |Z|, Tight junctions (Rb), cell-
electrode adherence (α), and cell membrane integrity (Cm), and were 
modelled against a no cell control. Total impedance (Z) is a composite value 
of resistive and capacitive parts, where Rb, α and Cm measurements are 
deconvolved into their respective parameters corresponding to biologically 
significant cell behaviour.	
Real time impedance |Z| monitoring showed highly-sensitive dose-response 
to CPZ with a decrease of impedance at all frequencies. The lowest dose, 
25µM, had least effect on impedance. At 50µM impedance decreased to 0.6 
after 5 hours and recovered to 0.8 after 10 hours. A CPZ concentration of 
100µM shows an impedance decrease of approximately 50% within the first 
2 hours of administration and continued decline thereafter.	
Barrier function (Rb) tight junction & Cellular adherence (alpha) also show a 
dose dependant disruption. However, Cell membrane integrity (Cm) shows 
cells given lower concentrations of CPZ remain in-tact, and in fact impedance 
increases slightly and is maintained in all doses but 100µM. This give an 






been disrupted at low dose, whereas overall membrane capacitance has 







                                                                         
 
 
Figure 5.4 Real time impedance measurements using ECIS Zθ system 
A) Post-challenge impedance kinetics showing 24 hours treatment with 
CPZ in confluent HepaRG cells: CPZ caused a dose-dependent decline in 
normalized resistance - a global indicator of cellular status. B) Rb (cell-cell tight 
junctions): CPZ disrupted tight junctions in a concentration- and time- dependent manner; 
compared with control values. Subjecting HepaRg to 100µM CPZ caused Rb to decrease 
after 6 hours with marginal recovery around 15 hours. C) α basolateral adhesion): Cell-
substrate adhesion disruption was detected in a concentration dependent manner, 
suggesting some loosening of cells from the electrode surface. At 100µM CPZ, cell 
adhesiveness decreased, but showed an increase around 10 hours suggesting re-adherence 
of cells. D) Cm (membrane capacitance): membrane capacitance, reflecting cell membrane 
integrity, was significantly compromised at 100µM CPZ beginning at 2 hours post treatment. 
Some increase in Cm of 100µM CPZ was seen around 10 hours which is consistent with the 








5.3.4 Reference gene analysis 
Analysis of RGs revealed GAPDH, UBC and TOP1 to be the most stable set 
for use within this study (Figures 5.5 and 5.6 and Table 5). Results in the 
following sections showing expression of GOI have all been normalised to 








Table 5: Reference gene ranking for nanopattern project Ct and M Values 
generated by geNorm software Reference genes for chlorpromazine treatment using 
HepaRG™ P cells ranked in order of most to least stable in accordance to their M value 
 
 
Figure 5.5: Average Ct values for chlorpromazine project reference 
gene selection: Graphical representation of average Ct values are shown for all 12 









 Figure 5.6: V values generated by geNorm software. The optimal number 
of reference genes is determined by pairwise variation known as a V value. 
The lower the V value the more optimal the number of reference genes for 
use in nomalisation. In this study a combination of 4/5 reference genes is 
suggested for use in normalising genes of interest. Due to cost, 3 reference 








5.3.5 Expression of functional markers	
Hepatocyte nuclear factor 4α (HNF4α) directly regulates CAR and PXR 
mediated expression of CYP3A4, a major metabolic enzyme within the 
liver. While HNF4α does not show a statistically significant increase in either 
25 or 50µM, its up regulation at 25µM and low expression at 50µM correlates 
to the pattern seen in CYP3A4 at 25µM and 50µM. CYP3A4, is significantly 
up regulated at lower dose (25µM) of CPZ (p<0.05) when compared with 
untreated control. However, at 50µM CPZ, CYP3A4 expression is down 









Figure 5.7 qRTPCR of nuclear factor HNF4α and gene expression of 
CYP3A4 on HepaRG™ cells treated with chlorpromazine: mRNA expression 
of A) nuclear factor HNF4α and B) CYP3A4 in the HepaRG™ cells comparing untreated, 
25uM and 50uM cells treated with CPZ. Fold change is relative to untreated cells. (p<0.05) 
Results are presented as fold-changes in gene expression relative to untreated control 
calculated with the ΔΔCq method. (n=3, representing 3 independent experiments with 3 









5.3.5.1 Anti-apoptotic pathway  
Further demonstration of viability can be seen in the ratio of apoptotic and 
anti-apoptotic markers BAX and BCL2. The statistically significant down 
regulation shown in this ratio indicates that apoptotic pathways are not 
initiated, supporting data from other viability assays. This was further 
supported by finding no significant changes in nuclear apoptotic (p53) marker 
and with the significant induction of expression of anti-apoptotic (BCL-2) in 
CPZ treated cells, showing that apoptotic pathway induction is not induced by 









Figure 5.8 qRTPCR of Apoptotic and anti-apoptotic markers: mRNA 
expression (±SD) of a) ratio of apoptotic and anti-apoptotic factors Bax and Bcl2 (n=3). b) 
BCL2 (n=3) Statistically significant difference was seen in the BAX/BCL2 ratio indicating 
down regulation of apoptotic factors (p<0.0001). This is supported by upregulation of anti-
apoptotic marker BCL2 (p<0.0001) Results are presented as fold-changes in gene 
expression relative to untreated control calculated with the ΔΔCq method. (n=3, representing 










Statistically significant difference was seen in the BAX/BCL2 ratio indicating 
down regulation of apoptotic factors. This is supported by up-regulation of 
anti-apoptotic marker BCL2  
 
5.3.6 Changes of biliary transport proteins	
There are statistical differences in regulation of cellular membrane 
transporters ABCB1, ABCB4 and ABCB11 in HepaRG™ cells treated with 
CPZ (Figure 5.9).	
A statistically significant difference can be seen in the up-regulation of efflux 
phospholipid transporter ABCB4 between untreated HepaRG™ cells and the 
higher concentration of 50µM CPZ. While no statistical difference is reported 
between untreated and 25µM or between 25µM and 50µM, a dose 
dependant trend can be seen. ABCB1, responsible for xenobiotic efflux, 
shows a trend of down regulation at 25µM and a statistically significant up 
regulation between 25µM and 50µM. Whereas, bile acid export pump 
ABCB11 showed no detection at 25µM and down regulation at 50µM. Such 
increasing trends in efflux transporters can represent hepato-protective 
responses which aim to reduce intrahepatic accumulation of toxins while 
down regulation of bile acid transporters may indicate an impairment to the 









Figure 5.9 qRTPCR of membrane bound transporters ABCB4, ABCB1 
and ABCB11 mRNA expression of genes related to the drug efflux and phospholipids 
transport (ABCB1, ABCB4) and to the bile acid transport (ABCB11) in the HepaRG™ cells of 
untreated, 25µM and 50µM treated cells. Fold change is relative to untreated cells. A&B) 
There was a dose dependent increase of membrane transporters ABCB4 (n=4) (p<0.01). 
and ABCB1 (n=4)( p<0.001) This increase was significant between untreated control and 
50µM for ABCB4 and between 25µM and 50µM for ABCB1. C) Expression of bile acid 
transporter marker ABCB11 (n=4) was not detected at low dose CPZ and significantly down 
regulated at 50µM (p<0.01) Results are presented as fold-changes in gene expression 
relative to untreated control calculated with the ΔΔCq method. (n=3, representing 3 









5.3.7 Inflammatory and adaptive response 
When compared with untreated control, CPZ treated cells showed an 
increasing and significant dose dependant response in expression of pro-
inflammatory cytokines IL-6 and TNF-α. Up regulation of IL-6 at 50µM is 
almost a 10 fold increase compared to untreated control while TNFα showed 
a 2 fold increase at 25µM and a 9 fold increase at 50µM when compared to 
untreated control. (Figure 5.10) 
The increase in expression of anti-oxidant regulator NRF2, with increasing 
concentration of CPZ, though not significant may suggest cellular activation 
of this defence pathway associated with cholestasis induced by CPZ (Ma, 









Figure 5.10 Expression of cellular defence system and pro-
inflammatory markers. Expression of the oxidative defence and proinflammatory 
genes NRF2, TNFα and IL6 show a trend of upregulation with significant upregulation in both 
IL6 and TNFα  
A) The mRNA expression of the oxidative defence gene NRF2 is increased in 50uM treated 
cells when compared to untreated control though no significant difference is reported (n=4). 
B) Results show significant upregulation of mRNA expression of TNFα in 25uM and 50uM 
treated cells (p<0.001) compared to untreated control. (n=3) C) IL- 6 presents dose 
dependent increasing trend when compared with untreated cells, showing significance at 
50µM. (n=3)(p<0.005) Results are presented as fold-changes in gene expression relative to 
untreated control calculated with the ΔΔCq method. (n=3, representing 3 independent 
experiments with 3 technical replicates each experiment (B&C), n=4 representing 4 











Here, we show a novel approach forming a mechanistic view of CPZ toxicity 
encompassing traditional cell viability assays, impedance based quantitative 
measurements and mechanistic molecular techniques. This investigative 
method using the HepaRG™ co-culture of hepatocyte and cholangiocytes 
provides a unique opportunity to study the interaction of these cells when 
challenged with CPZ.  
5.4.1 Chlorpromazine 
CPZ is a neuroleptic drug used in the treatment of schizophrenia that has 
been known to cause acute intrahepatic cholestasis (IHC) (Antherieu et al., 
2012). Up to now, an idiosyncratic view of this drug has been used to 
describe the variances in liver injury and cholestasis between patients. It has 
also been speculated whether toxicity of CPZ is due to oxidative stress or an 
inflammatory response which damages TJs and contributes to a more fluidic 
cellular membrane. Evidence from this model shows a dose dependent 
adaptive, inflammatory response due to oxidative stress and down regulation 
of membrane functional proteins with no evidence of apoptosis within this 
dose range. Concentrations of CPZ were based on Antherieu et al., (2013), 
and the determination of the IC50 value of 80µM. From this we base 25 µM 







Historically, rat hepatocytes, or a sandwich culture of rat and human 
hepatocytes, have been the most reliable models for studying the toxic 
effects of CPZ (Dejanovic et al., 2016, Broeders et al., 2015, Eun et al., 
2015). However, a human in vitro model is needed to overcome intra-species 
variation and better predict outcomes in pre-clinical trials where cholestasis 
may be an unwanted consequence. For this reason, we have employed the 
HepaRG™ cell line, a co-culture of hepatocytes and cholangiocytes with 
intrinsic CYP activity, longevity in culture and functionality akin to PHHs. 
Using this well-established co-culture gives the advantage of assessing 
membrane transport proteins in a model known to metabolise both phase I 
and II enzymes (Antherieu et al., 2012). 
5.4.2 Tight junctions/ZO1	
Tight junctions are an essential component of the cellular structure of 
hepatocytes and bile secretion system helping to maintain hepatic polarity by 
separating the basolateral and apical domains as well as providing barrier 
function between blood and bile. There are many elements to tight junctions 







Figure 5.11 Pictoral representation of magnified tight junction complex:	
Tight junctions are composed of a variety of proteins including occludin, claudin and adheren  
complexes  Zonula occludens are proteins that make up part of the complex and also anchor 









ZO1 in particular is an attractive marker as it is attached to both occludin and 
claudin proteins and is anchored to the F-actin cytoskeleton. For this reason, 
we performed parallel staining of the F-actin cytoskeleton and membrane 
protein ZO1 which shows a loss of F-actin and ZO1 in a dose dependent 
response to CPZ (Figures 5.1 & 5.2).	
 
Assays measuring total ATP and metabolic function of the cells via 
PrestoBlue™ have been used to assess viability (Figure 5.3). We did not find 
significant difference in cell culture viability between different concentrations 
of CPZ.  
Although this may be in contrast with our findings of immunostaining, we 
speculate non-adherent cells which remain viable, would have been washed 
away during the staining process and would account for the discrepancy 
between cell survival seen in immunocytochemistry staining and viability 
assays. 
To further understand these results, we employed a real time, label free, 
impedance-based assay to record changes in the cell membrane and 
adhesion of the culture over a 24 hour period. 
5.4.3 ECIS 
Cell based impedance assays are an emerging technology in drug discovery 






insulating particles that alter impedance when cultured on top of micro-
electrodes. Therefore, an increase in impedance is a reflection of cellular 
growth kinetics. ECIS technology is able to decouple parameters of cell 
growth and cell-cell interaction through mathematical modelling and the use 
of multi-frequency measurements. The total impedance (encompassing 
resistive and capacitive components), can be deconvolved to show changes 
in morphology, membrane integrity, quality of basolateral adhesion and 
quality of cell-cell junctions (TJs), all contributing to a relative increase or 
decrease in impedance over time (Wegener, Giaver & Keese, 2000).  
Here we demonstrate that cells treated with CPZ show alterations to cell-cell 
junctions, basolateral adhesion and also to total membrane integrity. This 
principle in correlation with our data shows that the major changes to the cell 
membrane happen within the first 6 hours after application of the drug 
(Figure 5.4). However, the culture was monitored for a total of 24 hours after 
application of CPZ and some recovery was observed. The recovery of TJ’s, 
basolateral adhesion and cell membrane integrity after 6 hours in 25 and 
50µM concentrations is significant since the half-life of CPZ is 30 hours. This 
suggests damage is immediate and some recovery due to adaptation occurs 
within the first 30 hours (Figure 5.4). This highlights the usefulness of real 
time impedance as this may correlate to the results of cell viability assays 







This result differs from impedance signatures produced using acetaminophen 
(APAP) as a direct hepatotoxin. We previously showed dose dependant 
damage to HepaRG™ TJs with no recovery when challenged with APAP 
(Gamal et al., 2017). As ECIS is a highly sensitive technology, it is possible 
that different signatures could be seen depending on the mechanism behind 
toxicity.  
5.4.4 CYP3A4/HNF4α 
Alongside viability and impedance-based assays, we also investigated 
functional hepatic enzyme CYP3A4 and its nuclear receptor HNF4α using 
qRT-PCR as a means of assessing functional viability (Figure 5.7). Metabolic 
activity and CYP functionality are important in detoxification of the cellular 
environment and supports adaptive processes within the cell, where CYP450 
enzymes are an innate adaptive mechanism in hepatocytes when there is 
toxicity within the environment. Both CYP3A4 and its regulator HNF4α show 
a trend of up regulation at the lower dose indicating an adaptive response to 
low levels of toxicity within the cellular environment. The inhibition of CYP3A4 
and HNF4α at the higher dose suggests the induction of a stress response 
causing down regulation of these markers at higher doses. Here we show an 






5.4.5 Inflammatory and adaptive response	
Inflammatory and further adaptive responses were measured though the 
analysis of TNFα, NRF2 and IL6. An increased dose dependent response 
was found in all three genes.  
 
IL6 is an instigator of the innate and adaptive immune response. Expression 
is rapidly induced in instances of cellular stress and disease and is known to 
induce the anti-apoptotic pathway through BCL2 expression, as an adaptive 
response (Waxman and Kolliputi, 2009). Here we have shown up regulation 
of anti-apoptotic pathway by focusing on the BCL2 mRNA protein expression, 
indicating damage at sub toxic doses does not lead to apoptosis (Figure 
5.8). Up regulation of inflammatory cytokines may also go some way to 
explain the inhibition of CYP3A4 at 50µM within this model as CYP3A4 is 
down regulated in the presence of oxidative stress.  
 
5.4.6 Bile acid and membrane bound transporters 
To further understand mechanisms related to IHC we assessed several 
membrane transporter molecules. Decreased expression of bile acid 
transporter (ABCB11) suggests an impairment of this protein which is 
responsible for pumping toxic bile acids out of the cell. This inhibition of the 






as build up of bile acids are known to specifically target tight junction proteins 
(Raimondi et al., 2008, Chen et al., 2011)  
 
The significant increase of genes responsible for the efflux of toxins and 
phospholipids (ABCB4 and ABCB1) also shows an adaptive response at the 
cellular level. (Figure 5.9).  
 
5.4.7 Idiosyncratic presentation of CPZ induced cholestasis 
Due to up regulation of membrane bound proteins, we propose a mechanism 
whereby the idiosyncratic presentation of CPZ injury within the liver may be 
explained. Mutations or variants in ABCB1 and ABCB4 may contribute to the 
mechanism behind CPZ toxicity. When ABCB4 is knocked out in mice, an 
increase of reactive oxygen species is observed alongside lipid peroxidation 
causing damage within the cell (Tebbi et al., 2016). Variations of ABCB4 in 
humans are also well documented to cause cholestatic pathologies such as 
intrahepatic cholestasis in pregnancy, low phospholipid associated 
cholelithiasis, oral contraceptive induced cholestasis and 
cholangiocarcinomas (Wasmuth et al., 2007, Pasmant et al., 2012, Tougeron 
et al., 2012). There is also a correlation between ABCB1 and drug induced 
cholestasis in another antipsychotic drug, risperidone. Risperidone is a 
second generation antipsychotic drug which is also prescribed for patients 
with schizophrenia. Preliminary data of a Chinese cohort suggests that 






individual response to risperidone and aid in prescribing of the drug (Xing et 
al., 2006).  
While we can not propose that there is a mutation or genetic variant to 
ABCB4 or ABCB1 within this model, we can show that any inability to 
regulate these efflux proteins could lead to cholestatic disease and that drugs 
used to treat schizophrenia are known to target these transporters. It can 
also be hypothesised that patients with variations or mutations of these 
genes may not be able to upregulate in the presence of a toxic compound 
and that this may provide some insight into the idiosyncratic presentation of 
CPZ induced IHC.  
	
Here we describe a more mechanistic view of the damage caused by CPZ to 
both hepatocytes and cholangiocyte-like cells by using the HepaRG™ co-
culture, real time assessment of the onset of toxicity and evidence of 
structural changes within the membrane which negatively impact the function 
of efflux transport proteins inducing inflammatory downstream effects which 
activate adaptive responses for cell survival.  
Taken alongside viability assays, molecular data shows a dose dependent 
inflammatory and adaptive response induced by CPZ at non-toxic 25µM and 
sub-toxic 50µM concentrations. We observe an overall decrease in genes 
encoding proteins responsible for the initiation of apoptosis, no change in cell 
functionality or viability and an increase in pro-inflammatory cytokines TNFα 






through an inflammatory pathway (Figure 5.10). Further evidence of an 
adaptive response can be seen in the up-regulation of CYP3A4 at 25µM, and 
membrane bound transporters ABCB1 and ABCB4 alongside dose 
dependant increase of IL6 and its initiation of the BCL2 anti-apoptotic 
pathway. Further work could be undertaken to assess oxidative stress using 
flow cytometry to ascertain if there is a quantitative dose dependant response 
that would correlate gene expression of inflammatory and adaptive markers. 
Down regulation of bile acid transporters are also statistically significant as it 
impacts the structural integrity and TJs.  
To further investigate, a method using LC:MS/MS could be employed to 








5.5 Conclusion  
Conclusions of this study can be summarized in the following points.  
 
1. Chlorpromazine was not directly hepatotoxic to HepaRG™ cells 
2. Down-regulation of bile acid transporter (ABCB11) may be responsible 
for increased bile acids within the cell. 
3. ECIS showed dose dependent decrease of total impedance, with clear 
evidence of disruption of basolateral adhesion and cell membrane 
integrity 
4. Immunostaining confirmed disruption of adhesion (F-actin and ZO1) 
5. There was dose dependant up-regulation of inflammatory cytokines 
(IL6 and TNFa) 
6. Adaptive response was seen in upregulation of NRF2, ABCB1, 
ABCB4 expression with induction of anti-apoptotic marker BCL2 
7. We speculate that polymorphisms of ABCB1 and ABCB4 may affect 
















Chapter 6 Discussion and future work 
There is a need within the pharmaceutical sector to gain more insight into the 
mechanisms behind DILI and the safety and efficacy of new compounds. 
Hepatotoxicity is a common cause of attrition of drugs in late stage clinical 
trials. Therefore, a better model that mimics human liver physiology in vitro 
could help in the development of safer compounds.  
There are many in vitro models of DILI, yet none that have been put forward 
as an industry or gold standard. One of the biggest issues within research 
today is reproducibility of experimentation between laboratories. To tackle 
this, the Innovative Medicines Initiative (IMI) set out to assess if current cell 
models used in safety assessment distinguish between chemicals which 
cause DILI. The study design used 7 laboratories across the IMI. Nine 
compounds were used that are known to be hepatotoxic and 4 compounds 
that are known to be non-toxic. All laboratories used the same reagents, cell 
lines and procedures to test compounds and determine if DILI could be 
predicted in vitro using dosing regimes of either 24 or 72 hours. Inter and 
intra-variability was also assessed. 
The results showed inter-laboratory variation in all cells apart from 
HepaRG™s. They also showed that none of the cell models used was able to 






HepG2 cells were most accurate in predicting DILI despite the variations 
observed. 
While the design of their study was robust (7 laboratories using same 
protocols, reagents and cell types) it is unclear how many of these studies 
were combined to create the results presented. In Materials and Methods 
they state that inter-laboratory variation of several cell models were 
evaluated by at least 2 test sites. It is unclear why only 2 test sites were 
evaluated as 7 took part. 
While all cell types were grown the same across all laboratories, HepaRG™ 
cells were the only line not grown on either matrigel or collagen. It is well 
known that collagen and matrigel coated surfaces create better adhesion 
than standard TCP on both 2D and 3D models using hepatocytes (Zeigerer 
et al., 2017, Kubo et al., 2016, Aday et al., 2011, Wang et al., 2016 & 2004, 
Sanchez et al., 2000,). We have also shown within this thesis the role surface 
substrate plays in proliferation and differentiation. Therefore, it is unclear why 
HepaRG™ cells were treated differently within the Sison-Young study. This 
may have an impact on the results showing HepaRG™ cells lacking when 
compared to PHH and HepG2 as we have also shown in Chapter 3 how 







Another unclear point within this paper is the use of HepaRG™-P cells. Their 
use of Fresh HepaRG™s seemed to be based on passaging HepaRG™-P 
cells according to Biopredics protocol, then trypsinizing and reseeding them 
onto TCP as fully differentiated cells and running experiments on day 5. We 
know day 5 is too early to experiment on HepaRG™ fully differentiated cells 
due to lack of tight junctions which indicate hepatocyte polarity. This is 
evidenced by ECIS data shown in both APAP and CPZ experimentation 
(Gamal et al., 2017). 
Dosing regimes within the consortium were set up for either 24 or 72 hours. 
72 hour protocols take into consideration repeat dosing and is a good model 
to take forward, however, dosing solutions were made fresh daily. While this 
can be seen as a good practice, it can also introduce variability and for this 
reason, within our laboratory, we freeze down stock solutions so each aliquot 
should be directly comparable and reproducible. 
The groups used the same dose for each cell type rather than an optimal 
dose. This creates reproducibility, but could be criticised for not considering 
the level of CYP enzyme activity within each cell line. Using the same dose 
for all cell lines may have introduced toxicity issues, thereby confounding 
resazurin assay. Results for the resazurin assay were not shown in the main 
body of the paper, but materials and methods states that cells were 
incubated with resazurin for 1 hour. We have shown this to be too long for 






fluorescent metabolite resarufin is further metabolised into hydro-resorufin, 
which does not fluoresce and is undetectable, meaning a loss of optimal 
signal. 
Finally, while there are some aspects of this study which warrant further 
consideration (Reproducibility across various sites, multiple cell lines used, 
harmonized protocols and standardization) other aspects of this study fall into 
question. It is imperative that all cell cultures be treated the same in any DILI 
comparison to preserve reproducibility of results. The results of this study 
suggest that there was no cell model which was able to distinguish between 
DILI and non DILI compounds based on EC50. They also state that '...each 
compound varied per cell type across the relevant test sites.', HepG2 and 
Upcyte cells differed markedly between replicate experiments in the same 
laboratory, intra-laboratory analysis varied between compounds, and finally 
'Importantly, we detected different degrees of inter-laboratory variation 
across the cell types assessed.'. 
Contrary to the above study, we have shown the human hepatic HepaRG™ 
cell line to be a more relevant model for in vitro drug toxicity and 
development assays. 
The HepaRG™ cell line exhibits better functionality than C3A models and is 
comparable to PHHs. However, many in vitro models rely on exogenous 
compounds for differentiation and maturation. Finding a model that 






long term differentiated function could improve the outcome and high costs 
involved in using these models. Our first hypothesis tested whether we could 
improve the rate of growth, differentiation and functionality of the HepaRG™-
P cells without using exogenous agents such as DMSO. By growing the 
HepaRG™-P cells on various nanopattern and non pattern controls we have 
shown that cell surface substrate/treatment can effect differentiation and 
function of HepaRG™-P cells without the use of exogenous chemicals. While 
nanopits had some effect on function and growth compared to TCP, we saw 
a significant difference in the rate of differentiation and functional capabilities 
on the UP control. This prompted us to examine the role oxygen plasma may 
play in the growth and function of cells. Changes in phenotype due to surface 
chemistry is supported within the literature. Scherthaner (2012) reported the 
translocation of β-catenin from cell adhesion sites to the nucleus of 
endothelial progenitor cells. This was more or less profound when the 
chemical treatment of the surface was altered by introduction of polar oxygen 
and nitrogen groups This highlights the complex relationship between 
nanopatterned surfaces/structures and the chemical composition of the 
substrate and their effect on cell morphology and supports further 
investigation into surface treatment without nanopatterning. 
 
It has also been shown that various states of hyperoxia induce differentiation 
of this specific cell line (Van Wenum et al., 2018) and has also played a part 






implications for future work where various oxygen plasma coated surfaces 
could be compared to various states of hyper and hypo-oxia on HepaRG™ 
cells to determine its effect on differentiation and function. It may be of 
particular interest when assessing specific liver zonation as our model 
suggests a trend towards zone 3 specific cells. Future work could explore the 
hypothesis that oxygen plays a major role in the zonation of the liver. The 
oxygen gradient within the acini is well documented and experiments to 
replicate this in vitro could inform a more dynamic model of DILI. While the 
outcome of this study was unexpected, it is perhaps beneficial, for future 
manufacturing of this model, that surface chemistry, rather than 
nanopatterns, is key in directing earlier differentiation and function. The 
implications of this model based on surface treatment make it more 
accessible by designating a specific concentration of oxygen plasma which is 
easier to regulate in terms of reproducibility and keeps the cost of this model 
low.  However, there were some results within this study that require more 
consideration. For instance, the immunohistochemistry was sometimes 
limited to one or two biological replicates. While technical replicates are 
important and can show variation within an experiment, biological replicates 
are needed to show overall reproducibility. Staining of both CPS and GS 
within the nanopattern project was undertaken at the end of the project on 
one biological replicate with three technical replicates. Repeating this 
experiment and any others of an n value less than 3 would be needed to 






Chapter 3 that there was no positive control for the staining of CPS or GS. In 
the absence of a signal, such as the CPS stain, a positive control should be 
used to verify the technique and antibody and ensure that the protocol is 
sound. Similarly, when considering the gene expression data for SOX9 
(Figure 4.13), six biological replicates (with three technical replicates for each 
biological replicate) were used, but did not produce a result. Even though 
primers were validated by Primer Design, a positive control for SOX9 gene 
expression should have been tested alongside experimental conditions for 
verification of primers and technique.  
Monitoring DILI using a real time, non-invasive and label free platform could 
also be beneficial, providing useful information of the time course of injury 
caused by compounds. The ECIS ZΘ impedance-based assay is capable of 
this type of monitoring and has already been used extensively in in vitro 
models of toxicity. It is interesting to note that the ECIS arrays are treated 
with oxygen plasma instead of the standard industry corona treatment used 
by companies such as Corning. This may aid in adhesion of cells to the array 
and warrants further investigation. Dose dependant impedance assays can 
shed light on the mechanisms of action of new compounds by highlighting 
where damage occurs and how long it takes for damage to be seen. This 
may then be correlated with the half-life of the compound as in the CPZ 
model.  
Here we present a model of cholestasis using the HepaRG™ cell line. This is 






described as the inhibition of bile acid secretion within the liver, one way to 
further establish a model of cholestasis would be to measure bile acids both 
intra and extracellularly. This can be done using LC:MS/MS where 
supernatant and cell lysates can be assessed for total concentration of 
primary bile acids. It is known that HepaRG™ cells typically have a similar 
concentration of bile acids, both intra and extracellularly, to PHHs. 
(Woolbright et al., 2016, Sharanek et al., 2015). Therefore, establishing a 
model of cholestasis using ECIS and LC:MS/MS could be directly relatable to 
PHHs. Using HepaRG™s in such a model would give better reproducibility 
than PHHs as PHHs are difficult to maintain in culture and vary 
phenotypically from donor to donor.  
While we used qRTPCR to measure fold change of inflammatory cytokines, 
another option would be to measure them directly within cell supernatant. 
This would give more confidence in the gene expression data and may 
contribute further information to the model.  
 
 
Further work could also look at other model cholestatic compounds to assess 
the impedance signature, membrane transporters and inflammatory 
responses and compare the results to the current study. Also, while the study 
on chlorpromazine assessed the regulation of key genes responsible for 
transporting compounds out of the cell, it did not consider membrane bound 






solute carrier transporters (SLCs) organic cation transporters (OCTs) and 
organic anion transporters (OATs) and transporting polypeptides (OATPs), 
coupled with a quantification of parent compound turnover, could better 
inform studies interested in the absorption and elimination of new compounds 
and other drugs known to cause cholestasis.  
The HepaRG™ cell line is robust and versatile. It lends itself to many 
applications, and could lead to further disease in a dish models such as non-
alcoholic fatty liver disease (NAFLD). Within our group we have published a 
model of NAFLD using C3A cells and have extensively looked at the role fat 
plays in the accumulation of oxidative stress (Lockman et al., 2012, Lockman 
et al., 2016). It would be interesting to revisit this model using the HepaRG™ 
cell line and compare the results to previous data.  
It has also been shown that HepaRG™ cells are a good cell line for the 
creation of spheroids (Martucci et al., 2018). 3D cultures such as spheroids 
have several pros and cons. Theoretically, 3D cultures should mimic a more 
in vivo-like environment as multicellular contact promotes better cell-cell 
communication and confers biological relevance to a model. One of the 
problems with spheroids is in keeping the core cells viable. As the mass of 
the spheroid increases, cells at the core can die due to hypoxia and nutrient 







It has been shown that spheroids comprised of HepaRG™ cells maintain a 
viable core through the measurements of Promega Cell Titer glo -3D ATP 
assay and optical coherence tomography (OCT).  
Using HepaRG™ spheroids alongside the fat loading model used for NAFLD 
may give new insight into the absorbtion of fat into hepatocytes and the 
levels of toxicity caused by oxidative stress. 
 
Finally, using the tool kit of viability and biochemical assays, impedance 
based measurements, molecular and flow cytometry techniques described in 
this work, it is possible to build many different models of DILI or ‘disease on a 









Chapter 7 Supplementary Data 
 
7.1 Supplementary data to chapter 3  
LC:MS/MS 
Below are data sets of biotransformation used to produce 
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7.1.1 HRG sample data 
 
Sample HRG 2 
Phenacetin 2 
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3.57 2.10E+06 30.3 





1.81 1.69E+05 2.4 





2.63 1.15E+05 1.7 
Parent 0 180.1 
180.1 / 
110.0 
6.01 4.31E+06 62.2 
 
 

































3.6 1.31E+06 17.5 





4.17 4.59E+05 6.1 





2.66 1.09E+05 1.5 
Parent 0 180.1 
180.1 / 
110.0 
6.04 5.47E+06 72.7 







Sample HRG 3.2 phenacetin 




















3.55 1.56E+06 21 





1.74 2.54E+05 3.4 





2.61 8.88E+04 1.2 
Parent 0 180.1 
180.1 / 
110.0 









7.2 Supplementary data to chapter 2 materials and 
methods: Characterisation of PrestoBlue™ assay 
for use in C3A and HepaRG™ cell lines 
Very few studies have been carried out on the accuracy of PrestoBlue™ or 
how different plates, plate readers or cell lines react to this assay. The 
purpose of this supplementary section is to examine the accuracy of 
PrestoBlue™ to gauge cell proliferation and metabolic activity in C3A cells.  
 
PrestoBlue™ is a resazurin based reagent capable of assessing cell 
proliferation, viability and metabolic activity.  These three attributes run hand 
in hand in a given cell culture as the more proliferative your cells, the more 
metabolic activity you are likely to see, and if cells are metabolically active 
they will be viable. 
 
PrestoBlue™ is ideal as it is not an end point assay and it is hypothesised 
that using PrestoBlue™ at various points during a given cell culture will not 
have a significant effect on the culture itself.  
 
PrestoBlue™ works by testing mitochondrial enzyme activity (Xu et al., 2014). 






and is reduced through cellular respiration by NADPH, FAD, NADH and 
FMNH into resarufin which fluoresces red (Xu et al., 2014). The fluorescence 
or absorbance is directly proportional to the number of metabolically active or 
viable cells and can then be read at 520nm (Xu et al., 2014). 
 
7.2.1 PrestoBlue™ vs Alamar Blue™ 
 
Until recently Alamar Blue™ was the industry standard in resazurin based 
viability assays. Little is known of the difference between Alamar Blue™ and 
PrestoBlue™. However, the manufacturer of PrestoBlue™ has confirmed that 
they contain different buffers and it has been asserted that PrestoBlue™ is 
faster and has a higher sensitivity than Alamar Blue™ (Xu et al., 2014) 
 
Xu et al., (2014) used a number of incubation times and methods to assess 
the difference between PrestoBlue™, AlamarBlue™ and MTT™.  They found 
that  PrestoBlue™ was able to detect cells at a density of 5k after half an 
hour incubation while MTT could detect the same number of cells only after a 
3 hour incubation. 
 
7.2.2 Time dependency  
It is important to understand the processes involved within an assay and how 






assay the dark blue resazurin salt is reduced to a red fluorescent compound 
called resorufin. This compound is what is measured within this assay to give 
you an indication of how metabolically active your cells are. However, 
resorufin is then further reduced to hydro-resorufin which is colourless and 
cannot be detected. The material safety data sheet for PrestoBlue™ 
recommends an incubation time of 30 minutes in order to give the cells time 
to reduce resazurin into resorufin. Since we are using hepatocytes which can 
have a high metabolic rate, it was decided to test the hypothesis of a 30 
minute incubation to see if it was suitable for our particular cell line by taking 
a PrestoBlue™ reading once every 10 minutes for an hour. This would show 
the optimum time for reading by showing an increase in signal as the cells 
metabolize resazurin and a plateau where resorufin is visible and no further 
metabolism takes place. It was hypothesized that after such a plateau, a 
decline in signal would be apparent showing the further metabolism of 









Figure 7.1: Schematic of resazurin metabolism Within the assay, the non 
fluorescent resazurin is reduced to its metabolite of resorufin which fluoresces red. Further 
reduction of resorufin produces hydro-resorufin which does not emit a coloric or fluorescent 
signal.  
 
7.2.2.1 Day 0 seeding density readings 
C3A cells were thawed from liquid nitrogen at 37C. Cells were counted using 
the Countess cell counter described in Chapter 2. Cells were suspended in 
eppendorf tubes at differing densities of 2.5k, 5k, 10k, 20k, 40k, 80k, 100k 
and 160k cells per tube, (n=3 for each density). Cells were spun down at 5.6k 
rpm for 3 mins and the supernatant was discarded. Cells were resuspended 
in 100ul of PrestoBlue™ for 30 mins.  Cells were spun down into a pellet and 
the supernatant was taken into a white 96 well plate reader and read on a 
Glomax at 520nm.   
 
7.2.2.2 Day 1 and 3 seeding density readings  
C3A cells were seeded on a standard 96 well Corning plate at densities of 






density.  Cells were kept at 37C with 5% CO2. The PrestoBlue™ assay was 
performed 24 hours (Day 1) and 72 hours (Day 3) after seeding and readings 
were taken after cells were washed in PBS and then incubated for 30 











Figure 7.2: PrestoBlue™ standard curves C3A cells were seeded at 2.5, 5, 10, 
20, 40, 80, 100 and 160k cells per well (n=3) and PrestoBlue™ readings were taken at day 0 
in suspension then again at 24 and 72 hours. This established a standard curve which 
validated this technique as being sensitive enough for use with a range of cell seeding 








7.2.2.3 Day 3 time dependent reading 
C3A cells seeded at the above densities underwent PrestoBlue™ 
assessment on day 3. Readings were taken every 10 minutes for one hour 
on the Glomax at 520nm.  
 
 
Figure 7.3 PrestoBlue™ time dependant metabolism of substrate: 
Graphical representation of C3A cells grown at various seeding densities where readings 
were taken every 10 minutes for one hour. This shows that after 10 minutes little to no signal 
was detected, between 20 and 40 minutes a signal is detected and an increase is seen in 
metabolic proficiency up to 80k cells where signal plateaus before decline at 100k cells and 
beyond. Flourescent signals read at 50 and 60 minutes show increase in metabolism to 80k 
cells before dramatic drop 100k + indicating that after cell culture reaches 80k cells 
metabolic proficiency is high enough to metabolise resarufin into hydroresorufin thereby 








7.3 Optimisation of Reference Genes for use in 
HepaRG™ cell line- raw data 
MIQE guidelines were consulted throughout the processes of RG selection, 
sample preparation and analysis of data. Within these extensive guidelines, 
one of the most important factors to take into consideration is the selection of 
a set of three RGs that maintained stability throughout experimentation.  
It was decided that the same 12 RGs would be used for analysis on both the 
nanopattern and CPZ projects. It was interesting then to observe that the top 
3 genes recommended for the CPZ study were completely different from 
those selected for the nanopattern study. CYC1, SDHA and 18s were used 
as our panel of RGs for the nanopattern project while GAPDH, UBC and 
TOP1 were used for CPZ.  
Within the same cell line, under different conditions, there was not one gene 
recommended that was the same for both cohorts. This highlights the need 
for stringent adherence to RG selection in accordance with MIQE guidelines 
and current literature, as even within the same cell line, RGs can change in 
accordance to experimental conditions. Keeping this in mind it would perhaps 
be useful to adopt a more encompassing view of the transcriptome by using 
a microarray or RNAseq when evaluating the stability of RGs over a 









Figure 7.4 Sample screen shot of nanodrop measurement of RNA purity 
for HepaRG™-P cells at day 0: Nanodrop measurement of RNA from day 0 cell 
suspension: Graphical and quantitative representation of RNA quantity and quality of 















Figure 7.5 Representation of HepaRG™ cells on various 
different NPS and control HepaRG™ progenitors on TCP 
show commitment to the hepatocyte lineage ~day 14. 
Significantly, we identified earlier commitment to a hepatic 
lineage at day 6 on DSQ120. (A) – compared with both controls 
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